
<html lang="en"     class="pb-page"  data-request-id="0dd0610e-decf-419d-88da-3142a48aeeca"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00935;issue:issue:10.1021/jmcmar.2020.63.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C" /></meta><meta name="dc.Creator" content="Guangyi  Wang" /></meta><meta name="dc.Creator" content="Natalia  Dyatkina" /></meta><meta name="dc.Creator" content="Marija  Prhavc" /></meta><meta name="dc.Creator" content="Caroline  Williams" /></meta><meta name="dc.Creator" content="Vladimir  Serebryany" /></meta><meta name="dc.Creator" content="Yujian  Hu" /></meta><meta name="dc.Creator" content="Yongfei  Huang" /></meta><meta name="dc.Creator" content="Xiangyang  Wu" /></meta><meta name="dc.Creator" content="Tongqian  Chen" /></meta><meta name="dc.Creator" content="Wensheng  Huang" /></meta><meta name="dc.Creator" content="Vivek K.  Rajwanshi" /></meta><meta name="dc.Creator" content="Jerome  Deval" /></meta><meta name="dc.Creator" content="Amy  Fung" /></meta><meta name="dc.Creator" content="Zhinan  Jin" /></meta><meta name="dc.Creator" content="Antitsa  Stoycheva" /></meta><meta name="dc.Creator" content="Kenneth  Shaw" /></meta><meta name="dc.Creator" content="Kusum  Gupta" /></meta><meta name="dc.Creator" content="Yuen  Tam" /></meta><meta name="dc.Creator" content="Andreas  Jekle" /></meta><meta name="dc.Creator" content="David B.  Smith" /></meta><meta name="dc.Creator" content="Leonid  Beigelman" /></meta><meta name="dc.Description" content="Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The current standard of care for CHC can achieve cure rates above 95%; however, the drugs in current use are admi..." /></meta><meta name="Description" content="Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The current standard of care for CHC can achieve cure rates above 95%; however, the drugs in current use are admi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 20, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00935" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00935" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00935" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00935" /></link>
        
    
    

<title>Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00935" /></meta><meta property="og:title" content="Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0019.jpeg" /></meta><meta property="og:description" content="Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The current standard of care for CHC can achieve cure rates above 95%; however, the drugs in current use are administered for a period of 8–16 weeks. A combination of safe and effective drugs with a shorter treatment period is highly desirable. We report synthesis and biological evaluation of a series of 2′,3′- and 2′,4′-substituted guanosine nucleotide analogues. Their triphosphates exhibited potent inhibition of the HCV NS5B polymerase with IC50 as low as 0.13 μM. In the HCV replicon assay, the phosphoramidate prodrugs of these analogues demonstrated excellent activity with EC50 values as low as 5 nM. A lead compound AL-611 showed high levels of the nucleoside 5′-triphosphate in vitro in primary human hepatocytes and in vivo in dog liver following oral administration." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00935"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00935">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00935&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00935&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00935&amp;href=/doi/10.1021/acs.jmedchem.0c00935" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 10380-10395</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00843" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00939" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of <b>AL-611</b> as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Guangyi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guangyi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guangyi++Wang">Guangyi Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natalia Dyatkina</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natalia Dyatkina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#3d5359445c495654537d54494e13575357135e5250"><span class="__cf_email__" data-cfemail="157b716c74617e7c7b557c61663b7f7b7f3b767a78">[email protected]</span></a>. Phone: 650-635-5518.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natalia++Dyatkina">Natalia Dyatkina</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2330-7606" title="Orcid link">http://orcid.org/0000-0003-2330-7606</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marija Prhavc</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marija Prhavc</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marija++Prhavc">Marija Prhavc</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3365-4436" title="Orcid link">http://orcid.org/0000-0002-3365-4436</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Caroline Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Caroline Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Caroline++Williams">Caroline Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vladimir Serebryany</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vladimir Serebryany</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vladimir++Serebryany">Vladimir Serebryany</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yujian Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yujian Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yujian++Hu">Yujian Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongfei Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongfei Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongfei++Huang">Yongfei Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiangyang Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiangyang Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiangyang++Wu">Xiangyang Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tongqian Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tongqian Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tongqian++Chen">Tongqian Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wensheng Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wensheng Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wensheng++Huang">Wensheng Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vivek K. Rajwanshi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vivek K. Rajwanshi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vivek+K.++Rajwanshi">Vivek K. Rajwanshi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jerome Deval</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jerome Deval</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jerome++Deval">Jerome Deval</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Fung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Fung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Fung">Amy Fung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhinan Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhinan Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhinan++Jin">Zhinan Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Antitsa Stoycheva</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antitsa Stoycheva</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antitsa++Stoycheva">Antitsa Stoycheva</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1907-0319" title="Orcid link">http://orcid.org/0000-0003-1907-0319</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenneth Shaw</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenneth Shaw</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth++Shaw">Kenneth Shaw</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kusum Gupta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kusum Gupta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kusum++Gupta">Kusum Gupta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuen Tam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuen Tam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuen++Tam">Yuen Tam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Jekle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Jekle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Jekle">Andreas Jekle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David B. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David B. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+B.++Smith">David B. Smith</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Leonid Beigelman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leonid Beigelman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leonid++Beigelman">Leonid Beigelman</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00935&amp;href=/doi/10.1021%2Facs.jmedchem.0c00935" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 10380–10395</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 20, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 June 2020</li><li><span class="item_label"><b>Published</b> online</span>20 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00935" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00935</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10380%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGuangyi%2BWang%252C%2BNatalia%2BDyatkina%252C%2BMarija%2BPrhavc%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D18%26contentID%3Dacs.jmedchem.0c00935%26title%3DSynthesis%2Band%2BAnti-HCV%2BActivity%2Bof%2BSugar-Modified%2BGuanosine%2BAnalogues%253A%2BDiscovery%2Bof%2BAL-611%2Bas%2Ban%2BHCV%2BNS5B%2BPolymerase%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BChronic%2BHepatitis%2BC%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10395%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00935"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1656</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00935" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Guangyi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Natalia&quot;,&quot;last_name&quot;:&quot;Dyatkina&quot;},{&quot;first_name&quot;:&quot;Marija&quot;,&quot;last_name&quot;:&quot;Prhavc&quot;},{&quot;first_name&quot;:&quot;Caroline&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Vladimir&quot;,&quot;last_name&quot;:&quot;Serebryany&quot;},{&quot;first_name&quot;:&quot;Yujian&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Yongfei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Xiangyang&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Tongqian&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Wensheng&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Vivek&quot;,&quot;last_name&quot;:&quot;K. Rajwanshi&quot;},{&quot;first_name&quot;:&quot;Jerome&quot;,&quot;last_name&quot;:&quot;Deval&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Fung&quot;},{&quot;first_name&quot;:&quot;Zhinan&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Antitsa&quot;,&quot;last_name&quot;:&quot;Stoycheva&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;Shaw&quot;},{&quot;first_name&quot;:&quot;Kusum&quot;,&quot;last_name&quot;:&quot;Gupta&quot;},{&quot;first_name&quot;:&quot;Yuen&quot;,&quot;last_name&quot;:&quot;Tam&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Jekle&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;B. Smith&quot;},{&quot;first_name&quot;:&quot;Leonid&quot;,&quot;last_name&quot;:&quot;Beigelman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10380-10395&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00935&quot;},&quot;abstract&quot;:&quot;Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The current standard of care for CHC can achieve cure rates above 95%; however, the drugs in current use are administered for a period of 8–16 weeks. A combination of safe and effective drugs with a shorter treatment period is highly desirable. We report synthesis and biological evaluation of a series of 2′,3′- and 2′,4′-substituted guanosine nucleotide analogues. Their triphosphates exhibited potent inhibition of the HCV NS5B polymerase with IC50 as low as 0.13 μM. In the HCV replicon assay, the phosphoramidate prodrugs of these analogues demonstrated excellent activity with EC50 values as low as 5 nM. A lead compound AL-611 showed high levels of the nucleoside 5′-triphosphate in vitro in primary human hepatocytes and in vivo in dog liver following oral administration.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00935&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00935" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00935&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00935" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00935&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00935" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00935&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00935&amp;href=/doi/10.1021/acs.jmedchem.0c00935" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00935" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00935" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00935%26sid%3Dliteratum%253Aachs%26pmid%3D32816483%26genre%3Darticle%26aulast%3DWang%26date%3D2020%26atitle%3DSynthesis%2Band%2BAnti-HCV%2BActivity%2Bof%2BSugar-Modified%2BGuanosine%2BAnalogues%253A%2BDiscovery%2Bof%2BAL-611%2Bas%2Ban%2BHCV%2BNS5B%2BPolymerase%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BChronic%2BHepatitis%2BC%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D18%26spage%3D10380%26epage%3D10395%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/jmcmar.2020.63.issue-18/20200924/jmcmar.2020.63.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The current standard of care for CHC can achieve cure rates above 95%; however, the drugs in current use are administered for a period of 8–16 weeks. A combination of safe and effective drugs with a shorter treatment period is highly desirable. We report synthesis and biological evaluation of a series of 2′,3′- and 2′,4′-substituted guanosine nucleotide analogues. Their triphosphates exhibited potent inhibition of the HCV NS5B polymerase with IC<sub>50</sub> as low as 0.13 μM. In the HCV replicon assay, the phosphoramidate prodrugs of these analogues demonstrated excellent activity with EC<sub>50</sub> values as low as 5 nM. A lead compound <b>AL-611</b> showed high levels of the nucleoside 5′-triphosphate in vitro in primary human hepatocytes and in vivo in dog liver following oral administration.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The standard of care for hepatitis C has changed rapidly with the advent of new therapies and other developments. Combinations of sofosbuvir/velpatasvir or sofosbuvir/ledipasvir are part of the preferred regimens in the AASLD guidelines<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> and can achieve cure rates above 95%. Therapy with these direct antiviral agents can cure persons infected with HCV, and the treatment period is typically 12 weeks. Drugs in chronic use may develop resistance and show more adverse effects with time. Therefore, a combination of safe and effective drugs with a shorter treatment period is highly desirable. A shorter treatment therapy is expected to increase both patient compliance and treatment accessibility to patients infected by HCV. Nucleoside analogues have excellent records as antiviral drugs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Their triphosphate metabolites may selectively inhibit viral targets, particularly viral polymerases, effectively preventing viral replication.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The well-known HCV drug sofosbuvir, a uridine analogue, is widely used in HCV therapies.<a onclick="showRef(event, 'ref2 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref6">(2,6)</a> Another nucleoside drug-candidate BMS094 (INX-189), which is a prodrug of 2′-<i>C</i>-methylguanosine <b>1</b>, is also well known for its very potent activity against HCV infection.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, the drug was halted in a clinical trial owing to its severe toxicity.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Two more guanosine prodrugs of 2′-deoxy-2′-α-fluoro-2′-β-<i>C</i>-methylguanosine <b>2</b>: PSI-661,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> a phosphoramidate nucleotide, and PSI-938,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> a cyclic phosphate nucleotide, were reported. Both compounds are metabolized to the same active 5′-triphosphate of <b>2</b>. Despite the potent clinical anti-HCV activity, development of these compounds was discontinued, with PSI-938 halted due to hepatic toxicity observed with extended dosing in the clinic. Recently, a new phosphoramidate prodrugs AT-527 was reported.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Its active metabolite is also 5′-triphosphate of <b>2</b>. AT-527 demonstrated potent, pan-genotypic activity against hepatitis C virus and is now in clinical development. Incorporation of the guanosine nucleoside triphosphate into host RNA by human mitochondrial RNA polymerase (HMRP) was at least partially responsible for the toxicity.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In fact, the HCV nucleosides that are either an approved drug (such as sofosbuvir) or were successful in clinical trials (such as <b>AL-335</b><a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> or uprifosbuvir<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>) are pyrimidine analogues. In order to obtain guanosine derivatives with a good safety profile and high antiviral potency, we explored a variety of sugar-modified guanosine analogues. One of our approaches was to increase the complexity of the sugar moiety to limit off-target effects caused by interactions with host polymerases and therefore increase the chance to identify a safe nucleoside analogue. Toward this goal, we modified the sugar moiety by combining substituents at 2′-, 3′-, and 4′-positions. In this article, we report the synthesis, HCV NS5B inhibition, host polymerase inhibition, and HCV replicon activity of a series of guanosine analogues <b>4–10</b> having 2′,3′- and 2′,4′-disubstituted sugar moieties (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). For the lead prodrug <b>AL-611</b> (<b>42</b>), the in vivo and in vitro nucleoside 5′-triphosphate (NTP) formation, replicon activity, and cytotoxicity are also presented.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Sugar-modified guanosine analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Synthesis of compounds <b>4–7</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Starting nucleosides were prepared according to known procedures: <b>11a</b>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a><b>11b</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a><b>11c</b>,<a onclick="showRef(event, 'ref17 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref19">(17,19)</a> and <b>11d</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> N<sup>2</sup>-monomethoxytrytilated guanosines <b>11a–d</b> were subjected to direct iodination or were converted to the alkyl iodides via a tosyl intermediate. Treatment of 5′-iodo nucleosides <b>12a–d</b> with 2,3,4,6,7,8,9,10-octahydropyrimidol[1,2-<i>a</i>]azepine (DBU) then afforded olefins <b>13a–d</b>. Stereoselective introduction of 4′-fluorine on a nucleoside using iodine and silver fluoride was first described by Moffatt.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This method results in one isomer with 4′-fluorine on α phase of the ribose and was used for preparation of 4′-fluoro pyridine<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and pyrimidine<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> nucleosides. We used this approach for synthesis of compounds <b>14a</b>, <b>b</b>, <b>d</b> from <b>13a</b>, <b>b</b>, <b>d</b>. Subsequent benzoylation and silica gel chromatography gave <b>15a</b>, <b>b</b>, <b>d</b> as single isomers. Treatment of <b>13c</b> with <i>N</i>-iodosuccinimide (NIS) and triethylamine trihydrofluoride resulted in a mixture of stereoisomers, which were separated by high-performance liquid chromatography (HPLC). The <i>D</i>-ribo isomer <b>14c</b> was benzoylated to yield <b>15c</b>. Treatment of <b>15a–d</b> with sodium benzoate at elevated temperatures produced the perbenzoylated products <b>16a–d</b>. The target nucleosides <b>4–7</b> were obtained via global deprotection using ammonia or butylamine followed by HCl/dioxane. Configuration at C-4′ for <b>4–7</b> was confirmed by 2D NMR enhancement spectroscopy (NOESY). Interaction between H-8 and H-5′,5″ demonstrated that the 4′-F is on the α face of the ribose.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) TsCl, pyridine, 0 °C, 1 h; (ii) NaI, acetone, reflux, overnight, 41% for <b>12a</b>, 52% for <b>12b</b>, 41% for <b>12c</b>; (b) PPh<sub>3</sub>, imidazole, I<sub>2</sub>, THF, rt, overnight, 90% for <b>12d</b>; (c) DBU, THF, 60 °C, overnight, 60% for <b>13a</b>, 62% for <b>13b</b>, 67% for <b>13c</b>, 83% for <b>13d</b>; (d) AgF, I<sub>2</sub>, DCM, rt, 3 h; (e) NEt<sub>3</sub>·3HF, NIS, CH<sub>3</sub>CN, rt, 2 h, 16% for <b>14c</b>; (f) BzCl, DMAP, Et<sub>3</sub>N, DCM, rt, overnight, 81% for <b>15c</b>; (g) BzCl, pyridine; (h) HMPA, NaOBz, 15-crown-5, 48 h, 60 °C, yield for 3 steps 15% for <b>16a</b> from <b>13a</b>, 6% for <b>16b</b>, 11% for <b>16d</b>; (j) NH<sub>3</sub>/MeOH, 49% for 2 steps for <b>17c</b>; (k) <i>n</i>-butylamine, rt, 80% for <b>17a</b>, 86% for <b>17b</b>, 75% for <b>17d</b>; and (l) HCl/dioxane, CH<sub>3</sub>CN, 80% for <b>4</b>, 73% for <b>5</b>, 81% for <b>6</b>, 36% for <b>7</b>.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>9</b> and <b>10</b> is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Starting 3-fluoro-<i>O</i>-methylriboside <b>18</b> was prepared as described earlier.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Condensation of <b>18</b> with 6-chloro-2-aminopurine under Vorbruggen conditions gave nucleoside <b>19</b> with good yield. Monomethoxytrityl protection of the heterocyclic base and subsequent debenzoylation resulted in nucleoside <b>20</b>. 2,2,6,6-Tetramethylpiperidine 1-oxyl (TEMPO)-mediated oxidation of the 2′-alcohol to the ketone provided intermediate <b>21</b> with high yield. Grignard methylation of ketone <b>21</b> followed by fluorination with diethylaminosulfur trifluoride (DAST) afforded 2′,3′-dideoxy-2′,3′-difluoronucleoside <b>22</b> as a single isomer, which was transformed to guanosine <b>9</b> under standard conditions.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BSA, TMSOTf, CH<sub>3</sub>CN, 80 °C, 16 h, 72%; (b) (i) TrCl, Et<sub>3</sub>N, DMAP, DMF, 45 °C, 24 h, 81%; (ii) NH<sub>3</sub>/MeOH, rt, 4 h, 78%; (c) (i) TEMPO, PhI(OAc)<sub>2</sub>, AcOH, DCM, rt, 16 h, 100%; (d) (i) CH<sub>3</sub>MgBr, ether, 2 h, −30 °C, 20%; (ii) DAST, DCM, rt, 2 h, 22%; (e) (i) NaOMe, 2-mercaptoethanol, 12 h, 65 °C; (ii) BCl<sub>3</sub>, DCM, −75 °C, 0.5 h, 55% for 2 steps; (f) (i) CH<sub>3</sub>Ph<sub>3</sub>PBr, LiHMDS, THF, rt, 4 h, 34%; (ii) AcOH, MeOH, 50 °C, 5 h, 60%; (iii) AcCl, pyridine, DCM, rt, 2 h, 65%; (g) TsCl, PhSiH<sub>3</sub>, EtOH, 30 °C, 2.5 h, 29%; (h) BCl<sub>3</sub>, DCM, −30 °C, 3 h; and (j) NaOMe, 2-mercaptoethanol, 12 h, 60 °C, 26% for 2 steps.</p></p></figure><div class="NLM_p">Ketone <b>21</b> could be converted to the exocyclic alkene <b>23</b> by treatment with potassium salt of methylphosphonium bromide followed by subsequent detritylation and acetylation of the purine base. Compound <b>23</b> was a subjected to a hydrochlorination reaction<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> with TsCl in the presence of Co catalyst<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>24</b> to yield the desired 2′-Cl guanosine <b>25</b> as a single isomer. Exclusive formation of the desired α-isomer of the 2′-chloride was most likely due to the steric congestion of the β face of the ribose. Debenzylation of <b>25</b> with BCl<sub>3</sub> afforded <b>26</b> which was treated with NaOMe and thioethanol to provide target guanosine <b>10</b>. Stereoconfiguration at C-2′ for both <b>9</b> and <b>10</b> was proven by NMR. In both cases, NOE interaction between H-8 and 2′-CH<sub>3</sub> demonstrated the methyl to be on the β-face of the nucleoside.</div><div class="NLM_p">Nucleosides <b>1</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><b>2</b>,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>3</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and <b>8</b><a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> were synthesized according to published procedures. All nucleosides <b>1–10</b> in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> were converted to their 5′-<i>O</i>-triphosphates for testing in viral and human polymerase assays.</div><div class="NLM_p">Guanosine analogues were shown to be weakly active in the HCV replicon assay. The weak potency is a result of poor phosphorylation at some stage of nucleoside phosphorylation cascade.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> For testing in cell-based assays, nucleosides were converted to monophosphate prodrugs to overcome the most discriminating the first phosphorylation step. Protection of the guanosine was necessary to avoid functional group incompatibility during prodrug synthesis. The 6-OEt group has been shown to be a viable guanosine prodrug motif.<a onclick="showRef(event, 'ref9 ref30'); return false;" href="javascript:void(0);" class="ref ref9 ref30">(9,30)</a></div><div class="NLM_p">Synthesis of the protected 6-OEt nucleosides <b>33</b> and <b>35</b> is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The amino group of the nucleoside <b>27</b><a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> was monomethoxytritylated, and the obtained product was treated with NaOEt to afford <b>28</b>. Fluorination of <b>28</b> was achieved using the same synthetic strategy, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, via formation of olefin <b>30</b>. Iodofluorination with triethylamine trihydrofluoride and NIS provided nucleoside <b>31</b> as a single isomer in a good yield. Nucleophilic substitution of the iodo moiety with OBz, together with simple protecting groups manipulations, yielded <b>33</b> and <b>35</b> as protected starting materials for the synthesis of prodrugs of 2′,4′-difluoro-2′-<i>C</i>-methyl-guanosine <b>6</b>. Nucleoside <b>33</b> was converted to cyclic phosphates <b>51–53</b>. Nucleoside <b>35</b> was a starting material for the preparation of phosphoroamidate prodrugs <b>39–50</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Protected 3′-<i>O</i>,<i>N</i><sup>2</sup>-bismonomethoxytrityl-O<sup>6</sup>-ethyl analogues of nucleosides <b>4</b>, <b>5</b>, and <b>7</b> were synthesized in a similar way, and the synthesis thereof described previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These compounds were converted to 5′-phosphoroamidate prodrugs <b>36–38</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) using standard conditions.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> All prodrugs were isolated as mixtures of diastereomers.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of synthesized prodrugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) MMTrCl, AgNO<sub>3</sub>, collidine, DCM, rt, overnight, 84%; (ii) NaOEt, EtOH, rt, 1 h, 98%; (b) I<sub>2</sub>, PPh<sub>3</sub>, imidazole, THF, rt, 5 h, 75%; (c) DBU, THF, 75 °C, 3 h, 37%; (d) NEt<sub>3</sub>·3HF, NIS, DCM, 0 °C, 2 h, 60%; (e) (i) BzCl, Py, rt, overnight; (ii) NaOBz, DMF, 15-crown-5, 100 °C, 48 h, 45% (for 2 steps); (f) <i>n</i>-butylamine, rt, overnight, 85%; (g) (i) MMTrCl, AgNO<sub>3</sub>, collidine, DCM, rt, overnight, 82%; (ii) NaOBz, DMF, 15-crown-5, 95 °C, 72 h, 65%; (h) <i>n</i>-butylamine, rt, overnight, 56%; and (j) (i) <i>tert</i>-BuMgCl, alkyl phosphorodichloridate, THF, rt, 2–3 h, 12–32%; (ii) HCl/dioxane, rt, 1 h, 95%.</p></p></figure><div class="NLM_p">Among these mixtures was a pair of P-isomeric prodrugs <b>41</b> and <b>42</b> (<b>AL-611</b>), which were separated from diastereomeric mixture <b>40</b> by RP HPLC. For assignment of the stereochemistry at the P-atom of <b>41</b> and <b>42</b> (<b>AL-611</b>), an alternative synthesis was performed. Nucleoside <b>35</b> was treated with <i>S</i>p-diastereomer of the phosphoramidating reagent reported by Ross et al.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Reaction with the 5′-hydroxyl group of <b>35</b> through selective nucleophilic displacement of pentafluorophenol resulted in <i>S</i>p-diastereomer identical to prodrug <b>42</b> by HPLC and <sup>1</sup>H NMR (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Therefore <b>42</b> (<b>AL-611</b>) was assigned as <i>S</i>p- and <b>41</b> as <i>R</i>p-diastereomer.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) <i>tert</i>-BuMgCl, THF, 5 °C, 1 h; (ii) HCl/CH<sub>3</sub>CN.</p></p></figure><div class="NLM_p last">Cyclophosphate prodrugs of guanosine analogues are known to demonstrate anti-HCV activity when tested in vitro and in vivo.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> We synthesized cyclophosphates <b>51–53</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) in one step by treatment of nucleoside <b>33</b> with the corresponding phosphodichloridate in the presence of <i>tert</i>-BuMgCl. Subsequent deprotection and isolation by silica chromatography yielded cyclophosphate prodrugs <b>51–53</b> as a mixture of isomers in moderate yields (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> X-ray Crystal Structure of Compound <b>42</b></h3><div class="NLM_p">The absolute stereochemistry of compound <b>42</b> (<b>AL-611</b>) was assigned by small-molecule X-ray crystallography, from a difraction data set with a resolution of 0.81 Å (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The chiralities of all stereocenters were confirmed as follows: P1 (<i>S</i>); C1 (<i>R</i>); C2 (<i>R</i>); C3 (<i>S</i>); C4 (<i>S</i>); C21 (<i>S</i>). Atom numbers of chiral centers are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Compound <b>42</b> is, unambiguosly, the <i>S</i>p isomer.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Inhibition of HCV NS5B Polymerase</h3><div class="NLM_p">To determine the inhibitory effect of nucleosides on HCV NS5B polymerase, the 5′-triphosphates of nucleosides <b>1–9</b> shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> were tested in an HCV polymerase assay. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, most of the NTPs demonstrated good inhibitory activity against HCV NS5B polymerase with IC<sub>50</sub> as low as 0.064 μM. Comparison of IC<sub>50</sub> values of 2′-<i>C</i>-methyl-GTP (<b>1-TP</b>) with its 4′-fluorinated analogue (<b>4-TP</b>) demonstrated increased potency for the 4′-fluorinated nucleotide (0.42 and 0.14 μM, respectively). 2′-Fluoro-2′-<i>C</i>-methyl-GTP (<b>2</b>-<b>TP</b>) and its 4′-fluorinated analogues (<b>6-TP</b>) demonstrated similar inhibition (0.099 and 0.16 μM, respectively). These data suggest that fluorination at the 4′-position does not alter inhibitory properties of compounds on NS5B. The replacement of the 2′-methyl (<b>4-TP</b> and <b>6-TP</b>) with a 2′-ethynyl group (<b>5-TP</b> and <b>7-TP</b>) appeared well tolerated with IC<sub>50</sub> values of 0.13–0.16 μM. Compound <b>3-TP</b> which has a 2′-α-chloro-2′-<i>C</i>-methyl substitution exhibited potent inhibition with an IC<sub>50</sub> value of 0.064 μM despite containing the larger Cl substituent. When fluorine was introduced at the 3′-position of <b>8-TP</b>, <b>9-TP</b>, and <b>10-TP</b>, measured inhibitory effects were lower than of the corresponding 3′-OH compounds <b>1-TP</b>, <b>2-TP</b>, and <b>3-TP</b>, suggesting that 3′-fluorination is not beneficial for inhibition of NS5B.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition of HCV Polymerase NS5B by Guanosine Triphosphates<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0014.gif" alt="" id="GRAPHIC-d7e1252-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">NTP</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> [μM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.099</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.064</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5-TP</b></td><td class="colsep0 rowsep0" align="left">CCH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7-TP</b></td><td class="colsep0 rowsep0" align="left">CCH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10-TP</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.76</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> indicates a concentration at which the activity of HCV NS5B polymerase is inhibited by 50%. Each IC<sub>50</sub> value is an average of <i>n</i> ≥ 2 determinations.</p></div></div></div><div class="NLM_p">To unravel the mechanism of action of 4′-fluorinated GTPs, <b>6-TP</b> was tested in a chain termination assay. We measured the incorporation of single nucleotides with fixed NS5B enzyme and RNA concentrations, using a polyacrylamide gel-based method, as previously described.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> We isolated the stable NS5B-RNA in the elongation mode and incubated this elongation complex (EC) with various combinations of nucleotides. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, when natural GTP is missing, the 10-mer EC cannot be further elongated (lane 1 and 2). When only GTP was added to the reaction, we observed the formation of the 11-mer product corresponding to single guanosine monophosphate incorporation (lane 3). When GTP, UTP, and ATP were added together to the reaction, we observed an expected 20-mer full-length RNA product (lane 4). Similarly, substituting natural GTP by 3′dGTP and <b>6-TP</b> supported the formation of a 11-mer product (lanes 5 and 7, respectively) but stopped further elongation to the full-length 20-mer product in the presence of UTP and ATP (lanes 6 and 8, respectively). Therefore, we concluded that incorporation of <b>6-TP</b> resulted in immediate chain termination.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Primer extension and chain termination with 6-TP. (A) Reaction scheme as described in Methods. (B) Reaction products shown on a sequencing gel. Lane 1, no NTP; lane 2, 10 μM ATP + 10 μM UTP; lane 3, 10 μM GTP; lane 4, 10 μM GTP + 10 μM ATP + 10 μM UTP; lane 5, 100 μM 3′dGTP; lane 6, 100 μM 3′dGTP + 10 μM ATP + 10 μM UTP; lane 7, 100 μM <b>6-TP</b>; lane 8, 100 μM <b>6-TP</b> + 10 μM ATP + 10 μM UTP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Inhibition of Human Polymerases</h3><div class="NLM_p">Host polymerases have been generally regarded as the primary off-targets for nucleoside analogues.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Association between HCV nucleoside inhibitors that interact with human mitochondrial DNA (hPolγ) and RNA (HMRP) polymerases and the observation of adverse events were reported.<a onclick="showRef(event, 'ref13 ref35'); return false;" href="javascript:void(0);" class="ref ref13 ref35">(13,35)</a> For assessment of the selectivity between viral and human polymerase inhibitions, selected NTPs from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were tested for inhibition of human DNA polymerases α, β, and γ as well as human RNA pol II.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The results are listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. None of the NTPs tested inhibited human DNA pol-β and human RNA pol II. However, <b>2-TP</b><a onclick="showRef(event, 'ref9 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref12">(9,12)</a> and <b>6-TP</b> showed appreciable inhibition of human DNA pol-α with 79 and 73% inhibition, respectively, at 100 μM. The inhibition by <b>2-TP</b> and <b>6-TP</b> might be caused by the replacement of 2′-OH with fluorine. Human DNA pol-α tolerated 2′-α-F nucleotide to a certain degree. Inhibition of human DNA pol-α by <b>2-TP</b> and <b>6-TP</b> and inhibition of human DNA pol-γ by <b>8-TP</b> should be noted. Inhibition of human DNA pol-γ by <b>8-TP</b> was higher (81%), <b>2-TP</b> and <b>6-TP</b> did not demonstrate any significant inhibition of hPolγ.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of Human Polymerases by Nucleoside Triphosphates</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">hPol-α</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">hPol-β</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">hPol-γ</th><th class="rowsep1 colsep0" align="center">hRNA pol II</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">NTP</th><th class="colsep0 rowsep0" align="center" char=".">% <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0c656264656e65786563624c3d3c3c">[email protected]</a> μM</th><th class="colsep0 rowsep0" align="center" char=".">standard deviation</th><th class="colsep0 rowsep0" align="center" char=".">% <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="7f161117161d160b1610113f4e4f4f">[email protected]</a> μM</th><th class="colsep0 rowsep0" align="center" char=".">standard deviation</th><th class="colsep0 rowsep0" align="center" char=".">% <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="30595e5859525944595f5e70010000">[email protected]</a> μM</th><th class="colsep0 rowsep0" align="center" char=".">standard deviation</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> [μM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1-Tp</b></td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td><td class="colsep0 rowsep0" align="char" char=".">15.3</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2-Tp</b></td><td class="colsep0 rowsep0" align="char" char=".">78.7</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">14.3</td><td class="colsep0 rowsep0" align="char" char=".">12.6</td><td class="colsep0 rowsep0" align="char" char=".">24.6</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3-Tp</b></td><td class="colsep0 rowsep0" align="char" char=".">36.0</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">21.1</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="char" char=".">38.4</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4-TP</b></td><td class="colsep0 rowsep0" align="char" char=".">36.0</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">20.9</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td><td class="colsep0 rowsep0" align="char" char=".">37.1</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6-TP</b></td><td class="colsep0 rowsep0" align="char" char=".">73.2</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="char" char=".">14.9</td><td class="colsep0 rowsep0" align="char" char=".">29.8</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8-TP</b></td><td class="colsep0 rowsep0" align="char" char=".">16.8</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char=".">81.0</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="center">>100</td></tr></tbody></table></div></div><div class="NLM_p">Six NTPs were tested in an assay investigating nucleotide incorporation by HMRP (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). <b>1-TP</b> (TP of INX-189’s parent nucleoside) was found to be incorporated significantly, which may have contributed to INX-189’s toxicity. The 4′-F analogue <b>4-TP</b> was able to reduce the incorporation, but the incorporation was still appreciable. When the 2′-OH was replaced by 2′-F, <b>2-TP</b><a onclick="showRef(event, 'ref9 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref12">(9,12)</a> could be incorporated but at a much lesser extent compared to <b>1-TP</b>. After introducing 4′-F to <b>2-TP</b>, the resulting <b>6-TP</b> was no longer the substrate of HMRP, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Replacing of 2′-OH with Cl resulted in <b>3-TP</b> which was significantly incorporated into the RNA, similar to <b>1-TP</b>. These results suggest that fluorine modification at the 2′ and 4′ positions disfavored the incorporation by HMRP. <b>8-TP</b> (3′-F-2′-<i>C</i>-Me GTP) was not a substrate of HMRP. Overall, the <b>6-TP</b> tested did not show any alarming inhibition of the human mitochondrial polymerases and low inhibition of DNA pol-α. However, the actual toxicity liability cannot be assessed until tested in animal studies and in human trials eventually. Based on the promising viral and human polymerase inhibition results, the nucleotide prodrugs of the 4′-F analogue <b>4–7</b> were evaluated in cell-based assays against HCV.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Incorporation of nucleotide by HMRP. Top, the RNA primer and the DNA template used in this assay. Bottom, nucleotide incorporation products shown on a sequencing gel. 100 μM nucleotide was used in each assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> HCV Replicon Activity</h3><div class="NLM_p">NTPs of 4′-fluorinated nucleosides <b>4–7</b> demonstrated similar inhibition of HCV polymerase NS5B. To compare their in vitro activity in an HCV subgenomic replicon system,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> we synthesized compounds <b>36–39</b>, phosphoramidate prodrugs of nucleosides <b>4</b>, <b>5</b>, <b>7</b>, and <b>6</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, 2′-ethynyl derivatives <b>36</b> and <b>38</b> demonstrated low antiviral activity and high cell toxicity. Prodrugs <b>37</b> and <b>39</b> of 2′-methyl nucleosides <b>4</b> and <b>6</b>, respectively, demonstrated comparable replicon activity and low toxicity. Considering that <b>6-TP</b> exhibited good inhibition of viral polymerase and was not a substrate of HMRP, we selected 2′,4′-difluoro-2′-<i>C</i>-methyl scaffold for prodrug development.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. HCV Replicon Activity of Phosphoroamidate Prodrugs of Nucleosides <b>4</b>, <b>5</b>, <b>6</b>, and <b>7</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0015.gif" alt="" id="GRAPHIC-d7e1858-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug</th><th class="colsep0 rowsep0" align="center" char=".">parent nucleoside</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> [μM]</th><th class="colsep0 rowsep0" align="center">CC<sub>50</sub> [μM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="."><b>5</b></td><td class="colsep0 rowsep0" align="left">CCH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="center">16.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="left">CCH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="center">3.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.066</td><td class="colsep0 rowsep0" align="center">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> indicates a concentration at which HCV replicon is inhibited by 50%. Each EC<sub>50</sub> value is an average of ≥2 independent determinations. CC<sub>50</sub> indicates a concentration of 50% cell viability.</p></div></div></div><div class="NLM_p">Several phosphoramidate prodrugs of nucleoside <b>6</b> shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> were synthesized and tested. INX-189 was used as a positive control. Compounds <b>39</b>, <b>40</b>, and <b>43–50</b> were tested as mixtures of diastereomers and showed activities ranging from 0.014 to 0.2 μM. Naphthalenyl-containing prodrugs <b>44</b>, <b>49</b>, and <b>50</b> were very potent (0.02–0.06 μM) but also showed significant cytotoxicity (56.9–80.5 μM). Increased lipophilicity of the ester moiety of <b>43</b>, <b>47</b>, and <b>48</b> also led to high activity in replicon assay. Prodrug <b>40</b> was selected for further investigation based on high selectivity index (SI > 7000) and taking into consideration that its phosphate moiety was proven to be not toxic.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Cyclophosphate prodrugs <b>51–53</b> did not show superior properties compared with phosphoramidates.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. HCV Replicon Activity of 2′,4′-Difluoro-2′-<i>C</i>-methylguanosine Phosphoroamidate Prodrugs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0016.gif" alt="" id="GRAPHIC-d7e2026-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug</th><th class="colsep0 rowsep0" align="center"><i>P</i>-chirality</th><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> [μM]</th><th class="colsep0 rowsep0" align="center">CC<sub>50</sub> [μM]</th><th class="colsep0 rowsep0" align="center">SI</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INX-189</td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.348</td><td class="colsep0 rowsep0" align="center">16.42</td><td class="colsep0 rowsep0" align="center">47.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">cyclohexyl</td><td class="colsep0 rowsep0" align="char" char=".">0.066</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>1500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b> (<b>41</b> + <b>42</b>)</td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>7000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">chiral, <i>R</i>p</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.057</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>1700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">chiral <i>S</i>p</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>20,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">neopentyl</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">naphthalen-1-yl</td><td class="colsep0 rowsep0" align="left">isobutyl</td><td class="colsep0 rowsep0" align="char" char=".">0.017</td><td class="colsep0 rowsep0" align="center">56.9</td><td class="colsep0 rowsep0" align="center">3000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isobutyl</td><td class="colsep0 rowsep0" align="char" char=".">0.042</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>2000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">Cyclopentyl</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="center">92.9</td><td class="colsep0 rowsep0" align="center">2700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">pentan-3-yl</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td><td class="colsep0 rowsep0" align="center">72.5</td><td class="colsep0 rowsep0" align="center">315</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">quinoline-5-yl</td><td class="colsep0 rowsep0" align="left">neopentyl</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">naphthalen-1-yl</td><td class="colsep0 rowsep0" align="left">neopentyl</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="center">39.6</td><td class="colsep0 rowsep0" align="center">660</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">naphthalen-1-yl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="center">80.5</td><td class="colsep0 rowsep0" align="center">4000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">322</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">isobutyl</td><td class="colsep0 rowsep0" align="char" char=".">1.34</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">achiral</td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">3000</td></tr></tbody></table></div></div><div class="NLM_p">Two stereoisomers of <b>40</b> were separated, and <b>41</b> and <b>42</b> were tested for replicon activity. <i>S</i>p-isomer <b>42</b> was 10 times more active than corresponding <i>R</i>p-isomer <b>41</b> (0.005 and 0.057 μM, respectively) with SI > 20,000. This <i>S</i>p-isomer <b>42</b> (<b>AL-611</b>) was selected for further evaluation.</div><div class="NLM_p">Prodrug <b>40</b> did not show any appreciable cytotoxicity in Huh-7 cells. To assess the potential cytotoxicity under more stringent conditions, this prodrug was tested in multiple cell lines for 8 days. The well-known toxic compound INX-189 was used as a control. Compound <b>40</b> demonstrated no measurable dose-dependent decreases in cell viability (CC<sub>50</sub> > 100 μM) across most cell lines except for U937 and MT-4 cells where the concentration causing 50% cellular death was 10 and 92 μM, respectively. In all cases, the cytotoxicity of compound <b>40</b> was significantly lower than that observed for INX-189 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Eight Day Cytotoxicity (CC<sub>50</sub> μM) of Compound <b>40</b> in Six Cell Lines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0017.gif" alt="" id="GRAPHIC-d7e2403-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">cytotoxic concentration causing 50% inhibition (CC<sub>50</sub>) μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound/cell line</td><td class="colsep0 rowsep0" align="left">Huh-7</td><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">HeLa</td><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="left">MT4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INX-189</td><td class="colsep0 rowsep0" align="left">0.35 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.07</td><td class="colsep0 rowsep0" align="left">7.8 ± 0.6</td><td class="colsep0 rowsep0" align="left">13.4 ± 1.7</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.96 ± 0.2</td></tr></tbody></table></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo and In Vitro NTP Formation</h3><div class="NLM_p">NTP levels in the target tissue are important for in vivo efficacy of an antiviral nucleoside polymerase inhibitor. In vitro NTP formation in appropriate cell lines may provide the first assessment for predicting the in vivo NTP concentration. To understand difference in the extent of in vitro activation of the individual diastereomers <b>41</b> and <b>42</b> and the isomeric mixture <b>40,</b> the in vitro NTP levels were measured in fresh primary human hepatocytes as the most relevant cell line. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, high levels of <b>6-TP</b> were formed in human hepatocytes following an incubation of <b>40</b>, <b>41</b>, and <b>42</b> at 50 μM extracellular concentration for 24 hours.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. NTP Formation In Vitro and In Vivo</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">compound</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">human hepatocytes (pmol/million cells) at 24 h</th><th class="rowsep1 colsep0" align="center" char=".">dog liver NTP (μM) at 4 h</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">NMP</th><th class="colsep0 rowsep0" align="center" char=".">NTP</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="char" char=".">271</td><td class="colsep0 rowsep0" align="char" char=".">11.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char=".">67.1</td><td class="colsep0 rowsep0" align="char" char=".">174</td><td class="colsep0 rowsep0" align="char" char=".">6.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="char" char=".">321</td><td class="colsep0 rowsep0" align="char" char=".">22.3</td></tr></tbody></table></div></div><div class="NLM_p">The experiment presented in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> was conducted to determine time-course and steady state of NTP formation. In human hepatocytes, the steady state (equilibrium between NTP formation and degradation) was typically reached between 2 and 16 h (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The decrease in NTP formation beyond 24–48 h is likely due to decline in function of fresh hepatocytes, a known phenomenon. Intracellular concentrations of <b>6-TP</b> were measured at multiple dose concentrations to determine dose-linearity of the NTP formation. <b>6-TP</b> Intracellular concentrations increased dose proportionally between 0.5 and 10 μM of <b>40</b> incubation concentrations (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) but was not observed at >10 μM. At incubation concentrations beyond 10 μM, the NTP levels increased in less than dose proportional manner.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Time course of intracellular NTP in primary human hepatocytes following an incubation with <b>40</b> at 10 μM for 2–72 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Intracellular NTP concentration as a function of extracellular concentration of compound <b>40</b> in primary human hepatocytes. Data were collected from hepatocytes from three different human donors and expressed as mean ± standard deviation. Each experiment was conducted with 24 h of incubation of <b>40</b> with hepatocytes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following a 24 h incubation of <b>40</b> (∼1:1 mixture of <b>41</b> and <b>42</b>) in human hepatocytes, high concentrations of NTP were formed. Once formed and after the removal of <b>40</b> from the incubation media, NTP levels were maintained for 6 h before degradation (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The mean intracellular half-life of the NTP was estimated to be 11.2 ± 0.7 h (<i>n</i> = 3) in human hepatocytes.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Intracellular NTP concentration as a function of time in primary human hepatocytes following an initial 24 h incubation with <b>40</b> at 50 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In vivo NTP formation was evaluated in beagle dogs following a single oral administration of <b>40</b>, <b>41</b>, and <b>42</b> at 9.69 mg/kg (5 mg/kg parent nucleoside equivalent dose). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, liver NTP concentrations were 11.2, 6.3, and 22.3 μM at 4 h post dose of <b>40</b>, <b>41</b>, and <b>42</b>, respectively.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We demonstrated that guanosine nucleoside with properly modified ribose moiety can exhibit potent HCV replicon activity and acceptable safety properties. 5′-Triphosphates of 4′-fluorinated guanosine derivatives demonstrated potent inhibition in the HCV polymerase NS5B assay with IC<sub>50</sub> values as low as 0.13 μM. The 5′-triphosphate of 2′,4′-difluoro-2′-<i>C</i>-methyl-guanosine (<b>6-TP</b>) exhibited IC<sub>50</sub> 0.16 μM and was confirmed to be a chain terminator in a chain elongation assay using the HCV NS5B polymerase and showed no inhibition of human DNA polymerases β and γ as well as human RNA pol II while inhibition of human DNA polymerases α was low. Phosphoramidate prodrug of this nucleoside exhibited very potent HCV subgenomic replicon activity with EC<sub>50</sub> values as low as 5 nM.</div><div class="NLM_p last">The <i>S</i>p-diastereomer prodrug <b>42</b> (<b>AL-611</b>) was selected for preclinical toxicology studies based on the biochemical potency of <b>6-TP</b> combined with its good in vitro safety profile, corresponding in vivo NTP formation, and cell-based replicon potency. Compound was selected as a drug candidate but given the effectiveness of already approved therapies for HCV, a decision was taken to discontinue further development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All commercially obtained solvents and reagents were used as received. All solvents used for chemical reactions were of anhydrous grade, unless specifically indicated. Structures of the target compounds in this work were assigned by use of NMR and mass spectrometry (MS) spectroscopy. The purities of parent nucleosides and prodrugs were >95% as determined on an Agilent 1200 HPLC, Phenomenex, Synergi 4 μm Hydro RP 80 Å 150 × 4.6 mm, flow 1.5 mL/min using 0.5% HCOOH in water and 0.5% HCOOH in CH<sub>3</sub>CN as the mobile phase or 50 mM triethylammonium acetate (TEAA) in water and 50 mM TEAA in CH<sub>3</sub>CN as the mobile phase. The purities of triphosphates were >95% determined on the same column using linear gradient of CH<sub>3</sub>CN from 0 to 25% in 50 mM TEAA buffer (pH 7.5). <sup>1</sup>H-, <sup>19</sup>F-, and <sup>13</sup>C NMR spectra were recorded on a Bruker ADVANCE III (400 MHz) or a Varian 400MR (400 MHz) NMR spectrometer. Chemical shifts are reported in parts per million (ppm, δ) using residual solvent line as an internal reference. Splitting patterns are reported as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), or broad singlet (br s). Coupling constants (<i>J</i>) are reported in hertz (Hz). Mass spectrometric analyses for nucleosides were performed on an Agilent 1200 HPLC with Agilent 6110/6140/1956C MSD mass spectrometer using ESI as ionization. Work-up procedures for most of chemical reactions are the same or similar; therefore, unless specifically indicated, the work-up refers to the following procedure: the reaction mixture at 0 °C is quenched with water, diluted with EtOAc or dichloromethane (DCM), washed with 5% sodium bicarbonate and then with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. Purification on silica gel refers to flash chromatography on a silica gel column.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 5′-Deoxy-5′-iodo-2′-<i>C</i>-methyl-<i>N</i><sup><b>2</b></sup>-(methoxytrityl)guanosine (<b>12a</b>)</h3><div class="NLM_p last">TsCl (3.43 g, 17.5 mmol) was added to the cold solution of <b>11a</b> (5 g, 8.8 mmol) in pyridine (15 mL). The reaction mixture was stirred for 1 h at 0 °C and quenched with water. After usual work-up and without further purification, 5′-tosyl intermediate (6.3 g) was dissolved in acetone (60 mL) and treated with NaI (13.2 g, 88 mmol) overnight at reflux temperature. The reaction mixture was quenched with aq Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. After usual work-up and column chromatography (MeOH in DCM from 1 to 6%), nucleoside <b>12a</b> (2.4 g, 41%) was obtained as a white solid. MS, <i>m</i>/<i>z</i> 680.3 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.14 (s, 1H), 7.18–7.35 (m, 12H), 6.83–6.85 (m, 2H), 5.52 (s, 1H), 3.86–3.96 (m, 3H), 3.74 (s, 3H), 3.70–3.76 (m, 1H), 0.53 (s, 3H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 5′-Deoxy-5′-iodo-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>12b</b>)</h3><div class="NLM_p last">Compound <b>12b</b> (4 g, 52%) as a white solid was synthesized from 6.3 g of <b>11b</b> the same way as <b>12a</b>. MS, <i>m</i>/<i>z</i> 690.3 (M + 1)<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 5′-Deoxy-5′-iodo-2′-fluoro-2′-<i>C</i>-methyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>12c</b>)</h3><div class="NLM_p last">Compound <b>12c</b> (2.4 g, 41%) as a white solid was synthesized from 5.0 g of <b>11c</b> the same way as <b>12a</b>. MS, <i>m</i>/<i>z</i> 682.4 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.16–7.59 (m, 13H), 6.71–6.73 (m, 2H), 5.56 (d, <i>J</i> = 18.8 Hz, 1H), 3.25–4.07 (m, 7H), 0.64 (d, <i>J</i> = 22.4 Hz, 3H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5′-Deoxy-5′-iodo-2′-fluoro-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>12d</b>)</h3><div class="NLM_p last">To a solution of compound <b>11d</b> (3.1 g, 5.3 mmol) in dry THF (80 mL) at 0 °C ware added PPh<sub>3</sub> (2.8 g, 10.6 mmol) and imidazole (720 mg, 10.6 mmol) and stirred for 30 min. To this mixture was added the solution of I<sub>2</sub> (2.0 g, 8.0 mmol) in dry THF (10 mL) at 0 °C and stirred at rt for 18 h. The reaction was quenched with sat. aq Na<sub>2</sub>SO<sub>3</sub> (10 mL) and extracted with DCM (2 × 100 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and filtered. Evaporated residue was purified by silica gel chromatography (MeOH in DCM from 1 to 4%) to give <b>12d</b> (3.6 g, 90%) as a yellow solid. MS, <i>m</i>/<i>z</i> 692 (M + 1)<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4′,5′-Didehydro-5′-deoxy-2′-<i>C</i>-methyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>13a</b>)</h3><div class="NLM_p last">To the solution of iodide <b>12a</b> (11.5 g, 16.9 mmol) in dry THF (120 mL) was added DBU (12.87 g, 84.7 mmol) and heated overnight at 60 °C. The reaction was quenched with saturated NH<sub>4</sub>Cl solution. Usual work-up and chromatography (MeOH in DCM from 1 to 5%) yielded compound <b>13a</b> (5.5 g, 60%) as a white solid. MS, <i>m</i>/<i>z</i> 552.3 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.47 (s, 1H), 7.22–7.34 (m, 12H), 6.83–6.85 (m, 2H), 5.39 (s, 1H), 4.47 (s, 1H), 4.46 (s, 1H), 4.24 (s, 1H), 3.76 (s, 3H), 0.63 (s, 3H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4′,5′-Didehydro-5′-deoxy-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>13b</b>)</h3><div class="NLM_p last">Compound <b>13b</b> (2.0 g, 62%) as a white solid was synthesized from 4.0 g of <b>12b</b> in the same manner as <b>13a</b>. MS, <i>m</i>/<i>z</i> 602.2 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.65 (s, 1H), 7.18–7.34 (m, 12H), 6.82–6.86 (m, 2H), 5.52 (s, 1H), 4.70 (t, <i>J</i> = 1.8 Hz, 1H), 4.46 (t, <i>J</i> = 2.2 Hz, 1H), 4.27 (t, <i>J</i> = 1.8 Hz, 1H), 3.76 (s, 3H), 2.80 (s, 1H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 4′,5′-Didehydro-2′,5′-dideoxy-2′-fluoro-2′-<i>C</i>-methyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>13c</b>)</h3><div class="NLM_p last">Compound <b>13c</b> (1.9 g, 67%) was obtained from <b>12c</b> using the same procedure as for the compound <b>13a</b>. MS, <i>m</i>/<i>z</i> 554.4 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.12–7.32 (m, 13H), 6.71–6.73 (m, 2H), 5.56 (d, <i>J</i> = 14.8 Hz, 1H), 4.40–4.62 (m, 3H), 3.71 (s, 3H), 0.75 (d, <i>J</i> = 22.4 Hz, 3H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4′,5′-Didehydro-2′,5′-dideoxy-2′-fluoro-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>13d</b>)</h3><div class="NLM_p last">Compound <b>13d</b> (3.0 g, 83%) was obtained as a yellow solid from 4.4 g of <b>12d</b> using the same procedure as for the compound <b>13a</b>. MS, <i>m</i>/<i>z</i> 564 (M + 1)<sup>+</sup>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 2′5′-Dideoxy-2′,4′-difluoro-5′-iodo-2′-<i>C</i>-methyl-3′-<i>O</i>-benzoyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>15c</b>)</h3><div class="NLM_p last">To the ice-cold solution of <b>13c</b> (3.0 g, 5.4 mmol) in CH<sub>3</sub>CN (20 mL) was added Et<sub>3</sub>N·3HF (0.65 g, 4.1 mmol) followed by NIS (1.53 g, 6.78 mmol). The reaction mixture was kept at rt for 2 h. After usual work-up, C-4′ stereoisomers were separated by RP-HPLC (Waters X-bridge column 150 × 25 mm, 5 μm; gradient of 0.1% NH<sub>4</sub>HCO<sub>3</sub> in water and in CH<sub>3</sub>CN from 0 to 70%). To the solution of desired <i>R</i>-isomer <b>14c</b> (0.6 g, 0.9 mmol) in pyridine (10 mL) was added BzCl (145 mg, 1 mmol) and kept at rt for 3 h. After usual work-up and chromatography (25% to 50% EtOAc in hexane), compound <b>15c</b> (0.55 g, 13% for two steps) was isolated as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.08 (s, 1H), 7.10–7.97 (m, 17H), 6.70–6.72 (m, 2H), 5.86 (d, <i>J</i> = 17.2 Hz, 1H), 3.49–3.68 (m, 6H), 0.84 (d, <i>J</i> = 22.4 Hz, 3H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4′-Fluoro-2′,3′,5′-tri-<i>O</i>-benzoyl-2′-<i>C</i>-methyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>16a</b>)</h3><div class="NLM_p last">To an ice-cold solution of <b>13a</b> (2 g, 3.6 mmol) in DCM (80 mL) was added AgF (2.5 g, 20 mmol) and solution of I<sub>2</sub> (2 g, 8 mmol) in DCM (80 mL). The reaction mixture was stirred at rt for 3 h. The reaction mixture was quenched with solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and NaHCO<sub>3</sub>. After usual work-up, the crude 4′-fluorinated nucleoside <b>14a</b> (1.7 g) was dissolved in DCM (250 mL). 4-(Dimethylamino)pyridine (DMAP) (1.1 g, 9.6 mmol) was added, followed by Et<sub>3</sub>N (1.4 mL, 9.6 mmol) and BzCl (0.8 mL, 7.2 mmol). The reaction mixture was kept at rt overnight. After usual work-up and chromatography (3% MeOH in DCM), benzoate <b>15a</b> (1.5 g, 2 mmol) was isolated. It was dissolved in HMPA (40 mL), and NaOBz (7.2 g, 20 mmol) and 15-crown-5 (4.1 g, 20 mmol) were added and the mixture was stirred for 48 h at 60 °C. Usual work-up and chromatography (50% EtOAc in hexane) yielded 480 mg of <b>16a</b> (15% yield for 3 steps). MS, <i>m</i>/<i>z</i> 900.4 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.81–7.95 (m, 7H), 7.60–7.66 (m, 8H), 7.39–7.51 (m, 2H), 7.19–7.31 (m, 13H), 6.36 (s, 1H), 5.95 (d, <i>J</i> = 18 Hz, 1H), 4.50–4.70 (m, 2H), 3.72 (s, 3H), 1.41 (s, 3H).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4′-Fluoro-2′,3′,5′-tri-<i>O</i>-benzoyl-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>16b</b>)</h3><div class="NLM_p last">Compound <b>16b</b> (180 mg) was synthesized in 6% yield (for 3 steps) from <b>13b</b> by the sequence of transformations described above for <b>16a</b>. MS, <i>m</i>/<i>z</i> 910.4 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.83–7.93 (m, 7H), 7.19–7.83 (m, 21H), 6.76–6.78 (m, 2H), 6.36 (s, 1H), 5.92–5.97 (m, 1H), 4.50–4.70 (m, 2H), 3.72 (s, 3H), 1.40 (s, 3H).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 2′-Deoxy-2′,4′-difluoro-2′,3′,5′-tri-<i>O</i>-benzoyl-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>16d</b>)</h3><div class="NLM_p last">Compound <b>16d</b> was synthesized from <b>13d</b> by the sequence of transformations described for <b>16a</b>. The yield was 430 mg, 11% for 3 steps. MS, <i>m</i>/<i>z</i> 808 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 6.80–7.78 (m, 27H), 6.22 (d, <i>J</i> = 14.8 Hz, 1H), 4.30 (t, <i>J</i> = 9.2 Hz, 1H), 3.70 (s, 3H), 2.42 (d, <i>J</i> = 5.6 Hz, 1H).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4′-Fluoro-2′-<i>C</i>-methyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>17a</b>)</h3><div class="NLM_p last">The mixture of protected nucleoside <b>16a</b> (400 mg, 0.44 mmol) and <i>n</i>-butylamine (1.5 mL) was kept overnight at rt and then evaporated. The residue was purified by chromatography (MeOH in DCM from 4 to 15%) to yield 206 mg (80%) of the target <b>17a</b>. MS, <i>m</i>/<i>z</i> 586 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.01 (s, 1H), 7.24–7.34 (m, 12H) 6.84–6.86 (m, 2H), 5.54 (s, 1H), 4.09 (d, <i>J</i> = 24.0 Hz, 1H), 3.76 (s, 3H), 3.64–3.73 (m, 2H), 0.59 (s, 3H). <sup>19</sup>F NMR (CD<sub>3</sub>OD): δ −123.24.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4′-Fluoro-2′-<i>C</i>-ethynyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>17b</b>)</h3><div class="NLM_p last">Compound <b>17b</b> (100 mg, 86%) was obtained from <b>16b</b> using the same procedure as for the compound <b>17a</b>. MS, <i>m</i>/<i>z</i> 598 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.89 (s, 1H), 7.18–7.35 (m, 12H), 6.83–6.87 (m, 2H), 5.64 (s, 1H), 4.45–4.58 (m, 1H), 3.76 (s, 3H), 3.62–3.70 (m, 2H), 2.69 (s, 1H).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 2′-Deoxy-2′,4′-difluoro-2′-<i>C</i>-methyl-<i>N</i><sup>2</sup>-(methoxytrityl)guanosine (<b>17c</b>)</h3><div class="NLM_p last">Solution of <b>15c</b> (0.65 g, 0.8 mmol), NaOBz (1.15 g, 8 mmol), and 15-crown-5 (1.77 g, 8 mmol) in dimethylformamide (DMF) (10 mL) was stirred for 48 h at 100 °C. Usual work-up and chromatography (15–50% EtOAc in hexane) yielded 500 mg of <b>16c</b>. Obtained nucleoside was treated with NH<sub>3</sub>/MeOH (50 mL) for 18 h at rt. Solvent was evaporated, and the residue was purified by chromatography (MeOH in DCM from 1 to 4%) to give <b>17c</b> as a white solid. Yield: 231 mg (49% for 2 steps). MS, <i>m</i>/<i>z</i> 590.3 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.93 (s, 1H), 7.22–7.31 (m, 12H), 6.83–6.85 (m, 2H), 5.65 (d, <i>J</i> = 16.0 Hz, 1H), 4.21–4.30 (m, 1H), 3.71–3.77 (m, 5H), 0.75 (d, <i>J</i> = 24.0 Hz, 3H). <sup>19</sup>F NMR (CD<sub>3</sub>OD): δ −125.1, −162.4.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4′-Fluoro-2′-<i>C</i>-methylguanosine (<b>4</b>)</h3><div class="NLM_p last">A solution of <b>17a</b> (261 mg, 0.44 mmol) in CH<sub>3</sub>CN (0.5 mL) and 4 N HCl/dioxane (0.05 mL) was kept at rt for 45 min and then evaporated. The crude residue was treated with CH<sub>3</sub>CN, precipitate was filtered, washed with CH<sub>3</sub>CN, and dried to yield <b>4</b> (112 mg, 80%). MS, <i>m</i>/<i>z</i> 314.6 (M – 1)<sup>−</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 9.00 (s, 1H), 6.23 (s, 1H), 4.44 (d, <i>J</i> = 19.5 Hz, 1H), 3.75–3.81 (m, 2H), 1.05 (s, 3H). <sup>19</sup>F NMR (CD<sub>3</sub>OD): δ −123.40.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4′-Fluoro-2′-<i>C</i>-ethynylylguanosine (<b>5</b>)</h3><div class="NLM_p last">Compound <b>5</b> was synthesized as described for <b>4</b> starting from <b>17b</b>. Yield: 104 mg (73%). MS, <i>m</i>/<i>z</i> 326.6 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.96 (s, 1H), 6.29 (s, 1H), 4.75 (d, <i>J</i> = 18.4 Hz, 1H), 3.79 (m, 2H), 2.80 (s, 1H). <sup>19</sup>F (DMSO-<i>d</i><sub>6</sub>): δ −124.24.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2′-Deoxy-2′,4′-difluoro-2′-<i>C</i>-methylguanosine (<b>6</b>)</h3><div class="NLM_p last">Compound <b>6</b> was synthesized as described for <b>4</b> starting from <b>17c</b>. Yield: 70 mg (81%). MS, <i>m</i>/<i>z</i> 317.6 (M – 1)<sup>−</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 11.08 (s, 1H), 8.16 (s, 1H), 6.87 (br, 2H), 6.28 (d, <i>J</i> = 1.6 Hz, 1H), 4.41 (d, <i>J</i> = 2.2 Hz, 1H), 3.70–3.63 (m, 2H), 1.05 (d, <i>J</i> = 2.3 Hz, 3H). <sup>19</sup>F NMR (DMSO-<i>d</i><sub>6</sub>): δ −122.0, −158.1; <sup>13</sup>C (DMSO-<i>d</i><sub>6</sub>): δ 156.6, 154.0, 150.7, 134.3, 116.6, 116.6 (d, <i>J</i> = 233 Hz), 98.6 (d, <i>J</i> = 184 Hz), 88.8 (d, <i>J</i> = 43 Hz), 71.3, 59.4 (d, <i>J</i> = 40 Hz), 17.2 (d, <i>J</i> = 25 Hz).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2′-Deoxy-2′,4′-difluoro-2′-<i>C</i>-ethynylguanosine (<b>7</b>)</h3><div class="NLM_p last">The mixture of protected nucleoside <b>16d</b> (430 mg, 0.47 mmol) and <i>n</i>-butylamine (1.5 mL) was kept overnight at rt and then evaporated yielding <b>17d</b>. The solution of crude <b>17d</b> in CH<sub>3</sub>CN (0.5 mL) and 4 N HCl/dioxane (0.05 mL) was kept at rt for 45 min and then evaporated. The crude residue was treated with CH<sub>3</sub>CN, precipitate was filtered, washed with CH<sub>3</sub>CN, and dried to yield <b>7</b> (60 mg, 36%). MS, <i>m</i>/<i>z</i> 326.5 (M – 1)<sup>−</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.75 (s, 1H), 7.79 (s, 1H), 6.60 (s, 2H), 6.36 (d, <i>J</i> = 8.0 Hz, 1H), 5.71 (br, 1H), 4.8 (br, 1H), 3.69–3.62 (m, 2H), 3.00–2.70 (m, 1H). <sup>19</sup>F NMR (DMSO-<i>d</i><sub>6</sub>): δ −122.0, −158.1. <sup>13</sup>C (DMSO-<i>d</i><sub>6</sub>): δ 156.5, 153.9, 150.9, 134.2, 116.4, 116.3 (d, <i>J</i> = 235 Hz), 93.2 (d, <i>J</i> = 186 Hz), 88.1 (d, <i>J</i> = 42 Hz), 82.7 (d, <i>J</i> = 8 Hz), 75.2 (d, <i>J</i> = 31 Hz), 73.5 (d, <i>J</i> = 20 Hz), 59.4 (d, <i>J</i> = 39 Hz).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 9-(2-<i>O</i>-Benzoyl-5-<i>O</i>-benzyl-3-deoxy-3-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-aminopurine (<b>19</b>)</h3><div class="NLM_p last">To a solution of 6-chloro-9<i>H</i>-purin-2-amine (9.4 g, 55.4 mmol) in CH<sub>3</sub>CN (100 mL) was added <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (33.8 g, 166.2 mmol). The resulting solution was stirred for 2 h at 80 °C. To this reaction mixture was added a solution of compound <b>18</b> (10 g, 27.8 mmol) in CH<sub>3</sub>CN (100 mL) and trimethylsilyl trifluoromethanesulfonate (25 g, 112.6 mmol) at 0 °C. The resulting solution was let to react overnight at 80 °C. Usual work-up and chromatography (50% EtOAc in hexanes) yielded nucleoside <b>19</b> as a white solid (10 g, 72%). MS, <i>m</i>/<i>z</i> 498 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.2–8.50 (m, 3H), 7.54–7.61 (m, 1H), 7.33–7.51 (m, 7H), 6.46 (d, <i>J</i> = 7.6 Hz, 1H), 5.96–6.04 (m, 1H), 5.58–5.59 (m, 1H), 5.36–5.46 (m, 2H), 4.57–4.71 (m, 3H), 3.71–3.84 (m, 2H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −197.52.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 9-(5-<i>O</i>-Benzyl-3-deoxy-3-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-(tritylamino)purine (<b>20</b>)</h3><div class="NLM_p last">To a solution of nucleoside <b>19</b> (3 g, 6 mmol) in DMF (50 mL) was added triethylamine (3.4 mL, 24.0 mmol), DMAP (298 mg, 2.4 mmol), and chlorotriphenylmethane (5.5 g, 20 mmol). The resulting solution was stirred for 24 h at 45 °C. The reaction was then quenched with MeOH (20 mL) and concentrated under vacuum. The residue was purified by column chromatography (35% EtOAc in hexanes) to get 3.6 g (81%) of N-tritylated nucleoside as a white solid. MS, <i>m</i>/<i>z</i> 740 (M + 1)<sup>+</sup>. Obtained nucleoside (3.0 g, 3.9 mmol) in methanolic ammonia (60 mL) was stirred for 4 h at rt. Evaporated residue was purified by column chromatography (50% EtOAc in hexanes) to yield compound <b>20</b> (2.0 g 78%) as a white solid MS, <i>m</i>/<i>z</i> 636.3 (M + 1)<sup>+</sup>.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 9-(5-<i>O</i>-Benzyl-3-deoxy-3-fluoro-2-oxo-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-(tritylamino)purine (<b>21</b>)</h3><div class="NLM_p last">To a solution of compound <b>20</b> (2.0 g, 3.0 mmol) in DCM (20 mL) were added iodobenzene diacetate (1.3 g, 4.0 mmol) and acetic acid (2 mL). It was followed by dropwise addition of a solution of TEMPO (0.15 g, 0.9 mmol) in DCM (5 mL) at 0 °C. The resulting solution was stirred for 16 h at rt then diluted with DCM (40 mL) and quenched with solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was crystallized from DCM/heptane (1:1 v/v) to yield ketone <b>21</b> (2.0 g, 100%) as a red solid. MS, <i>m</i>/<i>z</i> 652.9 (M + 1 + H<sub>2</sub>O)<sup>+</sup>.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 9-(5-<i>O</i>-Benzyl-2,3-dideoxy-2,3-difluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-aminopurine (<b>22</b>)</h3><div class="NLM_p last">To a solution of methylmagnesium bromide (3 M in ethyl ether, 10.5 mL) was added a solution of compound <b>21</b> (1.0 g, 1.6 mmol) in THF (7 mL) dropwise with stirring at −78 °C. The resulting solution was stirred for 2 h at −30 °C and then quenched with sat. aq NH<sub>4</sub>Cl (20 mL). Usual work-up and column chromatography purification (50% EtOAc in hexanes) yielded 206 mg (20%) of 2′-methylated nucleoside as yellow oil. MS, <i>m</i>/<i>z</i> 650 (M + 1)<sup>+</sup>. DAST (102 mg, 0.63 mmol) was added dropwise to the solution of obtained nucleoside in DCM (10 mL) at −78 °C. The resulting solution was stirred for 2 h at rt and then quenched with aq NaHCO<sub>3</sub>. Usual work-up and column chromatography purification (25% EtOAc in hexanes) yielded 2′-fluorinated nucleoside (45 mg, 22%) as a white solid. MS, <i>m</i>/<i>z</i> 652 (M + 1)<sup>+</sup>. A mixture of obtained nucleoside in MeOH (0.34 mL) was treated with AcOH (0.30 mL) for 12 h at 50 °C. Solvent was concentrated, and the residue was purified by silica gel chromatography (50% EtOAc in hexanes) to yield compound <b>22</b> (29 mg, 98%) as yellow oil. MS, <i>m</i>/<i>z</i> 410 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.32 (s, 1H), 7.28–7.41 (m, 5H), 6.20 (d, <i>J</i> = 16.8 Hz, 1H), 5.52 (s, 2H), 5.15–5.46 (m, 1H), 4.63–4.71 (m, 2H), 4.43–4.49 (m, 1H), 3.96–3.99 (m, 1H), 3.76–3.82 (m, 1H), 1.22–1.34 (m, 3H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −163.92, −221.81.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2′,3′-Dideoxy-2′,3′-difluoro-2′-<i>C</i>-methylguanosine (<b>9</b>)</h3><div class="NLM_p last">To a solution of compound <b>22</b> (25 mg, 0.06 mmol) in MeOH (2 mL) were added 2-mercaptoethanol (23.8 mg, 0.30 mmol) and sodium methylate (16.5 mg, 0.31 mmol). The resulting solution was stirred for 12 h at 65 °C. The pH value was adjusted to 7 with AcOH, and the solution was concentrated. Residue was purified by silica gel chromatography (10% MeOH in DCM) to yield 5-benzylated guanosine analogue (29 mg) as a white solid. MS, <i>m</i>/<i>z</i> 392 (M + H)<sup>+</sup>. A solution of obtained compound in DCM (0.5 mL) was cooled down to −78 °C. BCl<sub>3</sub> (1 M in heptane, 1 mL) was added, and the reaction mixture was left for 0.5 h at the same temperature. Reaction was quenched with MeOH, and the mixture was concentrated. The crude product was purified by Prep-HPLC (XBridge BEH Phenyl OBD Prep column, 19 × 150 mm) using 10–25% CH<sub>3</sub>CN in 10 mmol aq NH<sub>4</sub>HCO<sub>3</sub> for elution. Difluoronucleoside <b>9</b> (10 mg, 55%) was isolated as a white solid. MS, <i>m</i>/<i>z</i> 302.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.06 (s, 1H), 6.12–6.18 (m, 1H), 5.33–5.53 (m, 1H), 4.30 (m, 1H), 4.01–4.05 (m, 1H), 3.87–3.91 (m, 1H), 1.20 (d, <i>J</i> = 22.4 Hz, 3H), <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −163.03, −222.52. <sup>13</sup>C (DMSO-<i>d</i><sub>6</sub>): δ 156.7, 154.0, 150.5, 135.5, 116.8, 99.2 (dd, <i>J</i> = 183, 13 Hz), 89.9 (dd, <i>J</i> = 194, 15 Hz), 87.3 (dd, <i>J</i> = 38, 4 Hz), 59.6, 16.4 (d, <i>J</i> = 25 Hz).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 9-(5-<i>O</i>-Benzyl-2,3-dideoxy-3-fluoro-2-<i>C</i>-methylene-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-(acetylamino)purine (<b>23</b>)</h3><div class="NLM_p last">To a solution of methyltriphenylphosphonium bromide (28.2 g, 78.3 mmol) in THF (400 mL) under an inert atmosphere was added lithium bis(trimethylsilyl)amide (79 mL, 1 M in THF) dropwise with stirring at 0 °C. The resulting solution was stirred for 2 h at rt and then cooled to 0 °C. THF solution of ketone <b>21</b> (20 g, 31.5 mmol) was added. The resulting mixture was left for 4 h at rt. Reaction was quenched with sat. aq NH<sub>4</sub>Cl. Usual work-up and column chromatography purification (30% EtOAc in hexanes) yielded 2′-methylene derivative (6.8 g, 34%) as a yellow solid. MS, <i>m</i>/<i>z</i> 632 (M + H)<sup>+</sup>. Methanolic solution of this nucleoside was treated with AcOH (51 mL) for 16 h at 50 °C. Solvents were evaporated, and detritylated nucleoside was purified by silica gel chromatography (30% EtOAc in hexanes) to get 2.5 g (60%) of white solid. The obtained nucleoside was dissolved in pyridine (50 mL) and DCM (100 mL). AcCl (1.45 g, 18.5 mmol) was added dropwise, and the reaction mixture was kept at rt for 1 h. Reaction was quenched with MeOH and solvents were evaporated. Product was purified by silica gel chromatography (50% EtOAc in hexanes) to yield nucleoside <b>23</b> (1.8 g, 65%) as a white solid. MS, <i>m</i>/<i>z</i> 432 (M + 1)<sup>+</sup>.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 9-(5-<i>O</i>-Benzyl-2-chloro-2,3-dideoxy-3-fluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-(acetylamino)purine (<b>25</b>)</h3><div class="NLM_p last">To a solution of compound <b>23</b> (570 mg, 1.32 mmol) in dioxane (15 mL) under an inert atmosphere was added reagent <b>24</b> (24 mg, 0.04 mmol) and 4-toluene sulfonyl chloride (5.0 g, 26.23 mmol). The resulting solution was stirred for 1.5 h at 30 °C followed by dropwise addition of a solution of phenylsilane (143 mg, 1.32 mmol) in EtOH (10 mL). The resulting solution was kept for an additional 1 h at 30 °C. Solvents were evaporated, and the product was purified by silica gel chromatography (25% EtOAc in hexanes) to get nucleoside <b>25</b> (180 mg, 29%) as a yellow solid. MS, <i>m</i>/<i>z</i> 468.1 (M + 1)<sup>+</sup>.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 9-(2,3-Dideoxy-2-chloro-3-fluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-chloro-2-(acetylamino)purine (<b>26</b>)</h3><div class="NLM_p last">To a solution of compound <b>25</b> (60 mg, 0.13 mmol) in DCM (1.5 mL) under an inert atmosphere was added boron trichloride (1.2 mL, 1 M in hexane) dropwise at −78 °C. The resulting solution was stirred for 2 h at −78 °C and 3 h at −30 °C. The reaction was then quenched by the addition of MeOH/DCM (1.5 mL, 1/1). The resulting mixture was concentrated under reduced pressure to dryness to yield 45 mg of compound <b>26</b> which was used without purification for further reaction. MS, <i>m</i>/<i>z</i> 378.2 (M + 1)<sup>+</sup>.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2′,3′-Dideoxy-2′-chloro-3′-fluoro-2′-<i>C</i>-methylguanosine (<b>10</b>)</h3><div class="NLM_p last">To a solution of nucleoside <b>26</b> (200 mg, 0.53 mmol) in MeOH (20 mL) was added 2-mercaptoethanol (206 mg, 2.64 mmol) and NaOMe (476 mg, 30% in MeOH). The resulting solution was stirred for 3 h at 60 °C. The pH value of the solution was adjusted to 7 with acetic acid. The resulting mixture was concentrated and purified by Prep-HPLC (SunFire C18 OBD Prep Column, 19 × 100 mm; 15–35% MeCN in water). Guanosine <b>10</b> (44 mg, 26%) was isolated as a white solid. MS, <i>m</i>/<i>z</i> 318.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.16 (s, 1H), 6.33 (s, 1H), 5.46–5.25 (m, 1H), 4.28–4.37 (m, 1H), 3.94–4.03 (m, 1H), 3.78–3.88 (m, 1H), 1.40 (s, 3H). <sup>19</sup>F NMR (CD<sub>3</sub>OD): δ −208.26. <sup>13</sup>C (DMSO-<i>d</i><sub>6</sub>): δ 156.7, 154.0, 150.7, 135.2, 116.5, 91.0 (d, <i>J</i> = 196 Hz), 89.8 (d, <i>J</i> = 4 Hz), 80.6 (d, <i>J</i> = 22 Hz), 73.9 (d, <i>J</i> = 14 Hz), 59.2, 22.3.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 9-(2-Deoxy-2-fluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)-purine (<b>28</b>)</h3><div class="NLM_p last">To a solution of compound <b>27</b> (12.5 g, 23.8 mmol) in DCM (50 mL) were added AgNO<sub>3</sub> (8.1 g, 47.6 mmol), collidine (5.8 g, 47.6 mmol), and MMTrCl (11 g, 35.6 mmol). The reaction mixture was kept at rt overnight, quenched with MeOH, and filtered. Solvents were evaporated, and the residue was purified by column chromatography (5% MeOH in DCM) to get 16 g (84%) of N-tritylated nucleoside. A solution of this product in EtOH (150 mL) was treated with NaOEt (50 mL, 2 N in ethanol) at 0 °C. Resulting reaction mixture was kept at rt for 1 h. The pH was then adjusted to 7 with conc aq NH<sub>4</sub>Cl. Usual work-up and column chromatography purification (5% MeOH in DCM) afforded 10.9 g (98%) of nucleoside <b>28</b>. MS, <i>m</i>/<i>z</i> 600.5 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.13 (s, 1H), 7.51 (s, 1H), 7.15–7.30 (m 13H), 6.80 (m, 2H), 5.61 (d, <i>J</i> = 7.2 Hz, 1H), 5.25 (t, <i>J</i> = 5.0 Hz, 1H), 4.05 (br, 2H), 3.80 (m, 2H), 3.68 (s, 3H), 3.61 (m, 1H) 1.15 (br, 3H), 0.75 (br, 3H).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 9-(2,5-Dideoxy-2-fluoro-2-<i>C</i>-methyl-5-iodo-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)purine (<b>29</b>)</h3><div class="NLM_p last">Nucleoside <b>28</b> (10 g, 16.5 mmol), triphenylphosphine (5.4 g, 20.6 mmol), and imidazole (1.6 g, 24.7 mmol) were suspended in THF (30 mL), and the resulting mixture was cooled to 10 °C. Solution of iodine (5 g, 20 mmol) in THF (20 mL) was added, and the reaction mixture was stirred at rt for 5 h. The reaction was quenched with aq Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. Usual work-up and purification by column chromatography (2% MeOH in DCM) yielded nucleoside <b>29</b> (8.9 g, 75%) as a yellow solid. MS, <i>m</i>/<i>z</i> 710.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 9-(4,5-Didehydro-2,5-dideoxy-2-fluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)purine (<b>30</b>)</h3><div class="NLM_p last">To a solution of compound <b>29</b> (8 g, 11.3 mmol) in THF (40 mL) was added DBU (2.5 mL, 17 mmol), and the mixture was heated at 70–75 °C for 3 h. Reaction was quenched with 1 M solution of citric acid. Usual work-up and purification by column chromatography (20% EtOH in hexane) yielded nucleoside <b>30</b> (2.4 g, 35%) as a white solid. MS, <i>m</i>/<i>z</i> 582.4 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.42 (s, 1H), 7.19–7.29 (m, 12H), 6.78 (m, 2H), 6.30 (s, 1H), 5.8 (br, 1H), 4.6, 4.5, 4.3 (3br, 4H), 3.77 (m, 2H), 3.68 (s, 3H), 3.61 (m, 1H) 1.35 (br, 3H), 0.75 (br, 3H).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 9-(2,5-Dideoxy-2,4-difluoro-5-iodo-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)purine (<b>31</b>)</h3><div class="NLM_p last">To a stirred cold (0 °C) solution of nucleoside <b>30</b> (4.8 g, 8.2 mmol) in DCM (50 mL) was added triethylamine trihydrofluoride (2 mL, 12.6 mmol) followed by addition of NIS (2.7 g, 12 mmol). Reaction was allowed to proceed for 2 h at the same temperature and quenched with saturated solutions of NaHCO<sub>3</sub> and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (1:1). Usual work-up and purification by column chromatography (20% EtOH in hexane) afforded 3.5 g (60%) of nucleoside <b>31</b>. MS, <i>m</i>/<i>z</i> 728.1 (M + 1)<sup>+</sup>.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 9-(3,5-Di-<i>O</i>-benzoyl-2-deoxy-2,4-difluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)purine (<b>32</b>)</h3><div class="NLM_p last">To a solution of nucleoside <b>31</b> (2.1 g, 2.9 mmol) in pyridine (40 mL) was added BzCl (464 mg, 3.3 mmol), and the reaction mixture was kept at rt overnight. Usual work-up and chromatography on silica gel (20% EtOAc in hexane) yielded 2 g of 3′-O-benzoylated product. To a solution of this compound in DMF (60 mL) were added NaOBz (3.45 g, 24 mmol) and 15-crown-5 (5.31 g, 24 mmol), and the reaction mixture was stirred at 100 °C for 48 h. Solvent was evaporated. Usual work-up and column chromatography purification (20% EtOH in hexane) yielded 1.1 g (45% for 2 steps) of nucleoside <b>32</b>. MS, <i>m</i>/<i>z</i> 826.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 9-(2-Deoxy-2,4-difluoro-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)purine (<b>33</b>)</h3><div class="NLM_p last">A solution of <b>32</b> (1 g, 1.2 mmol) in <i>n</i>-butylamine (5 mL) was kept at rt overnight. Butylamine was evaporated, and the residue was purified by column chromatography (10% MeOH in DCM) to get 0.62 g (85%) of nucleoside <b>33</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.74 (br, 1H), 7.54 (s, 1H), 7.14–7.27 (m, 12H), 6.79 (m, 2H), 5.90 (br, 1H), 5.62 (br, 1H), 4.36 (br, 1H), 4.02 (br, 1H), 3.99 (q, <i>J</i> = 7.2 Hz, 2H), 3.67 (s, 3H), 3.62 (m, 2H) 1.14 (t, <i>J</i> = 7.2 Hz, 3H), 1.0 (br, 3H). MS, <i>m</i>/<i>z</i> 618.1 (M + 1)<sup>+</sup>.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 9-(5-<i>O</i>-Benzoyl-2-deoxy-2,4-difluoro-2-<i>C</i>-methyl-3-<i>O</i>-methoxytrityl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2(methoxytritylamino)purine (<b>34</b>)</h3><div class="NLM_p last">To a solution of <b>32</b> (10.0 g, 13.7 mmol) in DCM (100 mL) were added collidine (2.0 g, 16.5 mmol), MMTrCl (8.49 g, 27.5 mmol), and AgNO<sub>3</sub> (4.67 g, 27.5 mmol). The mixture was stirred at rt overnight. The solids were filtered off, and the filtrate was diluted with solution of NaHCO<sub>3</sub>. Organic layer was separated, washed with brine, and dried. The evaporated residue was purified by silica gel chromatography (20% EtOAc in hexane) to afford bistritylated nucleoside (11.7 g, 82%). MS, <i>m</i>/<i>z</i> 1000.2 (M + 1)<sup>+</sup>. To a solution of this compound (10.0 g, 10.0 mmol) in DMF (200 mL) were added 15-crown-5 (22 g, 100.0 mmol) and NaOBz (14.0 g, 100.0 mmol). The mixture was stirred for 72 h at 95 °C. After usual work-up and chromatography (10% EtOAc in hexane) nucleoside <b>34</b> (6.4 g, 65%) was isolated as a white solid. MS, <i>m</i>/<i>z</i> 994.2 (M + 1)<sup>+</sup>.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 9-(2-Deoxy-2,4-difluoro-3-<i>O</i>-methoxytrityl-2-<i>C</i>-methyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)-6-ethoxy-2-(methoxytritylamino)purine (<b>35</b>)</h3><div class="NLM_p last">A solution of <b>34</b> (6.0 g, 6.0 mmol) in <i>n</i>-butylamine (50 mL) was kept at rt overnight. Butylamine was evaporated, and the residue was purified by column chromatography (20% EtOAc in hexane) to yield <b>35</b> (3.7 g, 56%) as off-white foam. MS, <i>m</i>/<i>z</i> 890.2 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 6.80–7.60 (m, 29H), 6.24 (d, <i>J</i> = 18.3 Hz, 1H), 5.02 (s, 1H), 4.52–4.78 (m, 3H), 3.3.74–3.83 (m, 7H), 3.41–3.45 (m, 1H), 1.44–1.49 (m, 3H), 0.61 (d, <i>J</i> = 21.9 Hz, 3H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −120.16, 152.08.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> General Method for Preparation of Phosphoramidates</h3><div class="NLM_p">Dry nucleosides <b>35</b> (445 mg, 0.5 mmol) was dissolved in the mixture of dry CH<sub>3</sub>CN (4.5 mL) and <i>N</i>-methylimidazole (0.5 mL). The appropriate phosphorochloridate<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (2.0 mmol) was added, and the reaction mixture was kept overnight at rt or heated up to 70 °C for 2–10 h. Disappearance of starting nucleoside was controlled by LC–MS. After the reaction was completed, it was diluted with EtOAc (30 mL). The organic phase was washed with 10% citric acid, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and reduced to dryness. The residue was dissolved in CH<sub>3</sub>CN (5 mL), and 4 N HCl in dioxane (0.5 mL) was added. The mixture was kept for 1 h at ambient temperature and evaporated. The residue was purified on silica gel with gradient of MeOH in DCM from 2 to 15%. Prodrugs <b>40</b>, <b>43–50</b> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) were obtained as mixtures of <i>R</i>p and <i>S</i>p isomers with total yield 50–85%.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. MS and <sup>31</sup>P- and <sup>19</sup>F NMR (CD<sub>3</sub>OD) of Nucleoside Phosphoramidate Prodrugs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0018.gif" alt="" id="GRAPHIC-d7e4638-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug</th><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center"><sup>31</sup>P δ [ppm]</th><th class="colsep0 rowsep0" align="center"><sup>19</sup>F δ [ppm]</th><th class="colsep0 rowsep0" align="center" char=".">MS [M + 1]<sup>+</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">cyclohexyl</td><td class="colsep0 rowsep0" align="left">CCH</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">3.96; 4.02</td><td class="colsep0 rowsep0" align="left">–122.35</td><td class="colsep0 rowsep0" align="char" char=".">663.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">cyclohexyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">4.00; 4.11</td><td class="colsep0 rowsep0" align="left">–121.02</td><td class="colsep0 rowsep0" align="char" char=".">653.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">cyclohexyl</td><td class="colsep0 rowsep0" align="left">CCH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.94; 4.04</td><td class="colsep0 rowsep0" align="left">–122.9; −155.9</td><td class="colsep0 rowsep0" align="char" char=".">665.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">cyclohexyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.94, 4.09</td><td class="colsep0 rowsep0" align="left">–123.5; −156.8</td><td class="colsep0 rowsep0" align="char" char=".">655.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.98; 4.13</td><td class="colsep0 rowsep0" align="left">–123.2; −158.6</td><td class="colsep0 rowsep0" align="char" char=".">615.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">neopentyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.90; 4.08</td><td class="colsep0 rowsep0" align="left">–123.2; −158.5</td><td class="colsep0 rowsep0" align="char" char=".">643.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">naphthalen-1-yl</td><td class="colsep0 rowsep0" align="left">isobutyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">4.28; 4.43</td><td class="colsep0 rowsep0" align="left">–123.2; −158.5</td><td class="colsep0 rowsep0" align="char" char=".">679.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isobutyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.90; 4.06</td><td class="colsep0 rowsep0" align="left">–123.2; −158.6</td><td class="colsep0 rowsep0" align="char" char=".">629.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">cyclopentyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.99; 4.11</td><td class="colsep0 rowsep0" align="left">–123.2; −158.5</td><td class="colsep0 rowsep0" align="char" char=".">641.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">pentan-3-yl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">4.00; 4.07</td><td class="colsep0 rowsep0" align="left">–123.1; −158.6</td><td class="colsep0 rowsep0" align="char" char=".">643.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">quinoline-5-yl</td><td class="colsep0 rowsep0" align="left">neopentyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">4.15; 4.55</td><td class="colsep0 rowsep0" align="left">–123.5; −158.0</td><td class="colsep0 rowsep0" align="char" char=".">694.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">naphthalen-1-yl</td><td class="colsep0 rowsep0" align="left">neopentyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">4.28; 4.39</td><td class="colsep0 rowsep0" align="left">–123.1; −158.8</td><td class="colsep0 rowsep0" align="char" char=".">693.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">naphthalen-1-yl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">4.48; 4.36</td><td class="colsep0 rowsep0" align="left">–123.5; −158.0</td><td class="colsep0 rowsep0" align="char" char=".">665.1</td></tr></tbody></table></div></div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Separation of <i>S</i>p- (<b>42</b>) and <i>R</i>p-(<b>41</b>) Isomers from Isomeric Mixture <b>40</b></h3><div class="NLM_p">Mixture <b>40</b> was separated by RP HPLC on Synergy 4 μM Hydro-RP 80 Å (250 × 30 mm) column. A linear gradient of CH<sub>3</sub>CN in water from 40 to 70% in 26 min with flow rate 24 mL/min was used. Two compounds were eluted. The corresponding fractions were combined and concentrated. Analytical HPLC (Synergi 150 × 4.6 mm, 4 μm Hydro-RP 80 Å column, 50 mM TEAA in water and 50 mM in CH<sub>3</sub>CN, flow rate 2 mL/min) was performed with gradient from 40 to 60% B over 10 min.</div><div class="NLM_p">Compound <b>41</b> has retention time on analytical HPLC 7.77 min. MS, <i>m</i>/<i>z</i> 615.3 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.92 (s, 1H), 7.11–7.30 (m, 5H); 6.61 (s, 1H); 6.45 (d, 1H, <i>J</i> = 18 Hz), 5.99–6.05 (m, 2H); 4.74–4.84 (m, 2H), 4.30–4.50 (m, 4H); 3.70–3.80 (m, 1H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.15–1.18 (m, 6H), 1.06–1.09 (m, 9H). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>): δ 4.08. <sup>19</sup>F NMR (DMSO-<i>d</i><sub>6</sub>): δ −154.8, −190.3. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 172.6, 160.6, 160.1, 153.0, 150.5, 138.0, 129.5, 124.6, 120.1, 116.1 (d, <i>J</i> = 10 Hz), 113.8.0, 99.0 (br), 74.0 (br), 68.0, 65.3 (br), 61.7, 49.9, 21.3, 19.6, 17.0 (d, <i>J</i> = 25 Hz), 14.4.</div><div class="NLM_p last">Compound <b>42</b> (<b>AL-611</b>) has retention time on analytical HPLC 7.52 min. MS, <i>m</i>/<i>z</i> 615.2 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.94 (s, 1H), 7.15–7.38 (m, 5H); 6.61 (s, 2H); 6.44 (d, 1H, <i>J</i> = 18 Hz), 5.98–6.05 (m, 2H); 4.71–4.80 (m, 2H), 4.38–4.58 (m, 3H); 4.19–4.30 (m, 1H); 3.65–3.79 (m, 1H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.05–1.15 (m, 12H). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>): δ 4.24. <sup>19</sup>F NMR (DMSO-<i>d</i><sub>6</sub>): δ −154.8, −191.2. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 172.9, 161.0, 160.4, 151.0, 150.9, 138.5 (br), 130.0, 125.0, 120.6, 120.5, 114.5 (br), 114.5 (br), 98.5 (br), 73.8, 68.3, 62.1, 50.1, 21.7, 20.6, 17 (d, <i>J</i> = 25 Hz), 14.9.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Stereoselective Synthesis of Prodrug <b>42</b> (<b>AL-611</b>)</h3><div class="NLM_p last">Nucleoside <b>35</b> (890 mg, 1 mmol) and phosphoramidate <b>54</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (815 mg, 1.8 mmol) were dissolved in THF (15 mL) and cooled to 5 °C. <i>tert</i>-BuMgCl (1.5 mL, 1.0 M solution in THF) was added dropwise, and the reaction mixture was stirred for 1 h at the same temperature. Reaction was quenched with aq NH<sub>4</sub>Cl. Usual work-up was followed by column chromatography purification (20–60% EtOAc in hexanes). The corresponding fractions were concentrated and treated with the mixture of CH<sub>3</sub>CN and 36% HCl (10 mL, 9:1 v/v) for 40 min at ambient temperature. Solvents were evaporated, and the residue was purified on silica gel with gradient of MeOH in DCM from 2 to 10% to obtain 367 mg (60%) of <b>42</b>.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> General Method for Preparation of 3′,5′-Cyclophosphate Prodrugs <b>51–53</b></h3><div class="NLM_p">Nucleoside <b>33</b> (180 mg, 0.3 mmol) and <i>tert</i>-BuMgCl (1.2 mL, 1.0 M solution in THF) in dry THF (5 mL) were treated with alkyl phosphorodichloridate (0.45 mmol). Usual work-up was followed by column chromatography purification (2–5% MeOH in DCM). Protected prodrug was dissolved in CH<sub>3</sub>CN (5 mL), HCl in dioxane was added (0.5 mL), and the mixture was kept for 1 h at ambient temperature and evaporated. The residue was purified on silica gel with gradient of MeOH in DCM from 2 to 10%. Yields, <sup>31</sup>P, <sup>19</sup>F NMR, and MS are reported in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. MS and <sup>31</sup>P and <sup>19</sup>F NMR of 3′,5′-Cyclophosphate Prodrugs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">yield (for 2 steps) (%)</th><th class="colsep0 rowsep0" align="center"><sup>31</sup>P δ [ppm]</th><th class="colsep0 rowsep0" align="center"><sup>19</sup>F δ [ppm]</th><th class="colsep0 rowsep0" align="center">solvent</th><th class="colsep0 rowsep0" align="center" char=".">MS (M + 1)<sup>+</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>51</b></td><td class="colsep0 rowsep0" rowspan="4" align="center">30</td><td class="colsep0 rowsep0" align="left">–6.92,</td><td class="colsep0 rowsep0" align="left">–121.8;</td><td class="colsep0 rowsep0" rowspan="4" align="left">CD<sub>3</sub>OD</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">436.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">−7.92</td><td class="colsep0 rowsep0" align="left">−158.3;</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">−122.3;</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">−159.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>52</b></td><td class="colsep0 rowsep0" rowspan="2" align="center">10</td><td class="colsep0 rowsep0" align="left">–6.69,</td><td class="colsep0 rowsep0" align="left">–123.6;</td><td class="colsep0 rowsep0" rowspan="2" align="left">DMSO-<i>d</i><sub>6</sub></td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">464.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">−7.92</td><td class="colsep0 rowsep0" align="left">−158.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>53</b></td><td class="colsep0 rowsep0" rowspan="2" align="center">21</td><td class="colsep0 rowsep0" align="left">–7.13,</td><td class="colsep0 rowsep0" align="left">–123.1;</td><td class="colsep0 rowsep0" rowspan="2" align="left">DMSO-<i>d</i><sub>6</sub></td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">450.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">−9.03</td><td class="colsep0 rowsep0" align="left">−158.5</td></tr></tbody></table></div></div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> General Method for Preparation of NTPs</h3><div class="NLM_p">Dry nucleoside (0.05 mmol) was dissolved in PO(OMe)<sub>3</sub> (0.7 mL). <i>N</i>-Methylimidazole (0.009 mL, 0.11 mmol) was added followed by POCl<sub>3</sub> (0.009 mL, 0.11 mmol), and the mixture was kept at rt for 20–40 min. The reaction was controlled by LCMS and monitored by the appearance of corresponding nucleoside 5′-monophosphate. After completion of the reaction, tetrabutylammonium salt of pyrophosphate (150 mg) was added, followed by DMF (0.5 mL) to get a homogeneous solution. After 1.5 h at rt, the reaction was diluted with water (10 mL) and loaded on HiLoad 16/10 with Q Sepharose High Performance column. Separation was done in a linear gradient of NaCl from 0 to 1 N in 50 mM TRIS-buffer (pH 7.5). Triphosphate was eluted with 75–80% B. Corresponding fractions were concentrated. Desalting was achieved by RP HPLC on Synergy 4 μM Hydro-RP column. A linear gradient of CH<sub>3</sub>CN from 0 to 30% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution. The corresponding fractions were combined, concentrated, and lyophilized three times to remove excess of buffer. <sup>31</sup>P NMR, MS, and purity are presented in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. MS and <sup>31</sup>P NMR (D<sub>2</sub>O) of NTPs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">NTP</th><th class="colsep0 rowsep0" align="center"><sup>31</sup>P, δ [ppm]</th><th class="colsep0 rowsep0" align="center" char=".">MS [M – 1]<sup>−</sup></th><th class="colsep0 rowsep0" align="center" char=".">purity %<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2-TP</b></td><td class="colsep0 rowsep0" align="left">–9.59(d), −11.39(d), −21.06(t)</td><td class="colsep0 rowsep0" align="char" char=".">536.1</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3-TP</b></td><td class="colsep0 rowsep0" align="left">–11.05(d), −11.48(d), −23.36(t)</td><td class="colsep0 rowsep0" align="char" char=".">537.4</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4-TP</b></td><td class="colsep0 rowsep0" align="left">–10.88(d), −11.58(d), −23.24(t)</td><td class="colsep0 rowsep0" align="char" char=".">554.0</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5-TP</b></td><td class="colsep0 rowsep0" align="left">–10.98(d), −11.92(d), −23.25(t)</td><td class="colsep0 rowsep0" align="char" char=".">554.0</td><td class="colsep0 rowsep0" align="char" char=".">97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6-TP</b></td><td class="colsep0 rowsep0" align="left">–11.05(br), −12.02(d), −23.25(t)</td><td class="colsep0 rowsep0" align="char" char=".">564.0</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7-TP</b></td><td class="colsep0 rowsep0" align="left">–10.97(d), −11.92(d), −21.19(t)</td><td class="colsep0 rowsep0" align="char" char=".">556.2</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8-TP</b></td><td class="colsep0 rowsep0" align="left">–10.98(d), −11.99(d), −23.18(t)</td><td class="colsep0 rowsep0" align="char" char=".">566.0</td><td class="colsep0 rowsep0" align="char" char=".">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9-TP</b></td><td class="colsep0 rowsep0" align="left">–10.51(d), −11.41(d), −23.13(t)</td><td class="colsep0 rowsep0" align="char" char=".">540.0</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10-TP</b></td><td class="colsep0 rowsep0" align="left">–10.53(d), −11.56(d), −23.30(t)</td><td class="colsep0 rowsep0" align="char" char=".">556.4</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Analytical HPLC was performed on Phenomenex, Synergi 4 μM Hydro RP 80 Å 150 × 4.6 mm, flow 1.5 mL/min. A linear gradient of CH<sub>3</sub>CN from 0 to 25% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution.</p></div></div></div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> HCV RNA Polymerase Inhibition Assay</h3><div class="NLM_p last">The HCV polymerase RdRp activity was measured as the incorporation of radiolabeled ribonucleotide monophosphates into acid-insoluble RNA products using HCV NS5B and complementary internal ribosome entry site (cIRES)-derived RNA templates, as described previously.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> HCV polymerase reaction mixtures contained 50 nM cIRES template, 1 μM tritiated CTP, 1 μM ATP, 1 μM GTP, 0.5 μM UTP, 40 mM Tris-HCl (pH 8.0), 20 mM NaCl, 3 mM dithiothreitol (DTT), 4 mM MgCl<sub>2</sub>, serial diluted inhibitor, and 100 nM NS5B enzyme. Reaction mixtures were incubated for 2 h at 30 °C and stopped by RNA precipitation with the addition of equal volumes of 20% (w/v) trichloroacetic acid. MicroScint 20 (PerkinElmer, Waltham, MA) was added to the acid-insoluble RNA products and read on a MicroBeta Trilux (PerkinElmer, Waltham, MA).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Human DNA and RNA Polymerase Assays</h3><div class="NLM_p last">The enzymatic activity of human DNA and RNA polymerases was measured as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Briefly, activated calf thymus DNA was used as a substrate for the DdDp activity of DNA polymerase α, β, and γ, in a buffer containing 50 mM Tris HCl (pH 8.0), 60 mM KCl, 5 mM MgCl<sub>2</sub>, 4 mM DTT, 2 μM dCTP, 2 μM dATP, 2 μM dGTP, and 2.5 μCi 3H dTTP. The DNA product was precipitated in 20% (w/v) trichloroacetic acid. After the addition of 50 μL of MicroScint 20 (PerkinElmer, Waltham, MA), the precipitated high molecular weight DNA products were measured in a Trilux MicroBeta microplate scintillation reader (PerkinElmer, Waltham, MA). The RNA polymerase II mediated in vitro transcription was performed with commercially available HeLa cell nuclear extract (Promega; Madison). RNA products were resolved by electrophoresis on 6% Novex TBE Urea polyacrylamide gels (Invitrogen; Carlsbad, CA). The DdRp assay with the HMRP was performed under single turnover conditions where enzyme concentration was in excess of the primer/template (Jin Z, Antiviral Research 2017). Therefore, the <sup>33</sup>P-RNA/DNA primer/template (RNA: 5′-UUUUGCCGCGCC-3′ and DNA 3′-CGGCGCGG<u class="uu">C</u>ACGTAAGGG-5′) was used at a concentration of 100 nM, together with 320 nM enzyme. Each NTP (natural or analogues) was tested at 100 μM; ATP, UTP, and CTP were used to quantify the extent of mis-incorporation of an incorrect nucleotide opposite templating CMP. RNA products were resolved by electrophoresis on 22.5% TBE urea polyacrylamide sequencing gels. Quantification of the radiolabeled band was performed using a Typhoon PhosphorImager and the ImageQuant 5.2 software (GE Life Sciences).</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> HCV RNA Polymerase Chain Termination Assay</h3><div class="NLM_p last">The preparation of the NS5B EC was performed by an extension and pause reaction as previously described.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In summary, a 50 μL extension and pause reaction containing 6.5 μM NS5B, 20 μM pGG, 20 μM RNA template (3′-CCUAUAUUAG<u class="uu">C</u>AAUAUCUAA-5′), 25 μM ATP and 12.5 μM GTP in the optimized reaction buffer (40 mM Tris-Cl, pH 7.0, 40 mM NaCl, 5 mM DTT, and 2 mM MgCl<sub>2</sub>) was run for 2 h at 30 °C to generate a 9-mer, followed by the addition of 20 μM CTP containing 13 nM <sup>33</sup>P radiolabeled CTP, and incubated for 30 s at 30 °C to generate a 10-mer. All the active EC was precipitated out during the reaction and isolated by centrifugation at 16,000<i>g</i> for 5 min at room temperature using a bench top centrifuge. After centrifugation, the supernatant was removed and the remaining pellet was washed twice by additional resuspension in the wash buffer (40 mM Tris-Cl, pH 7.0, 20 mM NaCl, 5 mM DTT and 2 mM MgCl<sub>2</sub>) and centrifugation to remove residual contaminants. The final pellet containing the EC was resuspended and solubilized in 500 μL of a physiologically relevant reaction buffer (40 mM Tris-Cl, pH 7.4, 5 mM DTT, 2 mM MgCl<sub>2</sub>, 150 mM NaCl) to serve as the isolated EC for this study. Elongation reactions contained 5 μL of the 10-mer EC and 100 μM each final concentration of NTPs in a buffer containing 40 mM Tris-Cl, pH 7.4, 5 mM DTT, 2 mM MgCl<sub>2</sub>, and 150 mM NaCl. Reactions were incubated at 30 °C for 1 min and quenched with 20 μL of a gel loading buffer containing 90% formamide, 50 mM EDTA, 0.025% (w/v) bromophenol blue, and 0.025% (w/v) xylene cyanol FF and heated at 95 °C for 5 min. The samples were run on a 22.5% polyacrylamide gel (8 M urea) and exposed to a phosphorimager screen. The EC and subsequent incorporation products were quantified using a Typhoon PhosphorImager and Image Quant TL software (GE Life Sciences).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> HCV Replicon Assay</h3><div class="NLM_p last">Huh-7 cells harboring an autonomously replicating, subgenomic HCV replicon of the Con1 strain were maintained in Dulbecco’s modified Eagle’s medium (DMEM), 10% heat-inactivated fetal bovine serum (FBS), 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and nonessential amino acids (JRH Biosciences, Lenexa, KS), plus 0.25 mg/mL G418 (Invitrogen, Carlsbad, CA). The Huh-7 HCV replicon cell line was obtained from R. Bartenschlager’s Lab (University Heidelberg, Heidelberg, Germany) and was maintained and cultured in-house at Janssen BioPharma. The subgenomic HCV replicon encodes a neomycin phosphotransferase, which allows selective growth of HCV replicon-containing Huh-7cells over HCV replicon-negative Huh-7 cells in the presence of G418. The compound concentrations at which the HCV RNA level in the replicon cells is reduced by 50% (EC<sub>50</sub>) or by 90% (EC<sub>90</sub>) or the cell viability is reduced by 50% (CC<sub>50</sub>) were determined in HCV Con1 subgenomic replicon cells using 4-parameter curve fitting (SoftMax Pro) as described previously. Briefly, the replicon cells were incubated with compounds diluted in DMEM containing 2% FBS Briefly, the replicon cells were incubated with compounds diluted in DMEM containing 2% FBS and 0.5% dimethyl sulfoxide (DMSO) (without G418) at 37 °C. Total cellular RNA was extracted using an RNeasy-96 kit (Qiagen, Valencia, CA), and the copy number of the HCV RNA was determined in a quantitative, real-time, multiplex reverse transcription-PCR (QRT-PCR, or Taqman) assay. The cytotoxicity of compounds in the HCV replicon cells was measured under the same experimental settings. After 3 days of treatment, viability was determined with the CellTiter-Blue cell viability assay solution (Promega) in a Victor3 V 1420 multilabel counter (PerkinElmer), and 50% cytotoxic concentration (CC<sub>50</sub>) values were determined using the Microsoft Excel and XLFit 4.1 software.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 8 Days Cytotoxicity</h3><div class="NLM_p last">Long-term cytotoxicity assays were performed with Huh-7, HepG2, A549, HeLa, MT4, and U935 cells (1 × 10<sup>5</sup> cells/well) in collagen I-coated 96-well plates that were maintained for 8 days in the recommended medium without drug to ensure terminal differentiation prior to drug exposure. The cells were treated with compounds for 8 days and were refed every other day to ensure proper nutrition and exposure to the drug. At the end of treatment, cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). CC<sub>50</sub> values were determined using XLFit 4.1 software.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> NTP Formation In Vitro</h3><div class="NLM_p">The in vitro NTP formation experiments were conducted in primary human hepatocytes. The primary human hepatocytes from male and female donors of various ethnic backgrounds were purchased from Corning Life Science (Tewksbury, MA), BioIVT (Hicksville, NY), and Thermo Fisher Scientific (Waltham, MA). Primary human hepatocytes were seeded at 1.5–2 million cells/well in 6-well plates and maintained in Williams E. medium containing Life Tech’s proprietary supplement cocktail. The plated human hepatocytes in 3 mL of medium per well were acclimated overnight (>18 h) in a cell culture incubator at 37 °C, 5% CO<sub>2</sub>. Addition of a test article standard solution into each well achieved the target final incubation (extracellular) concentration. The cells were continually incubated at 37 °C, 5% CO<sub>2</sub> for the designated time. At the end of incubation, cells were washed twice with 700 μL of cold 0.9% sodium chloride solution before lysis with the addition of 700 μL of methanol/water (70/30, v/v). The cell lysate was transferred into an Eppendorf tube and stored at −20 °C for at least 3 h before analysis. After vortexing and centrifuging, the supernatant was dried and reconstituted with 500 μL of 1 mM ammonium phosphate solution. An internal standard (N<sup>6</sup>-benzoyladenosine) was added to a 50 μL aliquot of the supernatant before LC–MS/MS analysis for the NTP concentration. The NTP calibration standards for the analysis was constructed by spiking the NTP standard solutions into control cellular samples of human hepatocytes, which were incubated without the test article and treated in the same manner as study samples. Quantification of the NTP was conducted using Analyst software on a Sciex API 3200 or API 5000 tandem triple quadrupole mass spectrometer coupled to a Shimadzu LC-20AD HPLC system with a Leap Technologies HTC PAL autosampler. The HPLC column was a Phenomenex Gemini C18 (50 × 2 mm, 3 μm particle size) column employed a step gradient for chromatographic separation coupled with negative ion MS/MS detection of the NTP. Mobile phase A consisted of 3 mM ammonium formate and 10 mM dimethyl hexylamine (DMHA) in water, and mobile phase B consisted of 3 mM ammonium formate and 10 mM DMHA in 1:1 acetonitrile/water.</div><div class="NLM_p last">To obtain the intracellular half-life of the NTP, the primary human hepatocytes were initially incubated with the test article at 50 μM for 24 h at 37 °C, 5% CO<sub>2</sub> before the incubation media containing the test article was replaced with blank incubation media. The cells were placed back into the incubator after collection of the 0 h timepoint. Further timepoints for the NTP stability were collected at 3, 6, 10, 24, and 48 h. The half-life was calculated based on the assumption that the disappearance of NTP followed first-order kinetics. Thus<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_m001.gif" alt="" id="_i68" /></img></span>where <i>C</i><sub><i>t</i></sub> represents the intracellular concentration of NTP at time <i>t</i>, <i>C</i><sub>0</sub> represents the concentration of NTP at time zero extrapolated to time zero based on the selected terminal phase, <i>t</i> is the time, and <i>t</i><sub>1/2</sub> represents half-life of NTP.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> NTP Formation In Vivo</h3><div class="NLM_p last">The in vivo pharmacokinetic studies were conducted at Wuxi AppTec. The studies conformed to International regulations and guidelines regarding animal care and welfare, and the study protocols were reviewed and approved by Wuxi AppTec’s Institutional Animal Care and Use Committee (IACUC) prior to the study initiation. Male non-naïve beagle dogs (<i>n</i> = 2 per time point) were fasted overnight before administered orally with the test article. The test article was formulated as a solution in 40% PEG400 in water and administered at 9.69 mg/kg (5 mg/kg parent nucleoside equivalent dose). For liver tissue collection, animals were anesthetized with pentobarbital. A piece of liver (at least 1 g) was removed and immediately flash-frozen into liquid nitrogen to prevent any ex vivo degradation of the NTP. The frozen tissue was homogenized in an extraction solution in a sample tube set in a dry ice/ethanol bath to maintain cold temperature. The supernatant of the liver extracts was subjected to LC–MS/MS analysis for the concentrations of the NTP. The NTP calibration standards for the analysis were constructed by spiking the NTP working standard solutions into blank liver homogenate. The ACQUITY UPLC system used a Phenomenex Gemini C18 column (50 × 4.6 mm, 5 μm) with a step gradient for chromatographic separation. It was coupled with an AB-Sciex API 4000 mass spectrometer operated in the negative ion mode for NTP detection.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> X-ray Crystallography Methods</h3><div class="NLM_p">Single colorless needle-shaped crystals of compound <b>42</b> (<b>Al-611</b>) generated during compound purification were used. A suitable crystal (0.21 mm × 0.10 mm × 0.05 mm) was selected and mounted on a nylon loop with paratone oil on a Bruker APEX-II CCD diffractometer. The crystal was kept at <i>T</i> = 173(2) K during data collection. Using Olex2,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> the structure was solved with the ShelXT<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> structure solution program, using the direct methods solution method. The model was refined with version 2014/6 of XL<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> using Least Squares minimization.</div><div class="NLM_p">Crystal Data: C<sub>25</sub>H<sub>34</sub>F<sub>2</sub>N<sub>6</sub>O<sub>8</sub>P, <i>M</i><sub>r</sub> = 615.55, orthorhombic, <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, <i>a</i> = 7.8919(3) Å, <i>b</i> = 15.7818(6) Å, <i>c</i> = 22.8797(10) Å, α = β = γ = 90°, <i>V</i> = 2849.6(2) Å3, <i>T</i> = 173(2) K, <i>Z</i> = 4, <i>Z</i>′ = 1, μ(Cu Kα) = 1.490, 17,819 reflections measured, 5505 unique (<i>R</i><sub>int</sub> = 0.2423) which were used in all calculations. The final w<i>R</i><sub>2</sub> was 0.1612 (all data), and <i>R</i><sub>1</sub> was 0.0747 (<i>I</i> > 2(<i>I</i>)).</div><div class="NLM_p">Data were measured using ω and ϕ scans of 1.00° per frame for 45.00 s using Cu Kα radiation (sealed tube, 40 kV, 30 mA). The total number of runs and images was based on the strategy calculation from the program COSMO (Bruker, V1.61, 2009).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The achieved resolution was Θ = 72.153 (0.81 Å). Cell parameters were retrieved using the SAINT (Bruker, V8.34A, 2013)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> software and refined using SAINT on 1173 reflections, 7 of the observed reflections. Data reduction was performed using SAINT software which corrects for Lorentz polarization. The final completeness was 99.70 out to 72.153 in Θ. The absorption coefficient (μ) of this material was 1.490, and the minimum and maximum transmissions were 0.5937 and 0.7536.</div><div class="NLM_p last">The structure was solved in the space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> by direct methods using the ShelXT<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> structure solution program and refined by Least Squares using version 2014/6 of XL.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> All non-hydrogen atoms were refined anisotropically. Hydrogen atom positions were calculated geometrically and refined using the riding model. The structure refined by least squares method on F2, ShelXL-97, was incorporated in Olex2. All H atoms were placed in calculated positions and refined using a riding model. The Flack parameter was refined to 0.00(7). The absolute structure using Bayesian statistics on Bijvoet differences using the Olex2 results in 0.02(6) was determined. <i>Note</i>: The Flack parameter is used to determine chirality of the crystal studied, and the value should be near 0; a value of 1 means that the stereochemistry is incorrect, and the model should be inverted. A value of 0.5 means that the crystal consists of a racemic mixture of the two enantiomers.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00935" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58364" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58364" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00935?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00935</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00935/suppl_file/jm0c00935_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00935/suppl_file/jm0c00935_si_001.csv">jm0c00935_si_001.csv (3.56 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00935" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalia Dyatkina</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2330-7606" title="Orcid link">http://orcid.org/0000-0003-2330-7606</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b5dbd1ccd4c1dedcdbf5dcc1c69bdfdbdf9bd6dad8"><span class="__cf_email__" data-cfemail="d2bcb6abb3a6b9bbbc92bba6a1fcb8bcb8fcb1bdbf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guangyi Wang</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marija Prhavc</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3365-4436" title="Orcid link">http://orcid.org/0000-0002-3365-4436</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caroline Williams</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vladimir Serebryany</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yujian Hu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongfei Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiangyang Wu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tongqian Chen</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., No.
6, TaiHe Road, BDA, Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wensheng Huang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing, Co. Ltd., No.
6, TaiHe Road, BDA, Beijing 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vivek K. Rajwanshi</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerome Deval</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Fung</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhinan Jin</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antitsa Stoycheva</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1907-0319" title="Orcid link">http://orcid.org/0000-0003-1907-0319</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth Shaw</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kusum Gupta</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuen Tam</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Jekle</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David B. Smith</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leonid Beigelman</span> - <span class="hlFld-Affiliation affiliation">Janssen
BioPharma, Inc., 260
E. Grand Avenue, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        Aligos Therapeutics, 1 Corporate Drive, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We greatfully acknowledge Sushmita Chanda, Julian A. Symons, Hua Tan, and Lawrence M. Blatt for fruitful scientific discussions. We highly appreciate Mike Letavic and Robert Hendricks for critical review of the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">NTP</td><td class="NLM_def"><p class="first last">nucleoside 5′-triphosphate</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">2,2,6,6-tetramethylpiperidine 1-oxyl</p></td></tr><tr><td class="NLM_term">DAST</td><td class="NLM_def"><p class="first last">diethylaminosulfur trifluoride</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">HMPA</td><td class="NLM_def"><p class="first last">hexamethylphosphoric acid triamide</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>O</i>-bis(trimethylsilyl) acetamide</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">2,3,4,6,7,8,9,10-octahydropyrimidol[1,2-<i>a</i>]azepine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)pyridine</p></td></tr><tr><td class="NLM_term">TrCl</td><td class="NLM_def"><p class="first last">triphenylchloromethane</p></td></tr><tr><td class="NLM_term">MMTrCl</td><td class="NLM_def"><p class="first last">4-methoxytriphenylchloromethane</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74373" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74373" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span> </span><span class="NLM_article-title">HCV Guidance: Recommendations
for Testing, Managing, and Treating
Hepatitis C</span>. <a href="http://www.hcvguidelines.org" class="extLink">http://www.hcvguidelines.org</a> (accessed May 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=HCV+Guidance%3A+Recommendations%0Afor+Testing%2C+Managing%2C+and+Treating%0AHepatitis+C.+http%3A%2F%2Fwww.hcvguidelines.org+%28accessed+May+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHCV%2520Guidance%253A%2520Recommendations%250Afor%2520Testing%252C%2520Managing%252C%2520and%2520Treating%250AHepatitis%2520C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2014.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=24792751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvVait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2014&pages=119-124&author=M.+J.+Sofia&title=Beyond+sofosbuvir%3A+what+opportunity+exists+for+a+better+nucleoside%2Fnucleotide+to+treat+hepatitis+C%3F&doi=10.1016%2Fj.antiviral.2014.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?</span></div><div class="casAuthors">Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">119-124</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sofosbuvir is a liver-targeting uridine nucleotide prodrug inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase recently approved by the FDA and EU regulators for treatment of patients infected with genotype 1, 2, 3 and 4 virus.  The request for regulatory approval of the fixed-dose combination contg. sofosbuvir and the NS5A inhibitor ledipasvir is also under review.  Preclin. and clin. studies have shown that sofosbuvir is effective, safe and well tolerated.  Review of sofosbuvir's preclin. and clin. profile reveals a drug that has the potential to become the backbone of std. of care.  Pursuit of a next generation nucleos(t)ide HCV inhibitor that could compete with sofosbuvir would need to address whatever limitations sofosbuvir exhibits.  These include reduced efficacy in genotype 3 patients and use in severe renally impaired patients or those patients currently on drugs that are inducers of P-glycoprotein.  However, it has been shown that reduced efficacy in genotype 3 is largely eliminated when sofosbuvir is combined with another oral DAA.  Next-generation inhibitors would also benefit by enabling a reduced duration of therapy and an orthogonal resistance profile.  The more recent group of nucleos(t)ides in clin. development maintains similarities to sofosbuvir, in that they are uridine nucleotide prodrugs.  The question therefore remains whether these new agents will be sufficiently differentiated from sofosbuvir to provide any addnl. benefit to patients.  This paper forms part of a symposium in Antiviral Research on "Hepatitis C: next steps toward global eradication.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgsu_r7tRjWbVg90H21EOLACvtfcHk0lgRgOGN1POm5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvVait7o%253D&md5=fb15501e528dda16a6b55e85d4f37454</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DBeyond%2520sofosbuvir%253A%2520what%2520opportunity%2520exists%2520for%2520a%2520better%2520nucleoside%252Fnucleotide%2520to%2520treat%2520hepatitis%2520C%253F%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D107%26spage%3D119%26epage%3D124%26doi%3D10.1016%2Fj.antiviral.2014.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latt, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanny, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahota, A. K.</span></span> <span> </span><span class="NLM_article-title">Eight-week ledipasvir/ sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: single center, real world effectiveness and safety</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4759</span>– <span class="NLM_lpage">4766</span>, <span class="refDoi"> DOI: 10.3748/wjg.v23.i26.4759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.3748%2Fwjg.v23.i26.4759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=28765697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BC1cfjtlCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4759-4766&author=N.+L.+Lattauthor=B.+T.+Yannyauthor=D.+Gharibianauthor=R.+Gevorkyanauthor=A.+K.+Sahota&title=Eight-week+ledipasvir%2F+sofosbuvir+in+non-cirrhotic%2C+treatment-na%C3%AFve+hepatitis+C+genotype-1+patients+with+hepatitis+C+virus-RNA+%3C+6+million%3A+single+center%2C+real+world+effectiveness+and+safety&doi=10.3748%2Fwjg.v23.i26.4759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naive hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety</span></div><div class="casAuthors">Latt Nyan L; Yanny Beshoy T; Gharibian Derenik; Gevorkyan Rita; Sahota Amandeep K</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastroenterology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4759-4766</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  To evaluate sustained viral response (SVR) of 8-wk ledipasvir/sofosbuvir therapy among non-cirrhotic, genotype-1 hepatitis C virus (HCV) patients with RNA < 6 million IU/mL.  METHODS:  We performed a retrospective cohort study to examine SVR rates, predictors of treatment failure and safety analysis of 8-wk ledipasvir/sofosbuvir (LDV/SOF) therapy among non-cirrhotic, genotype 1 HCV patients with viral load < 6 million IU/mL.  Primary outcome was an achievement of SVR at 12 wk after treatment.  Secondary outcomes were identifying predictors of treatment failure and adverse events during treatment.  RESULTS:  Total 736 patients: 55% males, 51% Caucasians and 65% were genotype 1a.  Non-cirrhotic state of 53% was determined by clinical judgment (imaging, AST, platelet count) and 47% had documented liver fibrosis testing (biopsy, vibration-controlled transient elastography, serum biomarkers).  Overall SVR12 was 96%.  No difference in SVR12 was seen between patients whose non-cirrhotic state was determined by clinical judgment and patients who had fibrosis testing.  Age groups, gender, ethnicity and genotype 1 subtype did not predict SVR.  Non-cirrhotic state determined by clinical judgment based on simple, non-invasive tests were not associated with lower SVR [OR = 1.02, 95%CI: 0.48-2.17, P = 0.962].  The AUROC for hepatitis C RNA viral load was 0.734 (P < 0.001, 95%CI: 0.66-0.82).  HCV RNA 2.2 million IU/mL was identified as the cutoff value with sensitivity 73% and specificity 64%.  HCV RNA < 2.2 million IU/mL was associated with significantly higher SVR 98% with OR = 0.22 (95%CI: 0.1-0.49, P < 0.001) compared to SVR 92% in HCV RNA ≥ 2.2 million IU/mL.  No death or morbidities were reported.  CONCLUSION:  Our outcomes validate safety and effectiveness of 8-wk LDV/SOF therapy in non-cirrhotic, untreated HCV genotype 1 patients with HCV RNA < 6 million IU/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ2hBDUDUazz0O18WR3iAofW6udTcc2ebIhTP4dQtmC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfjtlCjug%253D%253D&md5=49fac145d84e322cd9a2bb79c4453532</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v23.i26.4759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v23.i26.4759%26sid%3Dliteratum%253Aachs%26aulast%3DLatt%26aufirst%3DN.%2BL.%26aulast%3DYanny%26aufirst%3DB.%2BT.%26aulast%3DGharibian%26aufirst%3DD.%26aulast%3DGevorkyan%26aufirst%3DR.%26aulast%3DSahota%26aufirst%3DA.%2BK.%26atitle%3DEight-week%2520ledipasvir%252F%2520sofosbuvir%2520in%2520non-cirrhotic%252C%2520treatment-na%25C3%25AFve%2520hepatitis%2520C%2520genotype-1%2520patients%2520with%2520hepatitis%2520C%2520virus-RNA%2520%253C%25206%2520million%253A%2520single%2520center%252C%2520real%2520world%2520effectiveness%2520and%2520safety%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2017%26volume%3D23%26spage%3D4759%26epage%3D4766%26doi%3D10.3748%2Fwjg.v23.i26.4759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seley-Radtke, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, M. K.</span></span> <span> </span><span class="NLM_article-title">The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2018.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=29649496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslOntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=66-86&author=K.+L.+Seley-Radtkeauthor=M.+K.+Yates&title=The+evolution+of+nucleoside+analogue+antivirals%3A+a+review+for+chemists+and+non-chemists.+Part+1%3A+Early+structural+modifications+to+the+nucleoside+scaffold&doi=10.1016%2Fj.antiviral.2018.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold</span></div><div class="casAuthors">Seley-Radtke, Katherine L.; Yates, Mary K.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66-86</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This is the first of two invited articles reviewing the development of nucleoside-analog antiviral drugs, written for a target audience of virologists and other non-chemists, as well as chemists who may not be familiar with the field.  Rather than providing a simple chronol. account, we have examd. and attempted to explain the thought processes, advances in synthetic chem. and lessons learned from antiviral testing that led to a few mols. being moved forward to eventual approval for human therapies, while others were discarded.  The present paper focuses on early, relatively simplistic changes made to the nucleoside scaffold, beginning with modifications of the nucleoside sugars of Ara-C and other arabinose-derived nucleoside analogs in the 1960's.  A future paper will review more recent developments, focusing esp. on more complex modifications, particularly those involving multiple changes to the nucleoside scaffold.  We hope that these articles will help virologists and others outside the field of medicinal chem. to understand why certain drugs were successfully developed, while the majority of candidate compds. encountered barriers due to low-yielding synthetic routes, toxicity or other problems that led to their abandonment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTNbV8qi9P4bVg90H21EOLACvtfcHk0lgiTQAKLeQYyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslOntrc%253D&md5=ccd9ad86ef8a1baf078e21747edef73d</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSeley-Radtke%26aufirst%3DK.%2BL.%26aulast%3DYates%26aufirst%3DM.%2BK.%26atitle%3DThe%2520evolution%2520of%2520nucleoside%2520analogue%2520antivirals%253A%2520a%2520review%2520for%2520chemists%2520and%2520non-chemists.%2520Part%25201%253A%2520Early%2520structural%2520modifications%2520to%2520the%2520nucleoside%2520scaffold%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D154%26spage%3D66%26epage%3D86%26doi%3D10.1016%2Fj.antiviral.2018.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seley-Radtke, K. L.</span></span> <span> </span><span class="NLM_article-title">The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: Complex modification to the nucleoside scaffold</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2018.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=30529089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSntrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=5-21&author=M.+K.+Yatesauthor=K.+L.+Seley-Radtke&title=The+evolution+of+antiviral+nucleoside+analogues%3A+a+review+for+chemists+and+non-chemists.+Part+II%3A+Complex+modification+to+the+nucleoside+scaffold&doi=10.1016%2Fj.antiviral.2018.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold</span></div><div class="casAuthors">Yates, Mary K.; Seley-Radtke, Katherine L.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-21</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This is the second of two invited articles reviewing the development of nucleoside analog antiviral drugs, written for a target audience of virologists and other non-chemists, as well as chemists who may not be familiar with the field.  As with the first paper, rather than providing a chronol. account, we have chosen to examine particular examples of structural modifications made to nucleoside analogs that have proven fruitful as various antiviral, anticancer, and other therapeutics.  The first review covered the more common, and in most cases, single modifications to the sugar and base moieties of the nucleoside scaffold.  This paper focuses on more recent developments, esp. nucleoside analogs that contain more than one modification to the nucleoside scaffold.  We hope that these two articles will provide an informative historical perspective of some of the successfully designed analogs, as well as many candidate compds. that encountered obstacles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTMhqxUaJfkbVg90H21EOLACvtfcHk0lgiTQAKLeQYyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSntrzL&md5=26d398d67fa3ae4c54318057eb18b35f</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DYates%26aufirst%3DM.%2BK.%26aulast%3DSeley-Radtke%26aufirst%3DK.%2BL.%26atitle%3DThe%2520evolution%2520of%2520antiviral%2520nucleoside%2520analogues%253A%2520a%2520review%2520for%2520chemists%2520and%2520non-chemists.%2520Part%2520II%253A%2520Complex%2520modification%2520to%2520the%2520nucleoside%2520scaffold%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D162%26spage%3D5%26epage%3D21%26doi%3D10.1016%2Fj.antiviral.2018.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, C.</span>; <span class="NLM_string-name">De Clercq, E.</span>; <span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Viral DNA polymerase inhibitors</span>. In  <i>Viral Genome Replication</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C. E.</span>, <span class="NLM_string-name">Gotte, M.</span>, <span class="NLM_string-name">Raney, K.</span></span>, Eds.; <span class="NLM_publisher-name">Springer Science and Business Media</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>; Chapter 22, pp  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">526</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1007%2Fb135974_22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=481-526&author=C.+Andrei&author=E.+De+Clercq&author=R.+Snoeckauthor=C.+E.+Cameron&author=M.+Gotte&author=K.+Raney&title=Viral+Genome+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fb135974_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252Fb135974_22%26sid%3Dliteratum%253Aachs%26aulast%3DAndrei%26aufirst%3DC.%26atitle%3DViral%2520DNA%2520polymerase%2520inhibitors%26btitle%3DViral%2520Genome%2520Replication%26aulast%3DCameron%26aufirst%3DC.%2BE.%26pub%3DSpringer%2520Science%2520and%2520Business%2520Media%26date%3D2009%26spage%3D481%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span>; <span class="NLM_string-name">Shih, I.-H.</span>; <span class="NLM_string-name">Zhong, W.</span></span> <span> </span><span class="NLM_article-title">Viral RNA polymerase inhibitors</span>. In  <i>Viral Genome Replication</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C. E.</span>, <span class="NLM_string-name">Gotte, M.</span>, <span class="NLM_string-name">Raney, K.</span></span>, Eds.; <span class="NLM_publisher-name">Springer Science and Business Media</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>; Chapter 23, pp  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">548</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1007%2Fb135974_23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=527-548&author=T.+Appleby&author=I.-H.+Shih&author=W.+Zhongauthor=C.+E.+Cameron&author=M.+Gotte&author=K.+Raney&title=Viral+Genome+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1007%2Fb135974_23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252Fb135974_23%26sid%3Dliteratum%253Aachs%26aulast%3DAppleby%26aufirst%3DT.%26atitle%3DViral%2520RNA%2520polymerase%2520inhibitors%26btitle%3DViral%2520Genome%2520Replication%26aulast%3DCameron%26aufirst%3DC.%2BE.%26pub%3DSpringer%2520Science%2520and%2520Business%2520Media%26date%3D2009%26spage%3D527%26epage%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span> <span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2481</span>– <span class="NLM_lpage">2531</span>, <span class="refDoi"> DOI: 10.1021/jm201384j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase&doi=10.1021%2Fjm201384j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span></div><div class="casAuthors">Sofia, Michael J.; Chang, Wonsuk; Furman, Phillip A.; Mosley, Ralph T.; Ross, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2481-2531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a Perspectives review and does not require an abstr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh0maPUC6grVg90H21EOLACvtfcHk0liPQzqp7Wur8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF&md5=3236ff10d16104b1a39d77f04774ac77</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531%26doi%3D10.1021%2Fjm201384j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vernachio, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleiman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorovits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patti, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madela, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljarah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">INX-08189, a phosphoramidate prodrug of 6-O-methyl-2’-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1851</span>, <span class="refDoi"> DOI: 10.1128/aac.01335-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1128%2FAAC.01335-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=21357300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCls7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1843-1851&author=J.+H.+Vernachioauthor=B.+Bleimanauthor=K.+D.+Bryantauthor=S.+Chamberlainauthor=D.+Hunleyauthor=J.+Hutchinsauthor=B.+Amesauthor=E.+Gorovitsauthor=B.+Gangulyauthor=A.+Hallauthor=A.+Kolykhalovauthor=Y.+Liuauthor=J.+Muhammadauthor=N.+Rajaauthor=C.+R.+Waltersauthor=J.+Wangauthor=K.+Williamsauthor=J.+M.+Pattiauthor=G.+Hensonauthor=K.+Madelaauthor=M.+Aljarahauthor=A.+Gillesauthor=C.+McGuigan&title=INX-08189%2C+a+phosphoramidate+prodrug+of+6-O-methyl-2%E2%80%99-C-methyl+guanosine%2C+is+a+potent+inhibitor+of+hepatitis+C+virus+replication+with+excellent+pharmacokinetic+and+pharmacodynamic+properties&doi=10.1128%2Faac.01335-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties</span></div><div class="casAuthors">Vernachio, John H.; Bleiman, Blair; Bryant, K. Dawn; Chamberlain, Stanley; Hunley, Damound; Hutchins, Jeff; Ames, Brenda; Gorovits, Elena; Ganguly, Babita; Hall, Andrea; Kolykhalov, Alexander; Liu, Yule; Muhammad, Jerry; Raja, Nicholas; Walters, C. Robin; Wang, Jin; Williams, Karen; Patti, Joseph M.; Henson, Geoffrey; Madela, Karolina; Aljarah, Mohamed; Gilles, Arnaud; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1843-1851</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">INX-08189 is an aryl-phosphoramidate of 6-O-methyl-2'-C-Me guanosine.  INX-08189 was highly potent in replicon assays, with a 50% effective concn. of 10 ± 6 nM against hepatitis C genotype 1b at 72 h.  The inhibitory effect on viral replication was rapid, with a 50% effective concn. (EC50) of 35 ± 8 nM at 24 h.  An intracellular 2'-C-Me guanosine triphosphate (2'-C-MeGTP) concn. of 2.43 ± 0.42 pmol/106 cells was sufficient to achieve 90% inhibition of viral replication.  In vitro resistance studies confirmed that the S282T mutation in the NS5b gene conferred an approx. 10-fold redn. in sensitivity to INX-08189.  However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90 of 344 ± 170 nM.  Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency both in wild-type and S282T-expressing replicons.  Genotype 1b replicons could be cleared after 14 days of culture when exposed to as little as 20 nM INX-08189.  No evidence of mitochondrial toxicity was obsd. after 14 days of INX-08189 exposure in both HepG2 and CEM human cell lines.  In vivo studies of rats and cynomolgus monkeys demonstrated that 2'-C-MeGTP concns. in liver equiv. to the EC90 could be attained after a single oral dose of INX-08189.  Rat liver 2'-C-MeGTP concns. were proportional to dose, sustained for greater than 24 h, and correlated with plasma concns. of the nucleoside metabolite 2'-C-Me guanosine.  The characteristics displayed by INX-08189 support its continued development as a clin. candidate for the treatment of chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxZta5SbOb7Vg90H21EOLACvtfcHk0liPQzqp7Wur8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCls7nI&md5=fa567daf81510977bf973dcdf9104a1b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1128%2FAAC.01335-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01335-10%26sid%3Dliteratum%253Aachs%26aulast%3DVernachio%26aufirst%3DJ.%2BH.%26aulast%3DBleiman%26aufirst%3DB.%26aulast%3DBryant%26aufirst%3DK.%2BD.%26aulast%3DChamberlain%26aufirst%3DS.%26aulast%3DHunley%26aufirst%3DD.%26aulast%3DHutchins%26aufirst%3DJ.%26aulast%3DAmes%26aufirst%3DB.%26aulast%3DGorovits%26aufirst%3DE.%26aulast%3DGanguly%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DKolykhalov%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMuhammad%26aufirst%3DJ.%26aulast%3DRaja%26aufirst%3DN.%26aulast%3DWalters%26aufirst%3DC.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DPatti%26aufirst%3DJ.%2BM.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DMadela%26aufirst%3DK.%26aulast%3DAljarah%26aufirst%3DM.%26aulast%3DGilles%26aufirst%3DA.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DINX-08189%252C%2520a%2520phosphoramidate%2520prodrug%2520of%25206-O-methyl-2%25E2%2580%2599-C-methyl%2520guanosine%252C%2520is%2520a%2520potent%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520replication%2520with%2520excellent%2520pharmacokinetic%2520and%2520pharmacodynamic%2520properties%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D1843%26epage%3D1851%26doi%3D10.1128%2Faac.01335-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pockros, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freilich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamparo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath-Chiozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, A. F.</span></span> <span> </span><span class="NLM_article-title">Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1002/hep.27488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1002%2Fhep.27488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=25251156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=409-416&author=T.+Ahmadauthor=P.+Yinauthor=J.+Saffitzauthor=P.+J.+Pockrosauthor=J.+Lalezariauthor=M.+Shiffmanauthor=B.+Freilichauthor=J.+Zamparoauthor=K.+Brownauthor=D.+Dimitrovaauthor=M.+Kumarauthor=D.+Manionauthor=M.+Heath-Chiozziauthor=R.+Wolfauthor=E.+Hughesauthor=A.+J.+Muirauthor=A.+F.+Hernandez&title=Cardiac+dysfunction+associated+with+a+nucleotide+polymerase+inhibitor+for+treatment+of+hepatitis+C&doi=10.1002%2Fhep.27488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C</span></div><div class="casAuthors">Ahmad, Tariq; Yin, Philip; Saffitz, Jeffrey; Pockros, Paul J.; Lalezari, Jacob; Shiffman, Mitchell; Freilich, Bradley; Zamparo, Joann; Brown, Kyle; Dimitrova, Dessislava; Kumar, Monica; Manion, Doug; Heath-Chiozzi, Margo; Wolf, Robert; Hughes, Eric; Muir, Andrew J.; Hernandez, Adrian F.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">409-416</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity.  In this study, we sought to better understand the potential off-target toxicities of new DAAs.  We retrospectively evaluated the clin. and pathol. findings of the sentinel case in a phase II study that led to clin. development discontinuation for BMS-986094, an HCV nucleotide polymerase (nonstructural 5B) inhibitor.  We also report on outcomes from other patients in the same study, including ECG changes, cardiovascular biomarkers, and transthoracic echocardiograms.  Thirty-four patients received IFN-free BMS-986094 regimens.  Six patients had left ventricular ejection fractions (LVEFs) <30%, 8 had LVEFs 30%-50%, and 11 required hospitalization for suspected cardiotoxicity.  Of the patients with LVEF <50%, 6 had normalization of systolic function after a median of 20 days.  T-wave inversions were the most sensitive predictor of LVEF dysfunction.  B-type natriuretic peptide levels increased over time and correlated with the degree of LVEF dysfunction.  Pathol. anal. of cardiac tissue revealed severe myocyte damage with elongated myofibrils without gross necrosis.  These findings were consistent with some results of recent primate studies that were conducted to further investigate the potential mechanisms of BMS-986094 toxicity.  Conclusion: A novel nucleotide analog polymerase inhibitor developed for HCV treatment may cause a toxic cardiomyopathy.  Ongoing surveillance of DAAs for cardiotoxicities may be beneficial, esp. among patients at higher risk for cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyEQeapTO5TrVg90H21EOLACvtfcHk0liPQzqp7Wur8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmsLrF&md5=b1d26affdc6c88bad4498a27fde2d062</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fhep.27488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27488%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DSaffitz%26aufirst%3DJ.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DShiffman%26aufirst%3DM.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DZamparo%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DManion%26aufirst%3DD.%26aulast%3DHeath-Chiozzi%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DHernandez%26aufirst%3DA.%2BF.%26atitle%3DCardiac%2520dysfunction%2520associated%2520with%2520a%2520nucleotide%2520polymerase%2520inhibitor%2520for%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D409%26epage%3D416%26doi%3D10.1002%2Fhep.27488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, B.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naduthambi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection</span>. <i>Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1021/ml100209f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100209f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=130-135&author=W.+Changauthor=D.+Baoauthor=B.-K.+Chunauthor=D.+Naduthambiauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+L.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=C.+Niuauthor=H.+M.+Steuerauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=Discovery+of+PSI-353661%2C+a+novel+purine+nucleotide+prodrug+for+the+treatment+of+HCV+infection&doi=10.1021%2Fml100209f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection</span></div><div class="casAuthors">Chang, Wonsuk; Bao, Donghui; Chun, Byoung-Kwon; Naduthambi, Devan; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine L.; Keilman, Meg; Lam, Angela M.; Niu, Congrong; Steuer, Holly Micolochick; Furman, Phillip A.; Otto, Michael J.; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-135</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus afflicts approx. 180 million people worldwide, and the development of direct acting antivirals may offer substantial benefit compared to the current std. of care.  Accordingly, prodrugs of 2'-deoxy-2'-fluoro-2'-C-methylguanosine monophosphate analogs were prepd. and evaluated for their anti-HCV efficacy and tolerability.  These prodrugs demonstrated >1000 fold greater potency than the parent nucleoside in a cell-based replicon assay as a result of higher intracellular triphosphate levels.  Further optimization led to the discovery of the clin. candidate PSI-353661, which has demonstrated strong in vitro inhibition against HCV without cytotoxicity and equipotent activity against both the wild type and the known S282T nucleoside/tide resistant replicon.  PSI-353661 is currently in preclin. development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYnXUT3TTRBbVg90H21EOLACvtfcHk0lhH5CcFXmFQZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsbfP&md5=81418285042a7e2ee30cbe12f4dc7874</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fml100209f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100209f%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DW.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChun%26aufirst%3DB.-K.%26aulast%3DNaduthambi%26aufirst%3DD.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%2BL.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DDiscovery%2520of%2520PSI-353661%252C%2520a%2520novel%2520purine%2520nucleotide%2520prodrug%2520for%2520the%2520treatment%2520of%2520HCV%2520infection%26jtitle%3DMed.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D130%26epage%3D135%26doi%3D10.1021%2Fml100209f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, B.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">2’-Deoxy-2’-α-fluoro-2’- -C-methyl 3’,5’-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7376</span>– <span class="NLM_lpage">7380</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.bmcl.2010.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=21050754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7376-7380&author=P.+G.+Reddyauthor=D.+Baoauthor=W.+Changauthor=B.-K.+Chunauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=B.+S.+Rossauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+L.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=C.+Niuauthor=H.+M.+Steuerauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=2%E2%80%99-Deoxy-2%E2%80%99-%CE%B1-fluoro-2%E2%80%99-+-C-methyl+3%E2%80%99%2C5%E2%80%99-cyclic+phosphate+nucleotide+prodrug+analogs+as+inhibitors+of+HCV+NS5B+polymerase%3A+discovery+of+PSI-352938&doi=10.1016%2Fj.bmcl.2010.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">2'-Deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938</span></div><div class="casAuthors">Reddy, P. Ganapati; Bao, Donghui; Chang, Wonsuk; Chun, Byoung-Kwon; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Ross, Bruce S.; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine L.; Keilman, Meg; Lam, Angela M.; Niu, Congrong; Steuer, Holly Micolochick; Furman, Phillip A.; Otto, Michael J.; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7376-7380</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel 2'-deoxy-2'-α-fluoro-2'-β-C-Me 3',5'-cyclic phosphate nucleotide prodrug analogs, e.g. I, were synthesized and evaluated for their in vitro anti-HCV activity and safety.  These prodrugs demonstrated a 10-100-fold greater potency than the parent nucleoside in a cell-based replicon assay due to higher cellular triphosphate levels.  Our structure-activity relationship (SAR) studies provided compds. that gave high levels of active triphosphate in rat liver when administered orally to rats.  These studies ultimately led to the selection of the clin. development candidate I (PSI-352938).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogleH0DTX3orVg90H21EOLACvtfcHk0lhH5CcFXmFQZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbzJ&md5=a70a63b690fffed2e37de03cd29dd958</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DChun%26aufirst%3DB.-K.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%2BL.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3D2%25E2%2580%2599-Deoxy-2%25E2%2580%2599-%25CE%25B1-fluoro-2%25E2%2580%2599-%2520-C-methyl%25203%25E2%2580%2599%252C5%25E2%2580%2599-cyclic%2520phosphate%2520nucleotide%2520prodrug%2520analogs%2520as%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520discovery%2520of%2520PSI-352938%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7376%26epage%3D7380%26doi%3D10.1016%2Fj.bmcl.2010.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, B.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Synthesis of PSI-352938: A β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3782</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1021/jo200060f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo200060f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVClur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=3782-3790&author=P.+G.+Reddyauthor=B.-K.+Chunauthor=H.-R.+Zhangauthor=S.+Rachakondaauthor=B.+S.+Rossauthor=M.+J.+Sofia&title=Stereoselective+Synthesis+of+PSI-352938%3A+A+%CE%B2-d-2%E2%80%B2-Deoxy-2%E2%80%B2-%CE%B1-fluoro-2%E2%80%B2-%CE%B2-C-methyl-3%E2%80%B2%2C5%E2%80%B2-cyclic+Phosphate+Nucleotide+Prodrug+for+the+Treatment+of+HCV&doi=10.1021%2Fjo200060f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Synthesis of PSI-352938: A β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyl-3',5'-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV</span></div><div class="casAuthors">Reddy, P. Ganapati; Chun, Byoung-Kwon; Zhang, Hai-Ren; Rachakonda, Suguna; Ross, Bruce S.; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3782-3790</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PSI-352938 is a novel 2'-deoxy-2'-α-fluoro-2'-β-C-Me 3',5'-cyclic phosphate nucleotide prodrug currently under investigation for the treatment of hepatitis C virus (HCV) infection.  PSI-352938 demonstrated superior characteristics in vitro that include broad genotype coverage, superior resistance profile, and high levels of active triphosphate in vivo in the liver compared to our first and second generation nucleoside inhibitors of this class.  Consequently, PSI-352938 was selected for further development and an efficient and scalable synthesis was sought to support clin. development.  We report an improved, diastereoselective synthesis of a key 1'-β-nucleoside intermediate 13 via SN2 displacement of 1-α-bromo ribofuranose sugar 16 with the potassium salt of 6-chloro-2-amino purine and an efficient method to prep. cis-Rp cyclic phosphate (PSI-352938) in a highly stereoselective manner without any chromatog. purifn.  The 1-α-bromo sugar 16 was stereospecifically prepd. from the corresponding 1-β-lactol in high yield under mild bromination conditions using CBr4/PPh3 (Appel reaction).  The desired cis-Rp 3',5'-cyclic phosphate construction was accomplished using iso-Pr phosphorodichloridate readily obtained from POCl3 and iso-Pr alc.  The base combination of Et3N/NMI was identified as a key factor for producing PSI-352938 as the major (>95%) diastereomer (cis-Rp) in high yield after the final cyclization step.  The current route described in this article was successfully used to produce PSI-352938 on multi-kilogram scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWT7SjER_bGbVg90H21EOLACvtfcHk0liSmjJTxHg0ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVClur0%253D&md5=df358665980670feff25531efb192b6c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjo200060f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo200060f%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DChun%26aufirst%3DB.-K.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DStereoselective%2520Synthesis%2520of%2520PSI-352938%253A%2520A%2520%25CE%25B2-d-2%25E2%2580%25B2-Deoxy-2%25E2%2580%25B2-%25CE%25B1-fluoro-2%25E2%2580%25B2-%25CE%25B2-C-methyl-3%25E2%2580%25B2%252C5%25E2%2580%25B2-cyclic%2520Phosphate%2520Nucleotide%2520Prodrug%2520for%2520the%2520Treatment%2520of%2520HCV%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D3782%26epage%3D3790%26doi%3D10.1021%2Fjo200060f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Good, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietropaolo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommadossi, J.-P.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0227104</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0227104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1371%2Fjournal.pone.0227104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=31914458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVemtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=S.+S.+Goodauthor=A.+Moussaauthor=X.-J.+Zhouauthor=K.+Pietropaoloauthor=J.-P.+Sommadossi&title=Preclinical+evaluation+of+AT-527%2C+a+novel+guanosine+nucleotide+prodrug+with+potent%2C+pan-genotypic+activity+against+hepatitis+C+virus&doi=10.1371%2Fjournal.pone.0227104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus</span></div><div class="casAuthors">Good, Steven S.; Moussa, Adel; Zhou, Xiao-Jian; Pietropaolo, Keith; Sommadossi, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0227104</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Despite the availability of highly effective direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infections, sustained viral response (SVR) rates remain suboptimal for difficult-to-treat patient populations such as those with HCV genotype 3, cirrhosis or prior treatment experience, warranting development of more potent HCV replication antivirals.  AT-527 is the hemi-sulfate salt of AT-511, a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate that has potent in vitro activity against HCV.  The EC50 of AT-511, detd. using HCV lab. strains and clin. isolates with genotypes 1-5, ranged from 5-28 nM.  The active 5'-triphosphate metabolite, AT-9010, specifically inhibited the HCV RNA-dependent RNA polymerase.  AT-511 did not inhibit the replication of other selected RNA or DNA viruses in vitro.  AT-511 was approx. 10-fold more active than sofosbuvir (SOF) against a panel of lab. strains and clin. isolates of HCV genotypes 1-5 and remained fully active against S282T resistance-assocd. variants, with up to 58-fold more potency than SOF.  In vitro, AT-511 did not inhibit human DNA polymerases or elicit cytotoxicity or mitochondrial toxicity at concns. up to 100 μM.  Unlike the other potent guanosine analogs PSI-938 and PSI-661, no mutagenic O6-alkylguanine bases were formed when incubated with cytochrome P 450 (CYP) 3A4, and AT-511 had IC50 values ≥25 μM against a panel of CYP enzymes.  In hepatocytes from multiple species, the active triphosphate was the predominant metabolite produced from the prodrug, with a half-life of 10 h in human hepatocytes.  When given orally to rats and monkeys, AT-527 preferentially delivered high levels of AT-9010 in the liver in vivo.  These favorable preclin. attributes support the ongoing clin. development of AT-527 and suggest that, when used in combination with an HCV DAA from a different class, AT-527 may increase SVR rates, esp. for difficult-to-treat patient populations, and could potentially shorten treatment duration for all patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg4kNQcDe-jrVg90H21EOLACvtfcHk0liSmjJTxHg0ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVemtLk%253D&md5=d42edf843eadb172e47b8681b4a4b8ba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0227104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0227104%26sid%3Dliteratum%253Aachs%26aulast%3DGood%26aufirst%3DS.%2BS.%26aulast%3DMoussa%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DX.-J.%26aulast%3DPietropaolo%26aufirst%3DK.%26aulast%3DSommadossi%26aufirst%3DJ.-P.%26atitle%3DPreclinical%2520evaluation%2520of%2520AT-527%252C%2520a%2520novel%2520guanosine%2520nucleotide%2520prodrug%2520with%2520potent%252C%2520pan-genotypic%2520activity%2520against%2520hepatitis%2520C%2520virus%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0227104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinkade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajwanshi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=28412183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsl2qs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2017&pages=151-161&author=Z.+Jinauthor=A.+Kinkadeauthor=I.+Beheraauthor=S.+Chaudhuriauthor=K.+Tuckerauthor=N.+Dyatkinaauthor=V.+K.+Rajwanshiauthor=G.+Wangauthor=A.+Jekleauthor=D.+B.+Smithauthor=L.+Beigelmanauthor=J.+A.+Symonsauthor=J.+Deval&title=Structure-activity+relationship+analysis+of+mitochondrial+toxicity+caused+by+antiviral+ribonucleoside+analogs&doi=10.1016%2Fj.antiviral.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs</span></div><div class="casAuthors">Jin, Zhinan; Kinkade, April; Behera, Ishani; Chaudhuri, Shuvam; Tucker, Kathryn; Dyatkina, Natalia; Rajwanshi, Vivek K.; Wang, Guangyi; Jekle, Andreas; Smith, David B.; Beigelman, Leo; Symons, Julian A.; Deval, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent cases of severe toxicity during clin. trials have been assocd. with antiviral ribonucleoside analogs (e.g. INX-08189 and balapiravir).  Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis.  Others have proposed that the prodrug moiety released from the ribonucleoside analogs might instead cause toxicity.  Here, we report the mitochondrial effects of several clin. relevant and structurally diverse ribonucleoside analogs including NITD-008, T-705 (favipiravir), R1479 (parent nucleoside of balapiravir), PSI-7851 (sofosbuvir), and INX-08189 (BMS-986094).  We found that efficient substrates and chain terminators of POLRMT, such as the nucleoside triphosphate forms of R1479, NITD-008, and INX-08189, are likely to cause mitochondrial toxicity in cells, while weaker chain terminators and inhibitors of POLRMT such as T-705 ribonucleoside triphosphate do not elicit strong in vitro mitochondrial effects.  Within a fixed 3'-deoxy or 2'-C-Me ribose scaffold, changing the base moiety of nucleotides did not strongly affect their inhibition const. (Ki) against POLRMT.  By swapping the nucleoside and prodrug moieties of PSI-7851 and INX-08189, we demonstrated that the cell-based toxicity of INX-08189 is mainly caused by the nucleoside component of the mol.  Taken together, these results show that diverse 2' or 4' mono-substituted ribonucleoside scaffolds cause mitochondrial toxicity.  Given the unpredictable structure-activity relationship of this ribonucleoside liability, we propose a rapid and systematic in vitro screen combining cell-based and biochem. assays to identify the early potential for mitochondrial toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBinliDlsUrVg90H21EOLACvtfcHk0liB46ruK2iDkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsl2qs7g%253D&md5=9882bc8f2be6475219392f0775cfa41b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DKinkade%26aufirst%3DA.%26aulast%3DBehera%26aufirst%3DI.%26aulast%3DChaudhuri%26aufirst%3DS.%26aulast%3DTucker%26aufirst%3DK.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DRajwanshi%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJekle%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DDeval%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%2520analysis%2520of%2520mitochondrial%2520toxicity%2520caused%2520by%2520antiviral%2520ribonucleoside%2520analogs%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D143%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.antiviral.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsertsvadze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streinu-Cercel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijgen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astruc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khorlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, J.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0204974</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0204974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1371%2Fjournal.pone.0204974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=30325939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=M.+McClureauthor=E.+Berlibaauthor=T.+Tsertsvadzeauthor=A.+Streinu-Cercelauthor=L.+Vijgenauthor=B.+Astrucauthor=A.+Patatauthor=C.+Westlandauthor=S.+Chandaauthor=Q.+Zhangauthor=T.+N.+Kakudaauthor=J.+Vuongauthor=N.+Khorlinauthor=L.+Beigelmanauthor=L.+M.+Blattauthor=J.+Fry&title=Safety%2C+tolerability%2C+and+pharmacokinetics+of+AL-335+in+healthy+volunteers+and+hepatitis+C+virus-infected+subjects&doi=10.1371%2Fjournal.pone.0204974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects</span></div><div class="casAuthors">McClure, Matthew W.; Berliba, Elina; Tsertsvadze, Tengiz; Streinu-Cercel, Adrian; Vijgen, Leen; Astruc, Beatrice; Patat, Alain; Westland, Christopher; Chanda, Sushmita; Zhang, Qingling; Kakuda, Thomas N.; Vuong, Jennifer; Khorlin, Nick; Beigelman, Leonid; Blatt, Lawrence M.; Fry, John</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0204974/1-e0204974/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection.  Methods This three-part randomized, double-blind study evaluated the safety and pharmacokinetics of single and multiple ascending oral doses of AL-335.  Healthy volunteers (HVs) received single doses of AL-335 (100-1,200 mg) or placebo in a fasted or fed (400 mg) state.  Non-cirrhotic subjects (HCV genotype [GT]1-4) and GT1-infected subjects with Child Pugh A cirrhosis received multiple doses of AL-335 (400, 800, 1,200 mg) or placebo once daily (QD) for 7 days.  Results Forty-eight HVs and 64 subjects with HCV GT1-4 were randomized and received treatment.  AL-335 was well tolerated in HVs and HCV-infected subjects with/without cirrhosis.  AL-335 was rapidly absorbed and converted to the metabolites ALS-022399 and ALS-022227.  ALS-022227 exposure increased less than dose-proportionally and was unaffected by food, while AL-335 and ALS-022399 exposure increased with food by 85% and 50%, resp., in HVs.  Rapid and dose-dependent redns. in HCV-RNA were obsd. in GT1-infected subjects.  In non-cirrhotic, GT1-4-infected subjects receiving AL-335 800 mg QD, potent antiviral activity was obsd., regardless of genotype (mean max. redns. in HCV-RNA of 4.0-4.8 log10 IU/mL).  The same dose in GT1-infected cirrhotic subjects resulted in a 3.5 log10 IU/mL mean max. redn. in HCV-RNA.  Conclusions AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile.  The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNd9ewfVm6rVg90H21EOLACvtfcHk0lgt5sJLSIGAgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFKgsr8%253D&md5=670b9fe950238a1d0d2da630c38a3768</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0204974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0204974%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DM.%26aulast%3DBerliba%26aufirst%3DE.%26aulast%3DTsertsvadze%26aufirst%3DT.%26aulast%3DStreinu-Cercel%26aufirst%3DA.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DAstruc%26aufirst%3DB.%26aulast%3DPatat%26aufirst%3DA.%26aulast%3DWestland%26aufirst%3DC.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DVuong%26aufirst%3DJ.%26aulast%3DKhorlin%26aufirst%3DN.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DFry%26aufirst%3DJ.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520AL-335%2520in%2520healthy%2520volunteers%2520and%2520hepatitis%2520C%2520virus-infected%2520subjects%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0204974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, J.</span></span> <span> </span><span class="NLM_article-title">Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">S82</span>, <span class="refDoi"> DOI: 10.1016/s0168-8278(17)30429-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2FS0168-8278%2817%2930429-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=S82&author=E.+Ganeauthor=M.+Stedmanauthor=D.+Apelianauthor=C.+Westlandauthor=J.+Vuongauthor=M.+Patelauthor=T.+Kakudaauthor=S.+Chandaauthor=L.+Blattauthor=L.+Beigelmanauthor=D.+Smithauthor=J.+Fry&title=Short+duration+treatment+with+AL-335+and+odalasvir%2C+with+or+without+simeprevir%2C+in+treatment+na%C3%AFve+patients+with+hepatitis+C+infection+with+or+without+cirrhosis&doi=10.1016%2Fs0168-8278%2817%2930429-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2817%2930429-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252817%252930429-4%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%26aulast%3DStedman%26aufirst%3DM.%26aulast%3DApelian%26aufirst%3DD.%26aulast%3DWestland%26aufirst%3DC.%26aulast%3DVuong%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DKakuda%26aufirst%3DT.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DFry%26aufirst%3DJ.%26atitle%3DShort%2520duration%2520treatment%2520with%2520AL-335%2520and%2520odalasvir%252C%2520with%2520or%2520without%2520simeprevir%252C%2520in%2520treatment%2520na%25C3%25AFve%2520patients%2520with%2520hepatitis%2520C%2520infection%2520with%2520or%2520without%2520cirrhosis%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D66%26spage%3DS82%26doi%3D10.1016%2Fs0168-8278%2817%2930429-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pianko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Ari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laursen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstoft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernsler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutko, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.-Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plank, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, R.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1016/s2468-1253(17)30159-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fs2468-1253%2817%2930159-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=28802816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BC1cfntVCltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=805-813&author=E.+J.+Ganeauthor=S.+Piankoauthor=S.+K.+Robertsauthor=A.+J.+Thompsonauthor=S.+Zeuzemauthor=E.+Zuckermanauthor=Z.+Ben-Ariauthor=G.+R.+Fosterauthor=K.+Agarwalauthor=A.+L.+Laursenauthor=J.+Gerstoftauthor=W.+Gaoauthor=H.-C.+Huangauthor=B.+Fitzgeraldauthor=D.+Fernslerauthor=J.+J.+Liauthor=A.+Grandhiauthor=H.+Liuauthor=F.-H.+Suauthor=S.+Wanauthor=Z.+Zengauthor=H.-L.+Chenauthor=F.+J.+Dutkoauthor=B.-Y.+T.+Nguyenauthor=J.+Wahlauthor=M.+N.+Robertsonauthor=E.+Barrauthor=W.+W.+Yehauthor=R.+M.+Plankauthor=J.+R.+Buttertonauthor=R.+Esteban&title=Safety+and+efficacy+of+an+8-week+regimen+of+grazoprevir+plus+ruzasvir+plus+uprifosbuvir+compared+with+grazoprevir+plus+elbasvir+plus+uprifosbuvir+in+participants+without+cirrhosis+infected+with+hepatitis+C+virus+genotypes+1%2C+2%2C+or+3+%28C-CREST-1+and+C-CREST-2%2C+part+A%29%3A+two+randomised%2C+phase+2%2C+open-label+trials&doi=10.1016%2Fs2468-1253%2817%2930159-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials</span></div><div class="casAuthors">Gane Edward J; Pianko Stephen; Roberts Stuart K; Thompson Alexander J; Zeuzem Stefan; Zuckerman Eli; Ben-Ari Ziv; Foster Graham R; Agarwal Kosh; Laursen Alex L; Gerstoft Jan; Gao Wei; Huang Hsueh-Cheng; Fitzgerald Brian; Fernsler Doreen; Li Jerry J; Grandhi Anjana; Liu Hong; Su Feng-Hsiu; Wan Shuyan; Zeng Zhen; Chen Huei-Ling; Dutko Frank J; Nguyen Bach-Yen T; Wahl Janice; Robertson Michael N; Barr Eliav; Yeh Wendy W; Plank Rebeca M; Butterton Joan R; Esteban Rafael</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">805-813</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed.  The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these combination regimens in individuals infected with genotypes 1, 2, or 3.  METHODS:  Part A of these phase 2, randomised, multicentre, open-label, clinical trials enrolled participants from 11 countries, aged 18 years or older, chronically infected with HCV genotypes 1, 2, or 3, with HCV RNA of at least 10 000 IU/mL, without evidence of cirrhosis, who had not received previous treatment for HCV infection.  Within each HCV genotype, participants were randomly assigned (1:1:1:1) with a block size of 4, to open-label treatment to one of four treatment groups: grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (300 mg/day); grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (450 mg/day); grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (300 mg/day); or grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (450 mg/day), according to a computer-generated allocation schedule.  Randomisation was centrally implemented using an interactive voice response system and integrated web response system.  The primary endpoint was the proportion of participants achieving sustained virological response at 12 weeks (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the end of all study therapy) in the per-protocol analysis set, which included all participants who were randomised and received at least one dose of study drug.  The trials are registered with ClinicalTrials.gov, numbers NCT02332707 and NCT02332720.  FINDINGS:  241 participants were randomised between Feb 18, 2015, and March 16, 2015. 240 participants completed 8 weeks of treatment and reached follow-up 12 weeks after the end of treatment.  Of the four regimens, grazoprevir plus ruzasvir plus uprifosbuvir 450 mg had the most consistently high SVR12 (>90%) for participants infected with genotype 1 (21 [91%] of 23), genotype 2 (15 [94%] of 16), and genotype 3 (20 [91%] of 22).  In particular, among those with genotype 2 infection, the grazoprevir plus ruzasvir plus uprifosbuvir 450 mg regimen had a higher SVR12 (15 [94%] of 16) than the grazoprevir plus ruzasvir plus uprifosbuvir 300 mg regimen (ten [71%] of 14), grazoprevir plus elbasvir plus uprifosbuvir 300 mg regimen (11 [69%] of 16), or grazoprevir plus elbasvir plus uprifosbuvir 450 mg regimen (nine [60%] of 15).  Overall, the most common adverse events were headache (55 [23%] of 240), fatigue (47 [20%] of 240), and nausea (32 [13%] of 240).  Two (<1%) of 240 participants had serious adverse events (pharyngeal abscess and keratitis), which were not considered drug related by the respective investigators.  INTERPRETATION:  These results support further evaluation of the three-drug direct-acting antiviral agent regimen of grazoprevir 100 mg plus ruzasvir 60 mg plus uprifosbuvir 450 mg among a more diverse HCV-infected population, including those with compensated cirrhosis, previous treatment with an interferon-containing regimen, and HCV-HIV co-infection.  FUNDING:  Merck & Co, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwDc6dMJIt6RBrI9DTGjC0fW6udTcc2eatuaDv1s_R0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfntVCltg%253D%253D&md5=e6db5c94fdb651b61ecb5f2e555c9dd5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fs2468-1253%2817%2930159-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs2468-1253%252817%252930159-0%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DZuckerman%26aufirst%3DE.%26aulast%3DBen-Ari%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DLaursen%26aufirst%3DA.%2BL.%26aulast%3DGerstoft%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DFitzgerald%26aufirst%3DB.%26aulast%3DFernsler%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DGrandhi%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DF.-H.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.-L.%26aulast%3DDutko%26aufirst%3DF.%2BJ.%26aulast%3DNguyen%26aufirst%3DB.-Y.%2BT.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26aulast%3DBarr%26aufirst%3DE.%26aulast%3DYeh%26aufirst%3DW.%2BW.%26aulast%3DPlank%26aufirst%3DR.%2BM.%26aulast%3DButterton%26aufirst%3DJ.%2BR.%26aulast%3DEsteban%26aufirst%3DR.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520an%25208-week%2520regimen%2520of%2520grazoprevir%2520plus%2520ruzasvir%2520plus%2520uprifosbuvir%2520compared%2520with%2520grazoprevir%2520plus%2520elbasvir%2520plus%2520uprifosbuvir%2520in%2520participants%2520without%2520cirrhosis%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotypes%25201%252C%25202%252C%2520or%25203%2520%2528C-CREST-1%2520and%2520C-CREST-2%252C%2520part%2520A%2529%253A%2520two%2520randomised%252C%2520phase%25202%252C%2520open-label%2520trials%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D2%26spage%3D805%26epage%3D813%26doi%3D10.1016%2Fs2468-1253%2817%2930159-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leisvuori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lönnberg, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 3’,5’-cyclic phosphate and thiophosphate esters of 2’-C-methyl ribonucleosides</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1512</span>– <span class="NLM_lpage">1520</span>, <span class="refDoi"> DOI: 10.1002/hlca.201200099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1002%2Fhlca.201200099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGhtrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2012&pages=1512-1520&author=A.+Leisvuoriauthor=Z.+Ahmedauthor=M.+Oraauthor=L.+Beigelmanauthor=L.+Blattauthor=H.+L%C3%B6nnberg&title=Synthesis+of+3%E2%80%99%2C5%E2%80%99-cyclic+phosphate+and+thiophosphate+esters+of+2%E2%80%99-C-methyl+ribonucleosides&doi=10.1002%2Fhlca.201200099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 3',5'-Cyclic Phosphate and Thiophosphate Esters of 2'-C-Methyl Ribonucleosides</span></div><div class="casAuthors">Leisvuori, Anna; Ahmed, Zafar; Ora, Mikko; Beigelman, Leonid; Blatt, Lawrence; Loennberg, Harri</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1512-1520</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">2'-C-Methylnucleosides are known to exhibit antiviral activity against Hepatitis C virus.  Since the inhibitory activity depends on their intracellular conversion to 5'-triphosphates, dosing as appropriately protected 5'-phosphates or 5'-phosphorothioates appears attractive.  For this purpose, four potential prodrugs of 2'-C-methylguanosine, i.e., 3',5'-cyclic phosphorothioate of 2'-C-methylguanosine I and 2'-C,O6-dimethylguanosine resp., the S-[(pivaloyloxy)methyl] ester of 2'-C,O6-dimethylguanosine 3',5'-cyclic phosphorothioate and the O-Me ester of 2'-C,O6-dimethylguanosine 3',5'-cyclic phosphate resp., have been prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNgtFTyoHvUrVg90H21EOLACvtfcHk0lg8D-rkO852iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGhtrvM&md5=07896f17fd724c34be943518191aca31</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fhlca.201200099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.201200099%26sid%3Dliteratum%253Aachs%26aulast%3DLeisvuori%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DZ.%26aulast%3DOra%26aufirst%3DM.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DL%25C3%25B6nnberg%26aufirst%3DH.%26atitle%3DSynthesis%2520of%25203%25E2%2580%2599%252C5%25E2%2580%2599-cyclic%2520phosphate%2520and%2520thiophosphate%2520esters%2520of%25202%25E2%2580%2599-C-methyl%2520ribonucleosides%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2012%26volume%3D95%26spage%3D1512%26epage%3D1520%26doi%3D10.1002%2Fhlca.201200099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Beigelman, L.</span>; <span class="NLM_string-name">Dyatkina, N.</span>; <span class="NLM_string-name">Symons, J. A.</span>; <span class="NLM_string-name">Smith, D. B.</span></span> <span> </span><span class="NLM_article-title">Substituted Nucleosides, Nucleotides and Analogs Thereof</span>. U.S. Patent <span class="NLM_patent">20,150,366,887 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+M.+Blatt&author=L.+Beigelman&author=N.+Dyatkina&author=J.+A.+Symons&author=D.+B.+Smith&title=Substituted+Nucleosides%2C+Nucleotides+and+Analogs+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DSubstituted%2520Nucleosides%252C%2520Nucleotides%2520and%2520Analogs%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, C.</span>; <span class="NLM_string-name">Wucherpfennig, K.</span>; <span class="NLM_string-name">Pyrdol, J.</span>; <span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Methods for treating cancer with anti bip or anti mica antibodies</span>. <span class="NLM_patent">WO 2015179627 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+Harvey&author=K.+Wucherpfennig&author=J.+Pyrdol&author=G.+Dranoff&title=Methods+for+treating+cancer+with+anti+bip+or+anti+mica+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DC.%26atitle%3DMethods%2520for%2520treating%2520cancer%2520with%2520anti%2520bip%2520or%2520anti%2520mica%2520antibodies%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Surleraux, D.</span>; <span class="NLM_string-name">Gosselin, G.</span></span> <span> </span><span class="NLM_article-title">Compounds and Pharmaceutical Compositions for Treatment of Viral Infections</span>. <span class="NLM_patent">TW I515000 B</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Surleraux&author=G.+Gosselin&title=Compounds+and+Pharmaceutical+Compositions+for+Treatment+of+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSurleraux%26aufirst%3DD.%26atitle%3DCompounds%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Treatment%2520of%2520Viral%2520Infections%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owen, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyden, J. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffatt, J. G.</span></span> <span> </span><span class="NLM_article-title">4’-Substituted nucleosides. 3. Synthesis of some 4’-fluorouridine derivatives</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3010</span>– <span class="NLM_lpage">3017</span>, <span class="refDoi"> DOI: 10.1021/jo00880a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00880a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADyaE28XltVyqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1976&pages=3010-3017&author=G.+R.+Owenauthor=J.+P.+H.+Verheydenauthor=J.+G.+Moffatt&title=4%E2%80%99-Substituted+nucleosides.+3.+Synthesis+of+some+4%E2%80%99-fluorouridine+derivatives&doi=10.1021%2Fjo00880a018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">4'-Substituted nucleosides.  3.  Synthesis of some 4'-fluorouridine derivatives</span></div><div class="casAuthors">Owen, Geoffrey R.; Verheyden, Julien P. H.; Moffatt, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3010-17</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The reaction of 1-(5-deoxy-2,3-O-isopropylidene-β-D-erythro-pent-4-enofuranosyl)uracil with IF in CH2Cl2 leads to the stereospecific formation of 5'-deoxy-4'-fluoro-5'-iodo-2',3'-O-isopropylideneuridine which can be converted into the 5'-azido deriv. (I) by vigorous treatment with LiN3 in DMF.  Treatment of I with nitrosyl tetrafluoroborate gave 2,5'-anhydro-4'-fluoro-2',3'-O-isopropylideneuridine which can be hydrolyzed to 4'-fluoro-2',3'-O-isopropylideneuridine (II).  The latter compd. was converted into 4'-fluoro-5'-O-sulfamoyluridine, the uracil analog. of nucleocidin, by treatment with sulfamoyl chloride followed by mild acidic hydrolysis.  4'-Fluorouridine 5'-phosphate was prepd. via conversion of II to its bis(2,2,2-trichloroethyl)phosphate ester followed by deblocking.  The unusual stabilities of 4'-fluorouridine derivs. are discussed.  In addn., treatment of 2',3'-methoxymethylene- and 2',3'-methoxyethylideneuridine derivs. with nitrosyl tetrafluoroborate gave 2,2'-anhydro-1-β-D-arabinofuranosyluracils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwRHEkJ1WrxrVg90H21EOLACvtfcHk0lg8D-rkO852iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltVyqs7c%253D&md5=047a45d0822a2efd40ef282597a45140</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo00880a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00880a018%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DG.%2BR.%26aulast%3DVerheyden%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DMoffatt%26aufirst%3DJ.%2BG.%26atitle%3D4%25E2%2580%2599-Substituted%2520nucleosides.%25203.%2520Synthesis%2520of%2520some%25204%25E2%2580%2599-fluorouridine%2520derivatives%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1976%26volume%3D41%26spage%3D3010%26epage%3D3017%26doi%3D10.1021%2Fjo00880a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajwanshi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinkade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-nucleosides as favipiravir (T-705) analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4611</span>– <span class="NLM_lpage">4624</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslWhsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4611-4624&author=G.+Wangauthor=J.+Wanauthor=Y.+Huauthor=X.+Wuauthor=M.+Prhavcauthor=N.+Dyatkinaauthor=V.+K.+Rajwanshiauthor=D.+B.+Smithauthor=A.+Jekleauthor=A.+Kinkadeauthor=J.+A.+Symonsauthor=Z.+Jinauthor=J.+Devalauthor=Q.+Zhangauthor=Y.+Tamauthor=S.+Chandaauthor=L.+Blattauthor=L.+Beigelman&title=Synthesis+and+anti-influenza+activity+of+pyridine%2C+pyridazine%2C+and+pyrimidine+C-nucleosides+as+favipiravir+%28T-705%29+analogues&doi=10.1021%2Facs.jmedchem.5b01933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues</span></div><div class="casAuthors">Wang, Guangyi; Wan, Jinqiao; Hu, Yujian; Wu, Xiangyang; Prhavc, Marija; Dyatkina, Natalia; Rajwanshi, Vivek K.; Smith, David B.; Jekle, Andreas; Kinkade, April; Symons, Julian A.; Jin, Zhinan; Deval, Jerome; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita; Blatt, Lawrence; Beigelman, Leonid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4611-4624</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Influenza viruses are responsible for seasonal epidemics and occasional pandemics which cause significant morbidity and mortality.  Despite available vaccines, only partial protection is achieved.  Currently, there are two classes of widely approved anti-influenza drugs: M2 ion channel blockers and neuraminidase inhibitors.  However, the worldwide spread of drug-resistant influenza strains poses an urgent need for novel antiviral drugs, particularly with a different mechanism of action.  Favipiravir (T-705), a broad-spectrum antiviral agent, has shown potent anti-influenza activity in cell-based assays, and its riboside I triphosphate inhibited influenza polymerase.  In one of our approaches to treat influenza infection, we designed, prepd., and tested a series of C-nucleoside analogs, which have an analogy to I and were expected to act by a similar antiviral mechanism as favipiravir.  Compd. II of this report exhibited potent inhibition of influenza virus replication in MDCK cells, and its triphosphate was a substrate of and demonstrated inhibitory activity against influenza A polymerase.  Metabolites of II are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRioGBuwYw4bVg90H21EOLACvtfcHk0ljyCWlcoF6YBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslWhsrs%253D&md5=971a0286f4635e72134d99f9f86320da</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01933%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DRajwanshi%26aufirst%3DV.%2BK.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DJekle%26aufirst%3DA.%26aulast%3DKinkade%26aufirst%3DA.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520anti-influenza%2520activity%2520of%2520pyridine%252C%2520pyridazine%252C%2520and%2520pyrimidine%2520C-nucleosides%2520as%2520favipiravir%2520%2528T-705%2529%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4611%26epage%3D4624%26doi%3D10.1021%2Facs.jmedchem.5b01933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoycheva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-HCV activities of 4’-fluoro-2’-substituted uridine triphosphates and nucleotide prodrugs: discovery of 4’-fluoro-2’- C-methyluridine 5’-phosphoramidate prodrug (AL-335) for the treatment of hepatitis C infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4555</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVenu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4555-4570&author=G.+Wangauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=C.+Williamsauthor=V.+Serebryanyauthor=Y.+Huauthor=Y.+Huangauthor=J.+Wanauthor=X.+Wuauthor=J.+Devalauthor=A.+Fungauthor=Z.+Jinauthor=H.+Tanauthor=K.+Shawauthor=H.+Kangauthor=Q.+Zhangauthor=Y.+Tamauthor=A.+Stoychevaauthor=A.+Jekleauthor=D.+B.+Smithauthor=L.+Beigelman&title=Synthesis+and+anti-HCV+activities+of+4%E2%80%99-fluoro-2%E2%80%99-substituted+uridine+triphosphates+and+nucleotide+prodrugs%3A+discovery+of+4%E2%80%99-fluoro-2%E2%80%99-+C-methyluridine+5%E2%80%99-phosphoramidate+prodrug+%28AL-335%29+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Facs.jmedchem.9b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'-C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Wang, Guangyi; Dyatkina, Natalia; Prhavc, Marija; Williams, Caroline; Serebryany, Vladimir; Hu, Yujian; Huang, Yongfei; Wan, Jinqiao; Wu, Xiangyang; Deval, Jerome; Fung, Amy; Jin, Zhinan; Tan, Hua; Shaw, Kenneth; Kang, Hyunsoon; Zhang, Qingling; Tam, Yuen; Stoycheva, Antitsa; Jekle, Andreas; Smith, David B.; Beigelman, Leonid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4555-4570</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C is a major liver disease caused by hepatitis C virus.  Current std. of care for HCV using direct-acting antiviral agents in combination can achieve cure rates above 95%.  However, the long term use of these drugs may lead to viral resistance and a higher rate of adverse effects.  Toward this goal, we made a significant effort in search of safe and effective nucleoside HCV inhibitors.  In this article, we report synthesis and biol. evaluation of a series of 4'-fluoro-2'-C-substituted uridines, e.g. I.  Triphosphates of the uridine analogs exhibited potent inhibition of HCV NS5B polymerase with IC50 values as low as 27 nM.  In an HCV sub-genomic replicon assay, the phosphoramidate prodrugs of these uridine analogs demonstrated very potent activity with EC50 values as low as 20 nM.  A lead compd. (Sp)-I demonstrated high levels of the NTP in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose.  Compd. (Sp)-I (AL-335) was selected for clin. development where it showed promising results in Phase 1 and II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCi7dY7StL_rVg90H21EOLACvtfcHk0ljyCWlcoF6YBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVenu7g%253D&md5=e20e066b0ac49975f6ad82c5ff9c82b3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00143%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DStoycheva%26aufirst%3DA.%26aulast%3DJekle%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520anti-HCV%2520activities%2520of%25204%25E2%2580%2599-fluoro-2%25E2%2580%2599-substituted%2520uridine%2520triphosphates%2520and%2520nucleotide%2520prodrugs%253A%2520discovery%2520of%25204%25E2%2580%2599-fluoro-2%25E2%2580%2599-%2520C-methyluridine%25205%25E2%2580%2599-phosphoramidate%2520prodrug%2520%2528AL-335%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4555%26epage%3D4570%26doi%3D10.1021%2Facs.jmedchem.9b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailopulo, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poopeiko, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prikota, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivets, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvasyuk, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiviral and cytostatic properties of 3’-deoxy-3’-fluoro- and 2’-azido-3’-fluoro-2’,3’-dideoxy-D-ribofuranosides of natural heterocyclic bases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2195</span>– <span class="NLM_lpage">2202</span>, <span class="refDoi"> DOI: 10.1021/jm00111a040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00111a040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADyaK3MXksFSitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=2195-2202&author=I.+A.+Mikhailopuloauthor=N.+E.+Poopeikoauthor=T.+I.+Prikotaauthor=G.+G.+Sivetsauthor=E.+I.+Kvasyukauthor=J.+Balzariniauthor=E.+De+Clercq&title=Synthesis+and+antiviral+and+cytostatic+properties+of+3%E2%80%99-deoxy-3%E2%80%99-fluoro-+and+2%E2%80%99-azido-3%E2%80%99-fluoro-2%E2%80%99%2C3%E2%80%99-dideoxy-D-ribofuranosides+of+natural+heterocyclic+bases&doi=10.1021%2Fjm00111a040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases</span></div><div class="casAuthors">Mikhailopulo, I. A.; Poopeiko, N. E.; Prikota, T. I.; Sivets, G. G.; Kvasyuk, E. I.; Balzarini, J.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2195-202</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 3'-deoxy-3'-fluoro- and 2'-azido-2',3'-dideoxy-3'-fluoro-D-ribofuranosides of natural heterocyclic bases were synthesized with the use of universal carbohydrate precursors, viz., 1-O-acetyl-2,5-di-O-benzoyl-3-deoxy-3-fluoro-D-ribofuranose and Me 2-azido-5-O-benzoyl-2,3-dideoxy-3-fluoro-β-D-ribofuranoside, resp.  The cytostatic and antiviral activities of the compds. were evaluated against a variety of tumor cell lines and DNA/RNA viruses, resp.  As the most active compd., from both a cytostatic and antiviral activity viewpoint, emerged 3'-deoxy-3'-fluoroadenosine (I).  It inhibited the proliferation of some tumor cell lines (i.e. murine leukemia L1210 and human T-lymphocyte MT-4) at a concn. of 0.2-2 μg/mL, and proved inhibitory to the replication of pos.-stranded RNA viruses (i.e. polio, Coxsackie, Sindbis, Semliki forest), double-stranded RNA viruses (i.e. reo), and some DNA viruses (i.e. vaccinia) at a concn. of 1-4 μg/mL, which is well below the cytotoxicity threshold (40 μg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Utul8wVwtbVg90H21EOLACvtfcHk0ljyCWlcoF6YBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksFSitbg%253D&md5=55360c8e7cfa3f5f23a44f45af7c6e2f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00111a040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00111a040%26sid%3Dliteratum%253Aachs%26aulast%3DMikhailopulo%26aufirst%3DI.%2BA.%26aulast%3DPoopeiko%26aufirst%3DN.%2BE.%26aulast%3DPrikota%26aufirst%3DT.%2BI.%26aulast%3DSivets%26aufirst%3DG.%2BG.%26aulast%3DKvasyuk%26aufirst%3DE.%2BI.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520antiviral%2520and%2520cytostatic%2520properties%2520of%25203%25E2%2580%2599-deoxy-3%25E2%2580%2599-fluoro-%2520and%25202%25E2%2580%2599-azido-3%25E2%2580%2599-fluoro-2%25E2%2580%2599%252C3%25E2%2580%2599-dideoxy-D-ribofuranosides%2520of%2520natural%2520heterocyclic%2520bases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D2195%26epage%3D2202%26doi%3D10.1021%2Fjm00111a040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic hydrochlorination of unactivated olefins with para-toluenesulfonyl chloride</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5758</span>– <span class="NLM_lpage">5760</span>, <span class="refDoi"> DOI: 10.1002/anie.200801760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1002%2Fanie.200801760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=18576460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsFKrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5758-5760&author=B.+Gasparauthor=E.+M.+Carreira&title=Catalytic+hydrochlorination+of+unactivated+olefins+with+para-toluenesulfonyl+chloride&doi=10.1002%2Fanie.200801760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic hydrochlorination of unactivated olefins with para-toluenesulfonyl chloride</span></div><div class="casAuthors">Gaspar, Boris; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">5758-5760</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The hydrochlorination of unactivated alkenes with p-toluenesulfonyl chloride is catalyzed by simple cobalt complexes of ligands I and II and proceeds under very mild conditions.  The ready availability of all components and the ease of execution render the method very convenient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJdFgqDojFSLVg90H21EOLACvtfcHk0ljLFvmpLjuOGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsFKrsr4%253D&md5=320a6e19ca59471cca3ff3c7af8ad443</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.200801760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200801760%26sid%3Dliteratum%253Aachs%26aulast%3DGaspar%26aufirst%3DB.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DCatalytic%2520hydrochlorination%2520of%2520unactivated%2520olefins%2520with%2520para-toluenesulfonyl%2520chloride%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D5758%26epage%3D5760%26doi%3D10.1002%2Fanie.200801760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Hydrazines and azides via the metal-matalyzed hydrohydrazination and hydroazidation of olefins</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">11693</span>– <span class="NLM_lpage">11712</span>, <span class="refDoi"> DOI: 10.1021/ja062355+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja062355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVKhsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=11693-11712&author=J.+Waserauthor=B.+Gasparauthor=H.+Nambuauthor=E.+M.+Carreira&title=Hydrazines+and+azides+via+the+metal-matalyzed+hydrohydrazination+and+hydroazidation+of+olefins&doi=10.1021%2Fja062355%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrazines and Azides via the Metal-Catalyzed Hydrohydrazination and Hydroazidation of Olefins</span></div><div class="casAuthors">Waser, Jerome; Gaspar, Boris; Nambu, Hisanori; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">11693-11712</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery, study, and implementation of the Co- and Mn-catalyzed hydrohydrazination and hydroazidation reactions of olefins are reported.  These reactions are equiv. to direct hydroaminations of C-C double bonds with protected hydrazines or hydrazoic acid but are based on a different concept in which the H and the N atoms come from two different reagents, a silane and an oxidizing nitrogen source (azodicarboxylate or sulfonyl azide).  The hydrohydrazination reaction using di-tert-Bu azodicarboxylate is characterized by its ease of use, large functional group tolerance, and broad scope, including mono-, di-, tri-, and tetrasubstituted olefins.  Key to the development of the hydroazidation reaction was the use of sulfonyl azides as nitrogen sources and the activating effect of tert-Bu hydroperoxide.  The reaction was found to be efficient for the functionalization of mono-, di-, and trisubstituted olefins, and only a few functional groups are not tolerated.  The alkyl azides obtained are versatile intermediates and can be transformed to the free amines or triazoles without isolation of the azides.  Preliminary mechanistic investigations suggest a rate-limiting hydrocobaltation of the alkene, followed by an amination reaction.  Radical intermediates cannot be ruled out and may be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOxkf-FFSDurVg90H21EOLACvtfcHk0ljLFvmpLjuOGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVKhsbc%253D&md5=18f4f26d8922ea3f64ddbdf113f6db09</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fja062355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja062355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWaser%26aufirst%3DJ.%26aulast%3DGaspar%26aufirst%3DB.%26aulast%3DNambu%26aufirst%3DH.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DHydrazines%2520and%2520azides%2520via%2520the%2520metal-matalyzed%2520hydrohydrazination%2520and%2520hydroazidation%2520of%2520olefins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D11693%26epage%3D11712%26doi%3D10.1021%2Fja062355%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosserman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getty, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassini, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2283</span>– <span class="NLM_lpage">2295</span>, <span class="refDoi"> DOI: 10.1021/jm030424e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030424e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVygtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2283-2295&author=A.+B.+Eldrupauthor=C.+R.+Allersonauthor=C.+F.+Bennettauthor=S.+Beraauthor=B.+Bhatauthor=N.+Bhatauthor=M.+R.+Bossermanauthor=J.+Brooksauthor=C.+Burleinauthor=S.+S.+Carrollauthor=P.+D.+Cookauthor=K.+L.+Gettyauthor=M.+MacCossauthor=D.+R.+McMastersauthor=D.+B.+Olsenauthor=T.+P.+Prakashauthor=M.+Prhavcauthor=Q.+Songauthor=J.+E.+Tomassiniauthor=J.+Xia&title=Structure-activity+relationship+of+purine+ribonucleosides+for+inhibition+of+hepatitis+C+virus+RNA-dependent+RNA+polymerase&doi=10.1021%2Fjm030424e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase</span></div><div class="casAuthors">Eldrup, Anne B.; Allerson, Charles R.; Bennett, C. Frank; Bera, Sanjib; Bhat, Balkrishen; Bhat, Neelima; Bosserman, Michele R.; Brooks, Jennifer; Burlein, Christine; Carroll, Steven S.; Cook, P. Dan; Getty, Krista L.; MacCoss, Malcolm; McMasters, Daniel R.; Olsen, David B.; Prakash, Thazha P.; Prhavc, Marija; Song, Quanlai; Tomassini, Joanne E.; Xia, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2283-2295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a continued effort to identify inhibitors of hepatitis C viral (HCV) replication, we report here the synthesis and evaluation of a series of nucleoside analogs and their corresponding triphosphates.  Nucleosides were evaluated for their ability to inhibit HCV RNA replication in a cell-based, subgenomic replicon system, while nucleoside triphosphates were evaluated for their ability to inhibit in vitro RNA synthesis mediated by the HCV RNA-dependent RNA polymerase, NS5B.  2'-C-Methyladenosine and 2'-C-methylguanosine were identified as potent inhibitors of HCV RNA replication, and the corresponding triphosphates were found to be potent inhibitors of HCV NS5B-mediated RNA synthesis.  The data generated in the cell-based assay demonstrated a fairly stringent structure-activity relationship around the active nucleosides.  Increase in steric bulk beyond Me on C2, change in the stereo- or regiochem. of the Me substituent, or change of identity of the heterobase beyond that of the endogenous adenine or guanine was found to lead to loss of inhibitory activity.  The results highlight the importance of the ribo configuration 2'- and 3'-hydroxy pharmacophores for inhibition of HCV RNA replication in the cell-based assay and demonstrate that inclusion of the 2'-C-methylribonucleoside pharmacophore leads to increased resistance to adenosine deaminase and purine nucleoside phosphorylase mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN5TEtkVswmbVg90H21EOLACvtfcHk0ljLFvmpLjuOGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVygtrg%253D&md5=a932a7398e472269f75c7ab029e8630f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm030424e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030424e%26sid%3Dliteratum%253Aachs%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26aulast%3DAllerson%26aufirst%3DC.%2BR.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DBera%26aufirst%3DS.%26aulast%3DBhat%26aufirst%3DB.%26aulast%3DBhat%26aufirst%3DN.%26aulast%3DBosserman%26aufirst%3DM.%2BR.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DCook%26aufirst%3DP.%2BD.%26aulast%3DGetty%26aufirst%3DK.%2BL.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DMcMasters%26aufirst%3DD.%2BR.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DTomassini%26aufirst%3DJ.%2BE.%26aulast%3DXia%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%2520of%2520purine%2520ribonucleosides%2520for%2520inhibition%2520of%2520hepatitis%2520C%2520virus%2520RNA-dependent%2520RNA%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2283%26epage%3D2295%26doi%3D10.1021%2Fjm030424e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Painter, G. R.</span>; <span class="NLM_string-name">Bluemling, G. R.</span></span> <span> </span><span class="NLM_article-title">Nucleotides and Nucleosides Therapeutic Composition and Uses Related Thereto</span>. <span class="NLM_patent">WO 2014124430 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+C.+Liotta&author=G.+R.+Painter&author=G.+R.+Bluemling&title=Nucleotides+and+Nucleosides+Therapeutic+Composition+and+Uses+Related+Thereto"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26atitle%3DNucleotides%2520and%2520Nucleosides%2520Therapeutic%2520Composition%2520and%2520Uses%2520Related%2520Thereto%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Öberg, B.</span></span> <span> </span><span class="NLM_article-title">Rational design of polymerase inhibitors as antiviral drugs</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2006.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2006.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=16820225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BD28vptlyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=90-95&author=B.+%C3%96berg&title=Rational+design+of+polymerase+inhibitors+as+antiviral+drugs&doi=10.1016%2Fj.antiviral.2006.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of polymerase inhibitors as antiviral drugs</span></div><div class="casAuthors">Oberg Bo</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">90-5</span>
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    </div><div class="casAbstract">Almost all viruses have polymerases which are suitable targets for antiviral drugs.  The development of selective polymerase inhibitors started with screening of compounds in virus-infected cell cultures and the mechanism of action was investigated once an inhibitor had been found.  Especially nucleoside analogs were screened as their triphosphates were potential substrates for polymerases.  However, the stepwise phosphorylation by cellular, and sometimes viral, kinases to the active triphosphate prevented a truly rational design of polymerase inhibitors.  Nucleotide analogs offers a type of compounds which could be designed in a more rational way than nucleoside analogs since the first, most selective, phosphorylation step is eliminated in the path to the active inhibitor.  The development of pyrophosphate analogs made rational design possible since these compounds act directly on the viral enzyme, but the room for structural variation was limited.  The non-nucleoside HIV reverse transcriptase inhibitors are direct inhibitors and can thus be designed in a truly rational way by use of structure information on the enzyme-inhibitor complex by use of X-ray and NMR.  This rational design of allosteric inhibitors is also being used in the development of inhibitors to other viral polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUCeYK-aH6vudfST00W0BcfW6udTcc2eaANS_30jJaMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vptlyisg%253D%253D&md5=b02d814cb215117f07e86ea4b727cb18</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2006.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2006.05.012%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596berg%26aufirst%3DB.%26atitle%3DRational%2520design%2520of%2520polymerase%2520inhibitors%2520as%2520antiviral%2520drugs%26jtitle%3DAntiviral%2520Res.%26date%3D2006%26volume%3D71%26spage%3D90%26epage%3D95%26doi%3D10.1016%2Fj.antiviral.2006.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N6- or O6-substituted purine or 2-aminopurine nucleoside monophosphates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5902</span>– <span class="NLM_lpage">5914</span>, <span class="refDoi"> DOI: 10.1021/jm200650j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200650j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5902-5914&author=E.+Murakamiauthor=H.+Baoauthor=R.+T.+Mosleyauthor=J.+Duauthor=M.+J.+Sofiaauthor=P.+A.+Furman&title=Adenosine+deaminase-like+protein+1+%28ADAL1%29%3A+characterization+and+substrate+specificity+in+the+hydrolysis+of+N6-+or+O6-substituted+purine+or+2-aminopurine+nucleoside+monophosphates&doi=10.1021%2Fjm200650j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Deaminase-like Protein 1 (ADAL1): Characterization and Substrate Specificity in the Hydrolysis of N6- or O6-Substituted Purine or 2-Aminopurine Nucleoside Monophosphates</span></div><div class="casAuthors">Murakami, Eisuke; Bao, Haiying; Mosley, Ralph T.; Du, Jinfa; Sofia, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5902-5914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human N6-methyl-AMP/dAMP aminohydrolase has been shown to be involved in metab. of pharmacol. important N6-substituted purine nucleosides and 5'-monophosphate prodrugs thereof.  This enzyme was cloned and expressed in E. coli, and mass spectroscopic anal. followed by amino acid sequence analyses indicated that the protein was adenosine deaminase-like protein isoform 1 (ADAL1).  An extensive structure-activity relationship study showed that ADAL1 was able to catalyze removal of different alkyl groups not only from N6-substituted purine or 2-aminopurine nucleoside monophosphates but also from O6-substituted compds.  The ADAL1 activity was susceptible to modifications in the phosphate moiety but not to changes in the sugar moiety.  Overall, our data indicated that ADAL1 specifically acts at the 6-position of purine and 2-aminopurine nucleoside monophosphates.  Our results may help designing of new therapeutic nucleoside/nucleotide prodrugs with desired metabolic profiles.  Furthermore, amino acid sequence anal. in conjunction with crystallog. data and metal anal. suggested that ADAL1 contains a catalytic zinc ion.  Finally, a potential physiol. role of ADAL1 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCnGE5y2oXY7Vg90H21EOLACvtfcHk0lgxnQXus-T5lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSmtbo%253D&md5=669d646f91563308262b0c010df3a0c6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm200650j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200650j%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DAdenosine%2520deaminase-like%2520protein%25201%2520%2528ADAL1%2529%253A%2520characterization%2520and%2520substrate%2520specificity%2520in%2520the%2520hydrolysis%2520of%2520N6-%2520or%2520O6-substituted%2520purine%2520or%25202-aminopurine%2520nucleoside%2520monophosphates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5902%26epage%3D5914%26doi%3D10.1021%2Fjm200650j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madela, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljarah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrica, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleiman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorovits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obikhod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernachio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamurty, C. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battina, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8632</span>– <span class="NLM_lpage">8645</span>, <span class="refDoi"> DOI: 10.1021/jm2011673</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2011673" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FmtlWjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8632-8645&author=C.+McGuiganauthor=K.+Madelaauthor=M.+Aljarahauthor=C.+Bourdinauthor=M.+Arricaauthor=E.+Barrettauthor=S.+Jonesauthor=A.+Kolykhalovauthor=B.+Bleimanauthor=K.+D.+Bryantauthor=B.+Gangulyauthor=E.+Gorovitsauthor=G.+Hensonauthor=D.+Hunleyauthor=J.+Hutchinsauthor=J.+Muhammadauthor=A.+Obikhodauthor=J.+Pattiauthor=C.+R.+Waltersauthor=J.+Wangauthor=J.+Vernachioauthor=C.+V.+S.+Ramamurtyauthor=S.+K.+Battinaauthor=S.+Chamberlain&title=Phosphorodiamidates+as+a+promising+new+phosphate+prodrug+motif+for+antiviral+drug+discovery%3A+application+to+anti-HCV+agents&doi=10.1021%2Fjm2011673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents</span></div><div class="casAuthors">McGuigan Christopher; Madela Karolina; Aljarah Mohamed; Bourdin Claire; Arrica Maria; Barrett Emma; Jones Sarah; Kolykhalov Alexander; Bleiman Blair; Bryant K Dawn; Ganguly Babita; Gorovits Elena; Henson Geoffrey; Hunley Damound; Hutchins Jeff; Muhammad Jerry; Obikhod Aleksandr; Patti Joseph; Walters C Robin; Wang Jin; Vernachio John; Ramamurty Changalvala V S; Battina Srinivas K; Chamberlain Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8632-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We herein report phosphorodiamidates as a significant new phosphate prodrug motif.  Sixty-seven phosphorodiamidates are reported of two 6-O-alkyl 2'-C-methyl guanosines, with significant variation in the diamidate structure.  Both symmetrical and asymmetric phosphorodiamidates are reported, derived from various esterified amino acids, both d and l, and also from various simple amines.  All of the compounds were evaluated versus hepatitis C virus in replicon assay, and nanomolar activity levels were observed.  Many compounds were noncytotoxic at 100 μM, leading to high antiviral selectivities.  The agents are stable in acidic, neutral, and moderately basic media and in selected biological media but show efficient processing by carboxypeptidases and efficiently yield the free nucleoside monophosphate in cells.  On the basis of in vitro data, eight leads were selected for additional in vivo evaluation, with the intent of selecting one candidate for progression toward clinical studies.  This phosphorodiamidate prodrug method may have broad application outside of HCV and antivirals as it offers many of the advantages of phosphoramidate ProTides but without the chirality issues present in most cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ8wY11iyNsRLDWw4HIq2sfW6udTcc2eZ-hWpeEhc24Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FmtlWjsQ%253D%253D&md5=5b7d43c2582a96a963e3927988054df7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm2011673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2011673%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMadela%26aufirst%3DK.%26aulast%3DAljarah%26aufirst%3DM.%26aulast%3DBourdin%26aufirst%3DC.%26aulast%3DArrica%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DKolykhalov%26aufirst%3DA.%26aulast%3DBleiman%26aufirst%3DB.%26aulast%3DBryant%26aufirst%3DK.%2BD.%26aulast%3DGanguly%26aufirst%3DB.%26aulast%3DGorovits%26aufirst%3DE.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DHunley%26aufirst%3DD.%26aulast%3DHutchins%26aufirst%3DJ.%26aulast%3DMuhammad%26aufirst%3DJ.%26aulast%3DObikhod%26aufirst%3DA.%26aulast%3DPatti%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DC.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DVernachio%26aufirst%3DJ.%26aulast%3DRamamurty%26aufirst%3DC.%2BV.%2BS.%26aulast%3DBattina%26aufirst%3DS.%2BK.%26aulast%3DChamberlain%26aufirst%3DS.%26atitle%3DPhosphorodiamidates%2520as%2520a%2520promising%2520new%2520phosphate%2520prodrug%2520motif%2520for%2520antiviral%2520drug%2520discovery%253A%2520application%2520to%2520anti-HCV%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8632%26epage%3D8645%26doi%3D10.1021%2Fjm2011673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapati Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of diastereomerically pure nucleotide phosphoramidates</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">8311</span>– <span class="NLM_lpage">8319</span>, <span class="refDoi"> DOI: 10.1021/jo201492m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo201492m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=8311-8319&author=B.+S.+Rossauthor=P.+Ganapati+Reddyauthor=H.-R.+Zhangauthor=S.+Rachakondaauthor=M.+J.+Sofia&title=Synthesis+of+diastereomerically+pure+nucleotide+phosphoramidates&doi=10.1021%2Fjo201492m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diastereomerically Pure Nucleotide Phosphoramidates</span></div><div class="casAuthors">Ross, Bruce S.; Ganapati Reddy, P.; Zhang, Hai-Ren; Rachakonda, Suguna; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8311-8319</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prodrugs of therapeutic nucleoside monophosphates masked as phosphoramidate derivs. have become an increasingly important class of antiviral drugs in pharmaceutical research for delivering nucleotides in vitro and in vivo.  Conventionally, phosphoramidate derivs. are prepd. as a mixt. of two diastereomers.  We report a class of stable phosphoramidate reagents contg. an amino acid ester and two phenolic groups, one unsubstituted and the other with electron-withdrawing substituents.  The reagents can be isolated as single diastereomers and reacted with the 5'-hydroxyl group of nucleosides through selective nucleophilic displacement of the substituted phenol to prep. single diastereomer phosphoramidate products.  This method has been used to prep. the HCV clin. candidate PSI-7977 I in high yield and high diastereomeric purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgDGdlH3gLa7Vg90H21EOLACvtfcHk0lhPDa1G2BRiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F&md5=747a893daa7d9c4784cc29619d05ab81</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo201492m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo201492m%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DGanapati%2BReddy%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520of%2520diastereomerically%2520pure%2520nucleotide%2520phosphoramidates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D8311%26epage%3D8319%26doi%3D10.1021%2Fjo201492m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoycheva, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2’-fluoro-4’-chloromethyl-cytidine triphosphate</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e1004995</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1004995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1371%2Fjournal.ppat.1004995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=26098424" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&author=J.+Devalauthor=J.+Hongauthor=G.+Wangauthor=J.+Taylorauthor=L.+K.+Smithauthor=A.+Fungauthor=S.+K.+Stevensauthor=H.+Liuauthor=Z.+Jinauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=A.+D.+Stoychevaauthor=V.+Serebryanyauthor=J.+Liuauthor=D.+B.+Smithauthor=Y.+Tamauthor=Q.+Zhangauthor=M.+L.+Mooreauthor=R.+Fearnsauthor=S.+M.+Chandaauthor=L.+M.+Blattauthor=J.+A.+Symonsauthor=L.+Beigelman&title=Molecular+basis+for+the+selective+inhibition+of+respiratory+syncytial+virus+RNA+polymerase+by+2%E2%80%99-fluoro-4%E2%80%99-chloromethyl-cytidine+triphosphate&doi=10.1371%2Fjournal.ppat.1004995"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004995%26sid%3Dliteratum%253Aachs%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DL.%2BK.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DStoycheva%26aufirst%3DA.%2BD.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMoore%26aufirst%3DM.%2BL.%26aulast%3DFearns%26aufirst%3DR.%26aulast%3DChanda%26aufirst%3DS.%2BM.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DMolecular%2520basis%2520for%2520the%2520selective%2520inhibition%2520of%2520respiratory%2520syncytial%2520virus%2520RNA%2520polymerase%2520by%25202%25E2%2580%2599-fluoro-4%25E2%2580%2599-chloromethyl-cytidine%2520triphosphate%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26doi%3D10.1371%2Fjournal.ppat.1004995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span> <span> </span><span class="NLM_article-title">Addressing the selectivity and toxicity of antiviral nucleosides</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2040206618758524</span>, <span class="refDoi"> DOI: 10.1177/2040206618758524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1177%2F2040206618758524" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2040206618758524&author=J.+Y.+Feng&title=Addressing+the+selectivity+and+toxicity+of+antiviral+nucleosides&doi=10.1177%2F2040206618758524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1177%2F2040206618758524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040206618758524%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26atitle%3DAddressing%2520the%2520selectivity%2520and%2520toxicity%2520of%2520antiviral%2520nucleosides%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2018%26volume%3D26%26spage%3D2040206618758524%26doi%3D10.1177%2F2040206618758524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadyar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakowicz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span> <span> </span><span class="NLM_article-title">Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1128/aac.01922-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1128%2FAAC.01922-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=26596942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFKit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=806-817&author=J.+Y.+Fengauthor=Y.+Xuauthor=O.+Barauskasauthor=J.+K.+Perryauthor=S.+Ahmadyarauthor=G.+Stepanauthor=H.+Yuauthor=D.+Babusisauthor=Y.+Parkauthor=K.+McCutcheonauthor=M.+Perronauthor=B.+E.+Schultzauthor=R.+Sakowiczauthor=A.+S.+Ray&title=Role+of+mitochondrial+RNA+polymerase+in+the+toxicity+of+nucleotide+inhibitors+of+hepatitis+C+virus&doi=10.1128%2Faac.01922-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus</span></div><div class="casAuthors">Feng, Joy Y.; Xu, Yili; Barauskas, Ona; Perry, Jason K.; Ahmadyar, Shekeba; Stepan, George; Yu, Helen; Babusis, Darius; Park, Yeojin; McCutcheon, Krista; Perron, Michel; Schultz, Brian E.; Sakowicz, Roman; Ray, Adrian S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">806-817</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Toxicity has emerged during the clin. development of many but not all nucleotide inhibitors (NI) of hepatitis C virus (HCV).  To better understand the mechanism for adverse events, clin. relevant HCV NI were characterized in biochem. and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration.  NI that were incorporated by the mitochondrial RNA polymerase (PolRMT) inhibited mitochondrial protein synthesis and showed a corresponding decrease in mitochondrial oxygen consumption in cells.  The nucleoside released by the prodrug balapiravir (R1626), 4'-azido cytidine, was a highly selective inhibitor of mitochondrial RNA transcription.  The nucleotide prodrug of 2'-C-Me guanosine, BMS-986094, showed a primary effect on mitochondrial function at submicromolar concns., followed by general cytotoxicity.  In contrast, NI contg. multiple ribose modifications, including the active forms of mericitabine and sofosbuvir, were poor substrates for PolRMT and did not show mitochondrial toxicity in cells.  In general, these studies identified the prostate cell line PC-3 as more than an order of magnitude more sensitive to mitochondrial toxicity than the commonly used HepG2 cells.  In conclusion, analogous to the role of mitochondrial DNA polymerase gamma in toxicity caused by some 2'-deoxynucleotide analogs, there is an assocn. between HCV NI that interact with PolRMT and the observation of adverse events.  More broadly applied, the sensitive methods for detecting mitochondrial toxicity described here may help in the identification of mitochondrial toxicity prior to clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJLNn7rQbeOrVg90H21EOLACvtfcHk0liYMFoGgnd0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFKit70%253D&md5=7cc35537b70729a9de882d2ac4b18a98</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FAAC.01922-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01922-15%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DAhmadyar%26aufirst%3DS.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DMcCutcheon%26aufirst%3DK.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSakowicz%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DA.%2BS.%26atitle%3DRole%2520of%2520mitochondrial%2520RNA%2520polymerase%2520in%2520the%2520toxicity%2520of%2520nucleotide%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D806%26epage%3D817%26doi%3D10.1128%2Faac.01922-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1862</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1021/jm5017279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5017279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1862-1878&author=G.+Wangauthor=J.+Devalauthor=J.+Hongauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=J.+Taylorauthor=A.+Fungauthor=Z.+Jinauthor=S.+K.+Stevensauthor=V.+Serebryanyauthor=J.+Liuauthor=Q.+Zhangauthor=Y.+Tamauthor=S.+M.+Chandaauthor=D.+B.+Smithauthor=J.+A.+Symonsauthor=L.+M.+Blattauthor=L.+Beigelman&title=Discovery+of+4%E2%80%B2-chloromethyl-2%E2%80%B2-deoxy-3%E2%80%B2%2C5%E2%80%B2-di-O-isobutyryl-2%E2%80%B2-fluorocytidine+%28ALS-8176%29%2C+a+first-in-class+RSV+polymerase+inhibitor+for+treatment+of+human+respiratory+syncytial+virus+infection&doi=10.1021%2Fjm5017279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection</span></div><div class="casAuthors">Wang, Guangyi; Deval, Jerome; Hong, Jin; Dyatkina, Natalia; Prhavc, Marija; Taylor, Joshua; Fung, Amy; Jin, Zhinan; Stevens, Sarah K.; Serebryany, Vladimir; Liu, Jyanwei; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita M.; Smith, David B.; Symons, Julian A.; Blatt, Lawrence M.; Beigelman, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1862-1878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading pathogen of childhood and is assocd. with significant morbidity and mortality.  To date, ribavirin is the only approved small mol. drug, which has limited use.  The only other RSV drug is palivizumab, a monoclonal antibody, which is used for RSV prophylaxis.  Clearly, there is an urgent need for small mol. RSV drugs.  This article reports the design, synthesis, anti-RSV activity, metab., and pharmacokinetics of a series of 4'-substituted cytidine nucleosides.  Among tested compds. 4'-chloromethyl-2'-deoxy-2'-fluorocytidine I exhibited the most promising activity in the RSV replicon assay with an EC50 of 0.15 μM.  The 5'-triphosphate of I (I-TP)inhibited RSV polymerase with an IC50 of 0.02 μM without appreciable inhibition of human DNA and RNA polymerases at 100 μM.  ALS-8176 II, the 3',5'-di-O-isobutyryl prodrug of I, demonstrated good oral bioavailability and a high level of I-TP in vivo.  Compd. II is a first-in-class nucleoside RSV polymerase inhibitor that demonstrated excellent anti-RSV efficacy and safety in a phase 2 clin. RSV challenge study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaKHh4AhV9drVg90H21EOLACvtfcHk0liYMFoGgnd0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D&md5=da9e883eb67f20ca259dec06a6a05367</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm5017279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5017279%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DChanda%26aufirst%3DS.%2BM.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204%25E2%2580%25B2-chloromethyl-2%25E2%2580%25B2-deoxy-3%25E2%2580%25B2%252C5%25E2%2580%25B2-di-O-isobutyryl-2%25E2%2580%25B2-fluorocytidine%2520%2528ALS-8176%2529%252C%2520a%2520first-in-class%2520RSV%2520polymerase%2520inhibitor%2520for%2520treatment%2520of%2520human%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1862%26epage%3D1878%26doi%3D10.1021%2Fjm5017279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Körner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herian, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theilmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenschlager, R.</span></span> <span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1126/science.285.5424.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line&doi=10.1126%2Fscience.285.5424.110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0liYMFoGgnd0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113%26doi%3D10.1126%2Fscience.285.5424.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span>; <span class="NLM_string-name">Vernachio, J.</span>; <span class="NLM_string-name">Battina, S.</span>; <span class="NLM_string-name">Ramamurty, C. V.</span>; <span class="NLM_string-name">Srinivas Rao, C.</span>; <span class="NLM_string-name">McGuigan, C.</span>; <span class="NLM_string-name">Brancale, A.</span></span> <span> </span><span class="NLM_article-title">Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment of Viral Infections</span>. U.S. Patent <span class="NLM_patent">20,140,286,903 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Chamberlain&author=J.+Vernachio&author=S.+Battina&author=C.+V.+Ramamurty&author=C.+Srinivas+Rao&author=C.+McGuigan&author=A.+Brancale&title=Substituted+Purine+Nucleosides%2C+Phosphoramidate+and+Phosphordiamidate+Derivatives+for+Treatment+of+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%26atitle%3DSubstituted%2520Purine%2520Nucleosides%252C%2520Phosphoramidate%2520and%2520Phosphordiamidate%2520Derivatives%2520for%2520Treatment%2520of%2520Viral%2520Infections%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7202</span>– <span class="NLM_lpage">7218</span>, <span class="refDoi"> DOI: 10.1021/jm100863x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-2%E2%80%B2-deoxy-2%E2%80%B2-%CE%B1-fluoro-2%E2%80%B2-%CE%B2-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus&doi=10.1021%2Fjm100863x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0ljUVnn8tArhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-2%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-%25CE%25B1-fluoro-2%25E2%2580%25B2-%25CE%25B2-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218%26doi%3D10.1021%2Fjm100863x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span>; <span class="NLM_string-name">Hutchins, J.</span>; <span class="NLM_string-name">Medela, K.</span>; <span class="NLM_string-name">McGuigan, C.</span>; <span class="NLM_string-name">Vernachio, J.</span>; <span class="NLM_string-name">Aljarah, M.</span>; <span class="NLM_string-name">Gilles, A.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidate Derivatives of Guanosine Nucleoside Compounds for Treatment of Viral Infections</span>. <span class="NLM_patent">WO 2010081082 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Chamberlain&author=J.+Hutchins&author=K.+Medela&author=C.+McGuigan&author=J.+Vernachio&author=M.+Aljarah&author=A.+Gilles&title=Phosphoramidate+Derivatives+of+Guanosine+Nucleoside+Compounds+for+Treatment+of+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%26atitle%3DPhosphoramidate%2520Derivatives%2520of%2520Guanosine%2520Nucleoside%2520Compounds%2520for%2520Treatment%2520of%2520Viral%2520Infections%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span> <span> </span><span class="NLM_article-title">Efficiency of incorporation and chain termination determines the inhibition potency of 2’-modified nucleotide analogs against hepatitis C virus polymerase</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3636</span>– <span class="NLM_lpage">3645</span>, <span class="refDoi"> DOI: 10.1128/aac.02666-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1128%2FAAC.02666-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=24733478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3636-3645&author=A.+Fungauthor=Z.+Jinauthor=N.+Dyatkinaauthor=G.+Wangauthor=L.+Beigelmanauthor=J.+Deval&title=Efficiency+of+incorporation+and+chain+termination+determines+the+inhibition+potency+of+2%E2%80%99-modified+nucleotide+analogs+against+hepatitis+C+virus+polymerase&doi=10.1128%2Faac.02666-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase</span></div><div class="casAuthors">Fung, Amy; Jin, Zhinan; Dyatkina, Natalia; Wang, Guangyi; Beigelman, Leo; Deval, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3636-3645, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ribonucleotide analog inhibitors of the RNA-dependent RNA polymerase of hepatitis C virus (HCV) represent one of the most exciting recent developments in HCV antiviral therapy.  Although it is well established that these mols. cause chain termination by competing at the triphosphate level with natural nucleotides for incorporation into elongating RNA, strategies to rationally optimize antiviral potency based on enzyme kinetics remain elusive.  In this study, we used the isolated HCV polymerase elongation complex to det. the pre-steady-state kinetics of incorporation of 2'F-2'C-Me-UTP, the active metabolite of the anti-HCV drug sofosbuvir. 2'F-2'C-Me-UTP was efficiently incorporated by HCV polymerase with apparent Kd (equil. const.) and kpol (rate of nucleotide incorporation at satg. nucleotide concn.) values of 113 ± 28 μM and 0.67 ± 0.05 s-1, resp., giving an overall substrate efficiency (kpol/Kd) of 0.0059 ± 0.0015 μM-1 s-1.  We also measured the substrate efficiency of other UTP analogs and found that substitutions at the 2' position on the ribose can greatly affect their level of incorporation, with a rank order of OH > F > NH2 > F-C-Me > C-Me > N3 > ara.  However, the efficiency of chain termination following the incorporation of UMP analogs followed a different order, with only 2'F-2'C-Me-, 2'C-Me-, and 2'ara-UTP causing complete and immediate chain termination.  The chain termination profile of the 2'-modified nucleotides explains the apparent lack of correlation obsd. across all mols. between substrate efficiency at the single-nucleotide level and their overall inhibition potency.  To our knowledge, these results provide the first attempt to use pre-steady-state kinetics to uncover the mechanism of action of 2'-modified NTP analogs against HCV polymerase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUNCxRgeI-hrVg90H21EOLACvtfcHk0ljUVnn8tArhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7zL&md5=6eda107d20100519f19d4399d1550cac</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1128%2FAAC.02666-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02666-14%26sid%3Dliteratum%253Aachs%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DDeval%26aufirst%3DJ.%26atitle%3DEfficiency%2520of%2520incorporation%2520and%2520chain%2520termination%2520determines%2520the%2520inhibition%2520potency%2520of%25202%25E2%2580%2599-modified%2520nucleotide%2520analogs%2520against%2520hepatitis%2520C%2520virus%2520polymerase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3636%26epage%3D3645%26doi%3D10.1128%2Faac.02666-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolomanov, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puschmann, H.</span></span> <span> </span><span class="NLM_article-title">OLEX2: a complete structure solution, refinement and analysis program</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1107/s0021889808042726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1107%2FS0021889808042726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=339-341&author=O.+V.+Dolomanovauthor=L.+J.+Bourhisauthor=R.+J.+Gildeaauthor=J.+A.+K.+Howardauthor=H.+Puschmann&title=OLEX2%3A+a+complete+structure+solution%2C+refinement+and+analysis+program&doi=10.1107%2Fs0021889808042726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">OLEX2: a complete structure solution, refinement and analysis program</span></div><div class="casAuthors">Dolomanov, Oleg V.; Bourhis, Luc J.; Gildea, Richard J.; Howard, Judith A. K.; Puschmann, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-341</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">New software, OLEX2, was developed for the detn., visualization and anal. of mol. crystal structures.  The software has a portable mouse-driven workflow-oriented and fully comprehensive graphical user interface for structure soln., refinement and report generation, as well as novel tools for structure anal.  OLEX2 seamlessly links all aspects of the structure soln., refinement and publication process and presents them in a single workflow-driven package, with the ultimate goal of producing an application which will be useful to both chemists and crystallographers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIYSUbyzIgxbVg90H21EOLACvtfcHk0ljs_DNbAqg7Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D&md5=7a2f9697b13b8e76de0e7dc5074ab229</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0021889808042726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889808042726%26sid%3Dliteratum%253Aachs%26aulast%3DDolomanov%26aufirst%3DO.%2BV.%26aulast%3DBourhis%26aufirst%3DL.%2BJ.%26aulast%3DGildea%26aufirst%3DR.%2BJ.%26aulast%3DHoward%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DPuschmann%26aufirst%3DH.%26atitle%3DOLEX2%253A%2520a%2520complete%2520structure%2520solution%252C%2520refinement%2520and%2520analysis%2520program%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2009%26volume%3D42%26spage%3D339%26epage%3D341%26doi%3D10.1107%2Fs0021889808042726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure refinement with SHELXL</span>. <i>Acta Crystallogr., Sect. C: Struct. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1107/s2053229614024218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1107%2FS2053229614024218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=25643710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=3-8&author=G.+M.+Sheldrick&title=Crystal+structure+refinement+with+SHELXL&doi=10.1107%2Fs2053229614024218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure refinement with SHELXL</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section C: Structural Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">ACSCGG</span>;
        ISSN:<span class="NLM_cas:issn">2053-2296</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The improvements in the crystal structure refinement program SHELXL have been closely coupled with the development and increasing importance of the CIF (Crystallog. Information Framework) format for validating and archiving crystal structures.  An important simplification is that now only one file in CIF format (for convenience, referred to simply as 'a CIF') contg. embedded reflection data and SHELXL instructions is needed for a complete structure archive; the program SHREDCIF can be used to ext. the and files required for further refinement with SHELXL.  Recent developments in SHELXL facilitate refinement against neutron diffraction data, the treatment of H atoms, the detn. of abs. structure, the input of partial structure factors and the refinement of twinned and disordered structures.  SHELXL is available free to academics for the Windows, Linux and Mac OS X operating systems, and is particularly suitable for multiple-core processors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk1_pNHwXR7Vg90H21EOLACvtfcHk0ljs_DNbAqg7Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D&md5=4a860804b50fc183e8a701098b98ef59</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS2053229614024218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053229614024218%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DCrystal%2520structure%2520refinement%2520with%2520SHELXL%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520C%253A%2520Struct.%2520Chem.%26date%3D2015%26volume%3D71%26spage%3D3%26epage%3D8%26doi%3D10.1107%2Fs2053229614024218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">A short history ofSHELX</span>. <i>Acta Crystallogr., Sect. A: Found. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/s0108767307043930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1107%2FS0108767307043930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=18156677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=112-122&author=G.+M.+Sheldrick&title=A+short+history+ofSHELX&doi=10.1107%2Fs0108767307043930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of SHELX</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section A: Foundations of Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACACEQ</span>;
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An account is given of the development of the SHELX system of computer programs from SHELX-76 to the present day.  In addn. to identifying useful innovations that have come into general use through their implementation in SHELX, a crit. anal. is presented of the less-successful features, missed opportunities and desirable improvements for future releases of the software.  An attempt is made to understand how a program originally designed for photog. intensity data, punched cards and computers over 10000 times slower than an av. modern personal computer has managed to survive for so long.  SHELXL is the most widely used program for small-mol. refinement and SHELXS and SHELXD are often employed for structure soln. despite the availability of objectively superior programs.  SHELXL also finds a niche for the refinement of macromols. against high-resoln. or twinned data; SHELXPRO acts as an interface for macromol. applications.  SHELXC, SHELXD and SHELXE are proving useful for the exptl. phasing of macromols., esp. because they are fast and robust and so are often employed in pipelines for high-throughput phasing.  This paper could serve as a general literature citation when one or more of the open-source SHELX programs (and the Bruker AXS version SHELXTL) are employed in the course of a crystal-structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLPYyJyJ2RbVg90H21EOLACvtfcHk0lhOdJMWSarxpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO&md5=8f91f10be4a9df74b2a9dad522c71e6e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0108767307043930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767307043930%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DA%2520short%2520history%2520ofSHELX%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D112%26epage%3D122%26doi%3D10.1107%2Fs0108767307043930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span> <i>COSMO-V1.61 Software
for the CCD Detector Systems for Determining
Data Collection Parameters</i>; <span class="NLM_publisher-name">Bruker Analytical
X-ray Systems</span>: <span class="NLM_publisher-loc">Madison, WI</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+COSMO-V1.61+Software%0Afor+the+CCD+Detector+Systems+for+Determining%0AData+Collection+Parameters%3B+Bruker+Analytical%0AX-ray+Systems%3A+Madison%2C+WI%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DCOSMO-V1.61%2520Software%250Afor%2520the%2520CCD%2520Detector%2520Systems%2520for%2520Determining%250AData%2520Collection%2520Parameters%26pub%3DBruker%2520Analytical%250AX-ray%2520Systems%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span> <i>SAINT-8.34A-2013
Software for the Integration of CCD Detector
System</i>; <span class="NLM_publisher-name">Bruker Analytical X-ray Systems</span>: <span class="NLM_publisher-loc">Madison, WI</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+SAINT-8.34A-2013%0ASoftware+for+the+Integration+of+CCD+Detector%0ASystem%3B+Bruker+Analytical+X-ray+Systems%3A+Madison%2C+WI%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSAINT-8.34A-2013%250ASoftware%2520for%2520the%2520Integration%2520of%2520CCD%2520Detector%250ASystem%26pub%3DBruker%2520Analytical%2520X-ray%2520Systems%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Tian</span>, <span class="hlFld-ContribAuthor ">Taotao  Qiang</span>, <span class="hlFld-ContribAuthor ">Chengyuan  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ren</span>, <span class="hlFld-ContribAuthor ">Minyi  Jia</span>, <span class="hlFld-ContribAuthor ">Jiayun  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingyi  Li</span>, <span class="hlFld-ContribAuthor ">Minge  Wan</span>, <span class="hlFld-ContribAuthor ">Xin  YuWen</span>, <span class="hlFld-ContribAuthor ">Han  Li</span>, <span class="hlFld-ContribAuthor ">Wenqiang  Cao</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113201. <a href="https://doi.org/10.1016/j.ejmech.2021.113201" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113201%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRNA-dependent%252BRNA%252Bpolymerase%252B%252528RdRp%252529%252Binhibitors%25253A%252BThe%252Bcurrent%252Blandscape%252Band%252Brepurposing%252Bfor%252Bthe%252BCOVID-19%252Bpandemic%26aulast%3DTian%26aufirst%3DLei%26date%3D2021%26volume%3D213%26spage%3D113201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miguel Angel  Martinez</span>, <span class="hlFld-ContribAuthor ">Sandra  Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Therapy Implications of Hepatitis C Virus Genetic Diversity. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 41. <a href="https://doi.org/10.3390/v13010041" title="DOI URL">https://doi.org/10.3390/v13010041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13010041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13010041%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DTherapy%252BImplications%252Bof%252BHepatitis%252BC%252BVirus%252BGenetic%252BDiversity%26aulast%3DMartinez%26aufirst%3DMiguel%2BAngel%26date%3D2021%26date%3D2020%26volume%3D13%26issue%3D1%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miguel Angel  Martinez</span>, <span class="hlFld-ContribAuthor ">Sandra  Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 139-157. <a href="https://doi.org/10.1007/978-981-16-0267-2_6" title="DOI URL">https://doi.org/10.1007/978-981-16-0267-2_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0267-2_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0267-2_6%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BAntiviral%252BTherapies%252Bfor%252BChronic%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMartinez%26aufirst%3DMiguel%2BAngel%26date%3D2021%26date%3D2021%26spage%3D139%26epage%3D157%26pub%3DSpringer%2520Singapore%26atitle%3DAntiviral%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DLiu%26aufirst%3DXinyong%26date%3D2021%26volume%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Sugar-modified guanosine analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) TsCl, pyridine, 0 °C, 1 h; (ii) NaI, acetone, reflux, overnight, 41% for <b>12a</b>, 52% for <b>12b</b>, 41% for <b>12c</b>; (b) PPh<sub>3</sub>, imidazole, I<sub>2</sub>, THF, rt, overnight, 90% for <b>12d</b>; (c) DBU, THF, 60 °C, overnight, 60% for <b>13a</b>, 62% for <b>13b</b>, 67% for <b>13c</b>, 83% for <b>13d</b>; (d) AgF, I<sub>2</sub>, DCM, rt, 3 h; (e) NEt<sub>3</sub>·3HF, NIS, CH<sub>3</sub>CN, rt, 2 h, 16% for <b>14c</b>; (f) BzCl, DMAP, Et<sub>3</sub>N, DCM, rt, overnight, 81% for <b>15c</b>; (g) BzCl, pyridine; (h) HMPA, NaOBz, 15-crown-5, 48 h, 60 °C, yield for 3 steps 15% for <b>16a</b> from <b>13a</b>, 6% for <b>16b</b>, 11% for <b>16d</b>; (j) NH<sub>3</sub>/MeOH, 49% for 2 steps for <b>17c</b>; (k) <i>n</i>-butylamine, rt, 80% for <b>17a</b>, 86% for <b>17b</b>, 75% for <b>17d</b>; and (l) HCl/dioxane, CH<sub>3</sub>CN, 80% for <b>4</b>, 73% for <b>5</b>, 81% for <b>6</b>, 36% for <b>7</b>.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BSA, TMSOTf, CH<sub>3</sub>CN, 80 °C, 16 h, 72%; (b) (i) TrCl, Et<sub>3</sub>N, DMAP, DMF, 45 °C, 24 h, 81%; (ii) NH<sub>3</sub>/MeOH, rt, 4 h, 78%; (c) (i) TEMPO, PhI(OAc)<sub>2</sub>, AcOH, DCM, rt, 16 h, 100%; (d) (i) CH<sub>3</sub>MgBr, ether, 2 h, −30 °C, 20%; (ii) DAST, DCM, rt, 2 h, 22%; (e) (i) NaOMe, 2-mercaptoethanol, 12 h, 65 °C; (ii) BCl<sub>3</sub>, DCM, −75 °C, 0.5 h, 55% for 2 steps; (f) (i) CH<sub>3</sub>Ph<sub>3</sub>PBr, LiHMDS, THF, rt, 4 h, 34%; (ii) AcOH, MeOH, 50 °C, 5 h, 60%; (iii) AcCl, pyridine, DCM, rt, 2 h, 65%; (g) TsCl, PhSiH<sub>3</sub>, EtOH, 30 °C, 2.5 h, 29%; (h) BCl<sub>3</sub>, DCM, −30 °C, 3 h; and (j) NaOMe, 2-mercaptoethanol, 12 h, 60 °C, 26% for 2 steps.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of synthesized prodrugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) MMTrCl, AgNO<sub>3</sub>, collidine, DCM, rt, overnight, 84%; (ii) NaOEt, EtOH, rt, 1 h, 98%; (b) I<sub>2</sub>, PPh<sub>3</sub>, imidazole, THF, rt, 5 h, 75%; (c) DBU, THF, 75 °C, 3 h, 37%; (d) NEt<sub>3</sub>·3HF, NIS, DCM, 0 °C, 2 h, 60%; (e) (i) BzCl, Py, rt, overnight; (ii) NaOBz, DMF, 15-crown-5, 100 °C, 48 h, 45% (for 2 steps); (f) <i>n</i>-butylamine, rt, overnight, 85%; (g) (i) MMTrCl, AgNO<sub>3</sub>, collidine, DCM, rt, overnight, 82%; (ii) NaOBz, DMF, 15-crown-5, 95 °C, 72 h, 65%; (h) <i>n</i>-butylamine, rt, overnight, 56%; and (j) (i) <i>tert</i>-BuMgCl, alkyl phosphorodichloridate, THF, rt, 2–3 h, 12–32%; (ii) HCl/dioxane, rt, 1 h, 95%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) <i>tert</i>-BuMgCl, THF, 5 °C, 1 h; (ii) HCl/CH<sub>3</sub>CN.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Primer extension and chain termination with 6-TP. (A) Reaction scheme as described in Methods. (B) Reaction products shown on a sequencing gel. Lane 1, no NTP; lane 2, 10 μM ATP + 10 μM UTP; lane 3, 10 μM GTP; lane 4, 10 μM GTP + 10 μM ATP + 10 μM UTP; lane 5, 100 μM 3′dGTP; lane 6, 100 μM 3′dGTP + 10 μM ATP + 10 μM UTP; lane 7, 100 μM <b>6-TP</b>; lane 8, 100 μM <b>6-TP</b> + 10 μM ATP + 10 μM UTP.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Incorporation of nucleotide by HMRP. Top, the RNA primer and the DNA template used in this assay. Bottom, nucleotide incorporation products shown on a sequencing gel. 100 μM nucleotide was used in each assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Time course of intracellular NTP in primary human hepatocytes following an incubation with <b>40</b> at 10 μM for 2–72 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Intracellular NTP concentration as a function of extracellular concentration of compound <b>40</b> in primary human hepatocytes. Data were collected from hepatocytes from three different human donors and expressed as mean ± standard deviation. Each experiment was conducted with 24 h of incubation of <b>40</b> with hepatocytes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/medium/jm0c00935_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Intracellular NTP concentration as a function of time in primary human hepatocytes following an initial 24 h incubation with <b>40</b> at 50 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00935/20200918/images/large/jm0c00935_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00935&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i75">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span> </span><span class="NLM_article-title">HCV Guidance: Recommendations
for Testing, Managing, and Treating
Hepatitis C</span>. <a href="http://www.hcvguidelines.org" class="extLink">http://www.hcvguidelines.org</a> (accessed May 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=HCV+Guidance%3A+Recommendations%0Afor+Testing%2C+Managing%2C+and+Treating%0AHepatitis+C.+http%3A%2F%2Fwww.hcvguidelines.org+%28accessed+May+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHCV%2520Guidance%253A%2520Recommendations%250Afor%2520Testing%252C%2520Managing%252C%2520and%2520Treating%250AHepatitis%2520C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2014.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=24792751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvVait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2014&pages=119-124&author=M.+J.+Sofia&title=Beyond+sofosbuvir%3A+what+opportunity+exists+for+a+better+nucleoside%2Fnucleotide+to+treat+hepatitis+C%3F&doi=10.1016%2Fj.antiviral.2014.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?</span></div><div class="casAuthors">Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">119-124</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sofosbuvir is a liver-targeting uridine nucleotide prodrug inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase recently approved by the FDA and EU regulators for treatment of patients infected with genotype 1, 2, 3 and 4 virus.  The request for regulatory approval of the fixed-dose combination contg. sofosbuvir and the NS5A inhibitor ledipasvir is also under review.  Preclin. and clin. studies have shown that sofosbuvir is effective, safe and well tolerated.  Review of sofosbuvir's preclin. and clin. profile reveals a drug that has the potential to become the backbone of std. of care.  Pursuit of a next generation nucleos(t)ide HCV inhibitor that could compete with sofosbuvir would need to address whatever limitations sofosbuvir exhibits.  These include reduced efficacy in genotype 3 patients and use in severe renally impaired patients or those patients currently on drugs that are inducers of P-glycoprotein.  However, it has been shown that reduced efficacy in genotype 3 is largely eliminated when sofosbuvir is combined with another oral DAA.  Next-generation inhibitors would also benefit by enabling a reduced duration of therapy and an orthogonal resistance profile.  The more recent group of nucleos(t)ides in clin. development maintains similarities to sofosbuvir, in that they are uridine nucleotide prodrugs.  The question therefore remains whether these new agents will be sufficiently differentiated from sofosbuvir to provide any addnl. benefit to patients.  This paper forms part of a symposium in Antiviral Research on "Hepatitis C: next steps toward global eradication.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgsu_r7tRjWbVg90H21EOLACvtfcHk0lgiJrdqKPLPLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvVait7o%253D&md5=fb15501e528dda16a6b55e85d4f37454</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DBeyond%2520sofosbuvir%253A%2520what%2520opportunity%2520exists%2520for%2520a%2520better%2520nucleoside%252Fnucleotide%2520to%2520treat%2520hepatitis%2520C%253F%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D107%26spage%3D119%26epage%3D124%26doi%3D10.1016%2Fj.antiviral.2014.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latt, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanny, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahota, A. K.</span></span> <span> </span><span class="NLM_article-title">Eight-week ledipasvir/ sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: single center, real world effectiveness and safety</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4759</span>– <span class="NLM_lpage">4766</span>, <span class="refDoi"> DOI: 10.3748/wjg.v23.i26.4759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.3748%2Fwjg.v23.i26.4759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=28765697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BC1cfjtlCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4759-4766&author=N.+L.+Lattauthor=B.+T.+Yannyauthor=D.+Gharibianauthor=R.+Gevorkyanauthor=A.+K.+Sahota&title=Eight-week+ledipasvir%2F+sofosbuvir+in+non-cirrhotic%2C+treatment-na%C3%AFve+hepatitis+C+genotype-1+patients+with+hepatitis+C+virus-RNA+%3C+6+million%3A+single+center%2C+real+world+effectiveness+and+safety&doi=10.3748%2Fwjg.v23.i26.4759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naive hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety</span></div><div class="casAuthors">Latt Nyan L; Yanny Beshoy T; Gharibian Derenik; Gevorkyan Rita; Sahota Amandeep K</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastroenterology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4759-4766</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  To evaluate sustained viral response (SVR) of 8-wk ledipasvir/sofosbuvir therapy among non-cirrhotic, genotype-1 hepatitis C virus (HCV) patients with RNA < 6 million IU/mL.  METHODS:  We performed a retrospective cohort study to examine SVR rates, predictors of treatment failure and safety analysis of 8-wk ledipasvir/sofosbuvir (LDV/SOF) therapy among non-cirrhotic, genotype 1 HCV patients with viral load < 6 million IU/mL.  Primary outcome was an achievement of SVR at 12 wk after treatment.  Secondary outcomes were identifying predictors of treatment failure and adverse events during treatment.  RESULTS:  Total 736 patients: 55% males, 51% Caucasians and 65% were genotype 1a.  Non-cirrhotic state of 53% was determined by clinical judgment (imaging, AST, platelet count) and 47% had documented liver fibrosis testing (biopsy, vibration-controlled transient elastography, serum biomarkers).  Overall SVR12 was 96%.  No difference in SVR12 was seen between patients whose non-cirrhotic state was determined by clinical judgment and patients who had fibrosis testing.  Age groups, gender, ethnicity and genotype 1 subtype did not predict SVR.  Non-cirrhotic state determined by clinical judgment based on simple, non-invasive tests were not associated with lower SVR [OR = 1.02, 95%CI: 0.48-2.17, P = 0.962].  The AUROC for hepatitis C RNA viral load was 0.734 (P < 0.001, 95%CI: 0.66-0.82).  HCV RNA 2.2 million IU/mL was identified as the cutoff value with sensitivity 73% and specificity 64%.  HCV RNA < 2.2 million IU/mL was associated with significantly higher SVR 98% with OR = 0.22 (95%CI: 0.1-0.49, P < 0.001) compared to SVR 92% in HCV RNA ≥ 2.2 million IU/mL.  No death or morbidities were reported.  CONCLUSION:  Our outcomes validate safety and effectiveness of 8-wk LDV/SOF therapy in non-cirrhotic, untreated HCV genotype 1 patients with HCV RNA < 6 million IU/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ2hBDUDUazz0O18WR3iAofW6udTcc2eagGOpeB6KoPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfjtlCjug%253D%253D&md5=49fac145d84e322cd9a2bb79c4453532</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v23.i26.4759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v23.i26.4759%26sid%3Dliteratum%253Aachs%26aulast%3DLatt%26aufirst%3DN.%2BL.%26aulast%3DYanny%26aufirst%3DB.%2BT.%26aulast%3DGharibian%26aufirst%3DD.%26aulast%3DGevorkyan%26aufirst%3DR.%26aulast%3DSahota%26aufirst%3DA.%2BK.%26atitle%3DEight-week%2520ledipasvir%252F%2520sofosbuvir%2520in%2520non-cirrhotic%252C%2520treatment-na%25C3%25AFve%2520hepatitis%2520C%2520genotype-1%2520patients%2520with%2520hepatitis%2520C%2520virus-RNA%2520%253C%25206%2520million%253A%2520single%2520center%252C%2520real%2520world%2520effectiveness%2520and%2520safety%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2017%26volume%3D23%26spage%3D4759%26epage%3D4766%26doi%3D10.3748%2Fwjg.v23.i26.4759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Seley-Radtke, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, M. K.</span></span> <span> </span><span class="NLM_article-title">The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2018.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=29649496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslOntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=66-86&author=K.+L.+Seley-Radtkeauthor=M.+K.+Yates&title=The+evolution+of+nucleoside+analogue+antivirals%3A+a+review+for+chemists+and+non-chemists.+Part+1%3A+Early+structural+modifications+to+the+nucleoside+scaffold&doi=10.1016%2Fj.antiviral.2018.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold</span></div><div class="casAuthors">Seley-Radtke, Katherine L.; Yates, Mary K.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66-86</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This is the first of two invited articles reviewing the development of nucleoside-analog antiviral drugs, written for a target audience of virologists and other non-chemists, as well as chemists who may not be familiar with the field.  Rather than providing a simple chronol. account, we have examd. and attempted to explain the thought processes, advances in synthetic chem. and lessons learned from antiviral testing that led to a few mols. being moved forward to eventual approval for human therapies, while others were discarded.  The present paper focuses on early, relatively simplistic changes made to the nucleoside scaffold, beginning with modifications of the nucleoside sugars of Ara-C and other arabinose-derived nucleoside analogs in the 1960's.  A future paper will review more recent developments, focusing esp. on more complex modifications, particularly those involving multiple changes to the nucleoside scaffold.  We hope that these articles will help virologists and others outside the field of medicinal chem. to understand why certain drugs were successfully developed, while the majority of candidate compds. encountered barriers due to low-yielding synthetic routes, toxicity or other problems that led to their abandonment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTNbV8qi9P4bVg90H21EOLACvtfcHk0lhSOjFHjF0blA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslOntrc%253D&md5=ccd9ad86ef8a1baf078e21747edef73d</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSeley-Radtke%26aufirst%3DK.%2BL.%26aulast%3DYates%26aufirst%3DM.%2BK.%26atitle%3DThe%2520evolution%2520of%2520nucleoside%2520analogue%2520antivirals%253A%2520a%2520review%2520for%2520chemists%2520and%2520non-chemists.%2520Part%25201%253A%2520Early%2520structural%2520modifications%2520to%2520the%2520nucleoside%2520scaffold%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D154%26spage%3D66%26epage%3D86%26doi%3D10.1016%2Fj.antiviral.2018.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seley-Radtke, K. L.</span></span> <span> </span><span class="NLM_article-title">The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: Complex modification to the nucleoside scaffold</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2018.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=30529089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSntrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=5-21&author=M.+K.+Yatesauthor=K.+L.+Seley-Radtke&title=The+evolution+of+antiviral+nucleoside+analogues%3A+a+review+for+chemists+and+non-chemists.+Part+II%3A+Complex+modification+to+the+nucleoside+scaffold&doi=10.1016%2Fj.antiviral.2018.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold</span></div><div class="casAuthors">Yates, Mary K.; Seley-Radtke, Katherine L.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-21</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This is the second of two invited articles reviewing the development of nucleoside analog antiviral drugs, written for a target audience of virologists and other non-chemists, as well as chemists who may not be familiar with the field.  As with the first paper, rather than providing a chronol. account, we have chosen to examine particular examples of structural modifications made to nucleoside analogs that have proven fruitful as various antiviral, anticancer, and other therapeutics.  The first review covered the more common, and in most cases, single modifications to the sugar and base moieties of the nucleoside scaffold.  This paper focuses on more recent developments, esp. nucleoside analogs that contain more than one modification to the nucleoside scaffold.  We hope that these two articles will provide an informative historical perspective of some of the successfully designed analogs, as well as many candidate compds. that encountered obstacles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTMhqxUaJfkbVg90H21EOLACvtfcHk0lhSOjFHjF0blA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSntrzL&md5=26d398d67fa3ae4c54318057eb18b35f</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DYates%26aufirst%3DM.%2BK.%26aulast%3DSeley-Radtke%26aufirst%3DK.%2BL.%26atitle%3DThe%2520evolution%2520of%2520antiviral%2520nucleoside%2520analogues%253A%2520a%2520review%2520for%2520chemists%2520and%2520non-chemists.%2520Part%2520II%253A%2520Complex%2520modification%2520to%2520the%2520nucleoside%2520scaffold%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D162%26spage%3D5%26epage%3D21%26doi%3D10.1016%2Fj.antiviral.2018.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, C.</span>; <span class="NLM_string-name">De Clercq, E.</span>; <span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Viral DNA polymerase inhibitors</span>. In  <i>Viral Genome Replication</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C. E.</span>, <span class="NLM_string-name">Gotte, M.</span>, <span class="NLM_string-name">Raney, K.</span></span>, Eds.; <span class="NLM_publisher-name">Springer Science and Business Media</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>; Chapter 22, pp  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">526</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1007%2Fb135974_22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=481-526&author=C.+Andrei&author=E.+De+Clercq&author=R.+Snoeckauthor=C.+E.+Cameron&author=M.+Gotte&author=K.+Raney&title=Viral+Genome+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fb135974_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252Fb135974_22%26sid%3Dliteratum%253Aachs%26aulast%3DAndrei%26aufirst%3DC.%26atitle%3DViral%2520DNA%2520polymerase%2520inhibitors%26btitle%3DViral%2520Genome%2520Replication%26aulast%3DCameron%26aufirst%3DC.%2BE.%26pub%3DSpringer%2520Science%2520and%2520Business%2520Media%26date%3D2009%26spage%3D481%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span>; <span class="NLM_string-name">Shih, I.-H.</span>; <span class="NLM_string-name">Zhong, W.</span></span> <span> </span><span class="NLM_article-title">Viral RNA polymerase inhibitors</span>. In  <i>Viral Genome Replication</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C. E.</span>, <span class="NLM_string-name">Gotte, M.</span>, <span class="NLM_string-name">Raney, K.</span></span>, Eds.; <span class="NLM_publisher-name">Springer Science and Business Media</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>; Chapter 23, pp  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">548</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1007%2Fb135974_23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=527-548&author=T.+Appleby&author=I.-H.+Shih&author=W.+Zhongauthor=C.+E.+Cameron&author=M.+Gotte&author=K.+Raney&title=Viral+Genome+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1007%2Fb135974_23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252Fb135974_23%26sid%3Dliteratum%253Aachs%26aulast%3DAppleby%26aufirst%3DT.%26atitle%3DViral%2520RNA%2520polymerase%2520inhibitors%26btitle%3DViral%2520Genome%2520Replication%26aulast%3DCameron%26aufirst%3DC.%2BE.%26pub%3DSpringer%2520Science%2520and%2520Business%2520Media%26date%3D2009%26spage%3D527%26epage%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span> <span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2481</span>– <span class="NLM_lpage">2531</span>, <span class="refDoi"> DOI: 10.1021/jm201384j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase&doi=10.1021%2Fjm201384j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span></div><div class="casAuthors">Sofia, Michael J.; Chang, Wonsuk; Furman, Phillip A.; Mosley, Ralph T.; Ross, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2481-2531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a Perspectives review and does not require an abstr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh0maPUC6grVg90H21EOLACvtfcHk0lhQDCEywEJ2CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF&md5=3236ff10d16104b1a39d77f04774ac77</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531%26doi%3D10.1021%2Fjm201384j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vernachio, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleiman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorovits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patti, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madela, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljarah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">INX-08189, a phosphoramidate prodrug of 6-O-methyl-2’-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1851</span>, <span class="refDoi"> DOI: 10.1128/aac.01335-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1128%2FAAC.01335-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=21357300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCls7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1843-1851&author=J.+H.+Vernachioauthor=B.+Bleimanauthor=K.+D.+Bryantauthor=S.+Chamberlainauthor=D.+Hunleyauthor=J.+Hutchinsauthor=B.+Amesauthor=E.+Gorovitsauthor=B.+Gangulyauthor=A.+Hallauthor=A.+Kolykhalovauthor=Y.+Liuauthor=J.+Muhammadauthor=N.+Rajaauthor=C.+R.+Waltersauthor=J.+Wangauthor=K.+Williamsauthor=J.+M.+Pattiauthor=G.+Hensonauthor=K.+Madelaauthor=M.+Aljarahauthor=A.+Gillesauthor=C.+McGuigan&title=INX-08189%2C+a+phosphoramidate+prodrug+of+6-O-methyl-2%E2%80%99-C-methyl+guanosine%2C+is+a+potent+inhibitor+of+hepatitis+C+virus+replication+with+excellent+pharmacokinetic+and+pharmacodynamic+properties&doi=10.1128%2Faac.01335-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties</span></div><div class="casAuthors">Vernachio, John H.; Bleiman, Blair; Bryant, K. Dawn; Chamberlain, Stanley; Hunley, Damound; Hutchins, Jeff; Ames, Brenda; Gorovits, Elena; Ganguly, Babita; Hall, Andrea; Kolykhalov, Alexander; Liu, Yule; Muhammad, Jerry; Raja, Nicholas; Walters, C. Robin; Wang, Jin; Williams, Karen; Patti, Joseph M.; Henson, Geoffrey; Madela, Karolina; Aljarah, Mohamed; Gilles, Arnaud; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1843-1851</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">INX-08189 is an aryl-phosphoramidate of 6-O-methyl-2'-C-Me guanosine.  INX-08189 was highly potent in replicon assays, with a 50% effective concn. of 10 ± 6 nM against hepatitis C genotype 1b at 72 h.  The inhibitory effect on viral replication was rapid, with a 50% effective concn. (EC50) of 35 ± 8 nM at 24 h.  An intracellular 2'-C-Me guanosine triphosphate (2'-C-MeGTP) concn. of 2.43 ± 0.42 pmol/106 cells was sufficient to achieve 90% inhibition of viral replication.  In vitro resistance studies confirmed that the S282T mutation in the NS5b gene conferred an approx. 10-fold redn. in sensitivity to INX-08189.  However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90 of 344 ± 170 nM.  Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency both in wild-type and S282T-expressing replicons.  Genotype 1b replicons could be cleared after 14 days of culture when exposed to as little as 20 nM INX-08189.  No evidence of mitochondrial toxicity was obsd. after 14 days of INX-08189 exposure in both HepG2 and CEM human cell lines.  In vivo studies of rats and cynomolgus monkeys demonstrated that 2'-C-MeGTP concns. in liver equiv. to the EC90 could be attained after a single oral dose of INX-08189.  Rat liver 2'-C-MeGTP concns. were proportional to dose, sustained for greater than 24 h, and correlated with plasma concns. of the nucleoside metabolite 2'-C-Me guanosine.  The characteristics displayed by INX-08189 support its continued development as a clin. candidate for the treatment of chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxZta5SbOb7Vg90H21EOLACvtfcHk0lhQDCEywEJ2CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCls7nI&md5=fa567daf81510977bf973dcdf9104a1b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1128%2FAAC.01335-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01335-10%26sid%3Dliteratum%253Aachs%26aulast%3DVernachio%26aufirst%3DJ.%2BH.%26aulast%3DBleiman%26aufirst%3DB.%26aulast%3DBryant%26aufirst%3DK.%2BD.%26aulast%3DChamberlain%26aufirst%3DS.%26aulast%3DHunley%26aufirst%3DD.%26aulast%3DHutchins%26aufirst%3DJ.%26aulast%3DAmes%26aufirst%3DB.%26aulast%3DGorovits%26aufirst%3DE.%26aulast%3DGanguly%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DKolykhalov%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMuhammad%26aufirst%3DJ.%26aulast%3DRaja%26aufirst%3DN.%26aulast%3DWalters%26aufirst%3DC.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DPatti%26aufirst%3DJ.%2BM.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DMadela%26aufirst%3DK.%26aulast%3DAljarah%26aufirst%3DM.%26aulast%3DGilles%26aufirst%3DA.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DINX-08189%252C%2520a%2520phosphoramidate%2520prodrug%2520of%25206-O-methyl-2%25E2%2580%2599-C-methyl%2520guanosine%252C%2520is%2520a%2520potent%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520replication%2520with%2520excellent%2520pharmacokinetic%2520and%2520pharmacodynamic%2520properties%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D1843%26epage%3D1851%26doi%3D10.1128%2Faac.01335-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pockros, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freilich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamparo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath-Chiozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, A. F.</span></span> <span> </span><span class="NLM_article-title">Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1002/hep.27488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1002%2Fhep.27488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=25251156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=409-416&author=T.+Ahmadauthor=P.+Yinauthor=J.+Saffitzauthor=P.+J.+Pockrosauthor=J.+Lalezariauthor=M.+Shiffmanauthor=B.+Freilichauthor=J.+Zamparoauthor=K.+Brownauthor=D.+Dimitrovaauthor=M.+Kumarauthor=D.+Manionauthor=M.+Heath-Chiozziauthor=R.+Wolfauthor=E.+Hughesauthor=A.+J.+Muirauthor=A.+F.+Hernandez&title=Cardiac+dysfunction+associated+with+a+nucleotide+polymerase+inhibitor+for+treatment+of+hepatitis+C&doi=10.1002%2Fhep.27488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C</span></div><div class="casAuthors">Ahmad, Tariq; Yin, Philip; Saffitz, Jeffrey; Pockros, Paul J.; Lalezari, Jacob; Shiffman, Mitchell; Freilich, Bradley; Zamparo, Joann; Brown, Kyle; Dimitrova, Dessislava; Kumar, Monica; Manion, Doug; Heath-Chiozzi, Margo; Wolf, Robert; Hughes, Eric; Muir, Andrew J.; Hernandez, Adrian F.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">409-416</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity.  In this study, we sought to better understand the potential off-target toxicities of new DAAs.  We retrospectively evaluated the clin. and pathol. findings of the sentinel case in a phase II study that led to clin. development discontinuation for BMS-986094, an HCV nucleotide polymerase (nonstructural 5B) inhibitor.  We also report on outcomes from other patients in the same study, including ECG changes, cardiovascular biomarkers, and transthoracic echocardiograms.  Thirty-four patients received IFN-free BMS-986094 regimens.  Six patients had left ventricular ejection fractions (LVEFs) <30%, 8 had LVEFs 30%-50%, and 11 required hospitalization for suspected cardiotoxicity.  Of the patients with LVEF <50%, 6 had normalization of systolic function after a median of 20 days.  T-wave inversions were the most sensitive predictor of LVEF dysfunction.  B-type natriuretic peptide levels increased over time and correlated with the degree of LVEF dysfunction.  Pathol. anal. of cardiac tissue revealed severe myocyte damage with elongated myofibrils without gross necrosis.  These findings were consistent with some results of recent primate studies that were conducted to further investigate the potential mechanisms of BMS-986094 toxicity.  Conclusion: A novel nucleotide analog polymerase inhibitor developed for HCV treatment may cause a toxic cardiomyopathy.  Ongoing surveillance of DAAs for cardiotoxicities may be beneficial, esp. among patients at higher risk for cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyEQeapTO5TrVg90H21EOLACvtfcHk0liFlspn9Gz9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmsLrF&md5=b1d26affdc6c88bad4498a27fde2d062</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fhep.27488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27488%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DSaffitz%26aufirst%3DJ.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DShiffman%26aufirst%3DM.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DZamparo%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DManion%26aufirst%3DD.%26aulast%3DHeath-Chiozzi%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DHernandez%26aufirst%3DA.%2BF.%26atitle%3DCardiac%2520dysfunction%2520associated%2520with%2520a%2520nucleotide%2520polymerase%2520inhibitor%2520for%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D409%26epage%3D416%26doi%3D10.1002%2Fhep.27488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, B.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naduthambi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection</span>. <i>Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1021/ml100209f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100209f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=130-135&author=W.+Changauthor=D.+Baoauthor=B.-K.+Chunauthor=D.+Naduthambiauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+L.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=C.+Niuauthor=H.+M.+Steuerauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=Discovery+of+PSI-353661%2C+a+novel+purine+nucleotide+prodrug+for+the+treatment+of+HCV+infection&doi=10.1021%2Fml100209f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection</span></div><div class="casAuthors">Chang, Wonsuk; Bao, Donghui; Chun, Byoung-Kwon; Naduthambi, Devan; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine L.; Keilman, Meg; Lam, Angela M.; Niu, Congrong; Steuer, Holly Micolochick; Furman, Phillip A.; Otto, Michael J.; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-135</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus afflicts approx. 180 million people worldwide, and the development of direct acting antivirals may offer substantial benefit compared to the current std. of care.  Accordingly, prodrugs of 2'-deoxy-2'-fluoro-2'-C-methylguanosine monophosphate analogs were prepd. and evaluated for their anti-HCV efficacy and tolerability.  These prodrugs demonstrated >1000 fold greater potency than the parent nucleoside in a cell-based replicon assay as a result of higher intracellular triphosphate levels.  Further optimization led to the discovery of the clin. candidate PSI-353661, which has demonstrated strong in vitro inhibition against HCV without cytotoxicity and equipotent activity against both the wild type and the known S282T nucleoside/tide resistant replicon.  PSI-353661 is currently in preclin. development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYnXUT3TTRBbVg90H21EOLACvtfcHk0liFlspn9Gz9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsbfP&md5=81418285042a7e2ee30cbe12f4dc7874</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fml100209f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100209f%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DW.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChun%26aufirst%3DB.-K.%26aulast%3DNaduthambi%26aufirst%3DD.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%2BL.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DDiscovery%2520of%2520PSI-353661%252C%2520a%2520novel%2520purine%2520nucleotide%2520prodrug%2520for%2520the%2520treatment%2520of%2520HCV%2520infection%26jtitle%3DMed.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D130%26epage%3D135%26doi%3D10.1021%2Fml100209f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, B.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">2’-Deoxy-2’-α-fluoro-2’- -C-methyl 3’,5’-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7376</span>– <span class="NLM_lpage">7380</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.bmcl.2010.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=21050754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7376-7380&author=P.+G.+Reddyauthor=D.+Baoauthor=W.+Changauthor=B.-K.+Chunauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=B.+S.+Rossauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+L.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=C.+Niuauthor=H.+M.+Steuerauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=2%E2%80%99-Deoxy-2%E2%80%99-%CE%B1-fluoro-2%E2%80%99-+-C-methyl+3%E2%80%99%2C5%E2%80%99-cyclic+phosphate+nucleotide+prodrug+analogs+as+inhibitors+of+HCV+NS5B+polymerase%3A+discovery+of+PSI-352938&doi=10.1016%2Fj.bmcl.2010.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">2'-Deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938</span></div><div class="casAuthors">Reddy, P. Ganapati; Bao, Donghui; Chang, Wonsuk; Chun, Byoung-Kwon; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Ross, Bruce S.; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine L.; Keilman, Meg; Lam, Angela M.; Niu, Congrong; Steuer, Holly Micolochick; Furman, Phillip A.; Otto, Michael J.; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7376-7380</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel 2'-deoxy-2'-α-fluoro-2'-β-C-Me 3',5'-cyclic phosphate nucleotide prodrug analogs, e.g. I, were synthesized and evaluated for their in vitro anti-HCV activity and safety.  These prodrugs demonstrated a 10-100-fold greater potency than the parent nucleoside in a cell-based replicon assay due to higher cellular triphosphate levels.  Our structure-activity relationship (SAR) studies provided compds. that gave high levels of active triphosphate in rat liver when administered orally to rats.  These studies ultimately led to the selection of the clin. development candidate I (PSI-352938).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogleH0DTX3orVg90H21EOLACvtfcHk0lj7MvBKJNurBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbzJ&md5=a70a63b690fffed2e37de03cd29dd958</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DChun%26aufirst%3DB.-K.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%2BL.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3D2%25E2%2580%2599-Deoxy-2%25E2%2580%2599-%25CE%25B1-fluoro-2%25E2%2580%2599-%2520-C-methyl%25203%25E2%2580%2599%252C5%25E2%2580%2599-cyclic%2520phosphate%2520nucleotide%2520prodrug%2520analogs%2520as%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520discovery%2520of%2520PSI-352938%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7376%26epage%3D7380%26doi%3D10.1016%2Fj.bmcl.2010.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, B.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Synthesis of PSI-352938: A β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3782</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1021/jo200060f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo200060f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVClur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=3782-3790&author=P.+G.+Reddyauthor=B.-K.+Chunauthor=H.-R.+Zhangauthor=S.+Rachakondaauthor=B.+S.+Rossauthor=M.+J.+Sofia&title=Stereoselective+Synthesis+of+PSI-352938%3A+A+%CE%B2-d-2%E2%80%B2-Deoxy-2%E2%80%B2-%CE%B1-fluoro-2%E2%80%B2-%CE%B2-C-methyl-3%E2%80%B2%2C5%E2%80%B2-cyclic+Phosphate+Nucleotide+Prodrug+for+the+Treatment+of+HCV&doi=10.1021%2Fjo200060f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Synthesis of PSI-352938: A β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyl-3',5'-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV</span></div><div class="casAuthors">Reddy, P. Ganapati; Chun, Byoung-Kwon; Zhang, Hai-Ren; Rachakonda, Suguna; Ross, Bruce S.; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3782-3790</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PSI-352938 is a novel 2'-deoxy-2'-α-fluoro-2'-β-C-Me 3',5'-cyclic phosphate nucleotide prodrug currently under investigation for the treatment of hepatitis C virus (HCV) infection.  PSI-352938 demonstrated superior characteristics in vitro that include broad genotype coverage, superior resistance profile, and high levels of active triphosphate in vivo in the liver compared to our first and second generation nucleoside inhibitors of this class.  Consequently, PSI-352938 was selected for further development and an efficient and scalable synthesis was sought to support clin. development.  We report an improved, diastereoselective synthesis of a key 1'-β-nucleoside intermediate 13 via SN2 displacement of 1-α-bromo ribofuranose sugar 16 with the potassium salt of 6-chloro-2-amino purine and an efficient method to prep. cis-Rp cyclic phosphate (PSI-352938) in a highly stereoselective manner without any chromatog. purifn.  The 1-α-bromo sugar 16 was stereospecifically prepd. from the corresponding 1-β-lactol in high yield under mild bromination conditions using CBr4/PPh3 (Appel reaction).  The desired cis-Rp 3',5'-cyclic phosphate construction was accomplished using iso-Pr phosphorodichloridate readily obtained from POCl3 and iso-Pr alc.  The base combination of Et3N/NMI was identified as a key factor for producing PSI-352938 as the major (>95%) diastereomer (cis-Rp) in high yield after the final cyclization step.  The current route described in this article was successfully used to produce PSI-352938 on multi-kilogram scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWT7SjER_bGbVg90H21EOLACvtfcHk0lj7MvBKJNurBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVClur0%253D&md5=df358665980670feff25531efb192b6c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjo200060f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo200060f%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DChun%26aufirst%3DB.-K.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DStereoselective%2520Synthesis%2520of%2520PSI-352938%253A%2520A%2520%25CE%25B2-d-2%25E2%2580%25B2-Deoxy-2%25E2%2580%25B2-%25CE%25B1-fluoro-2%25E2%2580%25B2-%25CE%25B2-C-methyl-3%25E2%2580%25B2%252C5%25E2%2580%25B2-cyclic%2520Phosphate%2520Nucleotide%2520Prodrug%2520for%2520the%2520Treatment%2520of%2520HCV%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D3782%26epage%3D3790%26doi%3D10.1021%2Fjo200060f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Good, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietropaolo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommadossi, J.-P.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0227104</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0227104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1371%2Fjournal.pone.0227104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=31914458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVemtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=S.+S.+Goodauthor=A.+Moussaauthor=X.-J.+Zhouauthor=K.+Pietropaoloauthor=J.-P.+Sommadossi&title=Preclinical+evaluation+of+AT-527%2C+a+novel+guanosine+nucleotide+prodrug+with+potent%2C+pan-genotypic+activity+against+hepatitis+C+virus&doi=10.1371%2Fjournal.pone.0227104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus</span></div><div class="casAuthors">Good, Steven S.; Moussa, Adel; Zhou, Xiao-Jian; Pietropaolo, Keith; Sommadossi, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0227104</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Despite the availability of highly effective direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infections, sustained viral response (SVR) rates remain suboptimal for difficult-to-treat patient populations such as those with HCV genotype 3, cirrhosis or prior treatment experience, warranting development of more potent HCV replication antivirals.  AT-527 is the hemi-sulfate salt of AT-511, a novel phosphoramidate prodrug of 2'-fluoro-2'-C-methylguanosine-5'-monophosphate that has potent in vitro activity against HCV.  The EC50 of AT-511, detd. using HCV lab. strains and clin. isolates with genotypes 1-5, ranged from 5-28 nM.  The active 5'-triphosphate metabolite, AT-9010, specifically inhibited the HCV RNA-dependent RNA polymerase.  AT-511 did not inhibit the replication of other selected RNA or DNA viruses in vitro.  AT-511 was approx. 10-fold more active than sofosbuvir (SOF) against a panel of lab. strains and clin. isolates of HCV genotypes 1-5 and remained fully active against S282T resistance-assocd. variants, with up to 58-fold more potency than SOF.  In vitro, AT-511 did not inhibit human DNA polymerases or elicit cytotoxicity or mitochondrial toxicity at concns. up to 100 μM.  Unlike the other potent guanosine analogs PSI-938 and PSI-661, no mutagenic O6-alkylguanine bases were formed when incubated with cytochrome P 450 (CYP) 3A4, and AT-511 had IC50 values ≥25 μM against a panel of CYP enzymes.  In hepatocytes from multiple species, the active triphosphate was the predominant metabolite produced from the prodrug, with a half-life of 10 h in human hepatocytes.  When given orally to rats and monkeys, AT-527 preferentially delivered high levels of AT-9010 in the liver in vivo.  These favorable preclin. attributes support the ongoing clin. development of AT-527 and suggest that, when used in combination with an HCV DAA from a different class, AT-527 may increase SVR rates, esp. for difficult-to-treat patient populations, and could potentially shorten treatment duration for all patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg4kNQcDe-jrVg90H21EOLACvtfcHk0liWJRpgI8yZoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVemtLk%253D&md5=d42edf843eadb172e47b8681b4a4b8ba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0227104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0227104%26sid%3Dliteratum%253Aachs%26aulast%3DGood%26aufirst%3DS.%2BS.%26aulast%3DMoussa%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DX.-J.%26aulast%3DPietropaolo%26aufirst%3DK.%26aulast%3DSommadossi%26aufirst%3DJ.-P.%26atitle%3DPreclinical%2520evaluation%2520of%2520AT-527%252C%2520a%2520novel%2520guanosine%2520nucleotide%2520prodrug%2520with%2520potent%252C%2520pan-genotypic%2520activity%2520against%2520hepatitis%2520C%2520virus%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0227104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinkade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajwanshi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=28412183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsl2qs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2017&pages=151-161&author=Z.+Jinauthor=A.+Kinkadeauthor=I.+Beheraauthor=S.+Chaudhuriauthor=K.+Tuckerauthor=N.+Dyatkinaauthor=V.+K.+Rajwanshiauthor=G.+Wangauthor=A.+Jekleauthor=D.+B.+Smithauthor=L.+Beigelmanauthor=J.+A.+Symonsauthor=J.+Deval&title=Structure-activity+relationship+analysis+of+mitochondrial+toxicity+caused+by+antiviral+ribonucleoside+analogs&doi=10.1016%2Fj.antiviral.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs</span></div><div class="casAuthors">Jin, Zhinan; Kinkade, April; Behera, Ishani; Chaudhuri, Shuvam; Tucker, Kathryn; Dyatkina, Natalia; Rajwanshi, Vivek K.; Wang, Guangyi; Jekle, Andreas; Smith, David B.; Beigelman, Leo; Symons, Julian A.; Deval, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent cases of severe toxicity during clin. trials have been assocd. with antiviral ribonucleoside analogs (e.g. INX-08189 and balapiravir).  Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis.  Others have proposed that the prodrug moiety released from the ribonucleoside analogs might instead cause toxicity.  Here, we report the mitochondrial effects of several clin. relevant and structurally diverse ribonucleoside analogs including NITD-008, T-705 (favipiravir), R1479 (parent nucleoside of balapiravir), PSI-7851 (sofosbuvir), and INX-08189 (BMS-986094).  We found that efficient substrates and chain terminators of POLRMT, such as the nucleoside triphosphate forms of R1479, NITD-008, and INX-08189, are likely to cause mitochondrial toxicity in cells, while weaker chain terminators and inhibitors of POLRMT such as T-705 ribonucleoside triphosphate do not elicit strong in vitro mitochondrial effects.  Within a fixed 3'-deoxy or 2'-C-Me ribose scaffold, changing the base moiety of nucleotides did not strongly affect their inhibition const. (Ki) against POLRMT.  By swapping the nucleoside and prodrug moieties of PSI-7851 and INX-08189, we demonstrated that the cell-based toxicity of INX-08189 is mainly caused by the nucleoside component of the mol.  Taken together, these results show that diverse 2' or 4' mono-substituted ribonucleoside scaffolds cause mitochondrial toxicity.  Given the unpredictable structure-activity relationship of this ribonucleoside liability, we propose a rapid and systematic in vitro screen combining cell-based and biochem. assays to identify the early potential for mitochondrial toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBinliDlsUrVg90H21EOLACvtfcHk0liWJRpgI8yZoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsl2qs7g%253D&md5=9882bc8f2be6475219392f0775cfa41b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DKinkade%26aufirst%3DA.%26aulast%3DBehera%26aufirst%3DI.%26aulast%3DChaudhuri%26aufirst%3DS.%26aulast%3DTucker%26aufirst%3DK.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DRajwanshi%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJekle%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DDeval%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%2520analysis%2520of%2520mitochondrial%2520toxicity%2520caused%2520by%2520antiviral%2520ribonucleoside%2520analogs%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D143%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.antiviral.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsertsvadze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streinu-Cercel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijgen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astruc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khorlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, J.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0204974</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0204974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1371%2Fjournal.pone.0204974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=30325939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=M.+McClureauthor=E.+Berlibaauthor=T.+Tsertsvadzeauthor=A.+Streinu-Cercelauthor=L.+Vijgenauthor=B.+Astrucauthor=A.+Patatauthor=C.+Westlandauthor=S.+Chandaauthor=Q.+Zhangauthor=T.+N.+Kakudaauthor=J.+Vuongauthor=N.+Khorlinauthor=L.+Beigelmanauthor=L.+M.+Blattauthor=J.+Fry&title=Safety%2C+tolerability%2C+and+pharmacokinetics+of+AL-335+in+healthy+volunteers+and+hepatitis+C+virus-infected+subjects&doi=10.1371%2Fjournal.pone.0204974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects</span></div><div class="casAuthors">McClure, Matthew W.; Berliba, Elina; Tsertsvadze, Tengiz; Streinu-Cercel, Adrian; Vijgen, Leen; Astruc, Beatrice; Patat, Alain; Westland, Christopher; Chanda, Sushmita; Zhang, Qingling; Kakuda, Thomas N.; Vuong, Jennifer; Khorlin, Nick; Beigelman, Leonid; Blatt, Lawrence M.; Fry, John</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0204974/1-e0204974/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection.  Methods This three-part randomized, double-blind study evaluated the safety and pharmacokinetics of single and multiple ascending oral doses of AL-335.  Healthy volunteers (HVs) received single doses of AL-335 (100-1,200 mg) or placebo in a fasted or fed (400 mg) state.  Non-cirrhotic subjects (HCV genotype [GT]1-4) and GT1-infected subjects with Child Pugh A cirrhosis received multiple doses of AL-335 (400, 800, 1,200 mg) or placebo once daily (QD) for 7 days.  Results Forty-eight HVs and 64 subjects with HCV GT1-4 were randomized and received treatment.  AL-335 was well tolerated in HVs and HCV-infected subjects with/without cirrhosis.  AL-335 was rapidly absorbed and converted to the metabolites ALS-022399 and ALS-022227.  ALS-022227 exposure increased less than dose-proportionally and was unaffected by food, while AL-335 and ALS-022399 exposure increased with food by 85% and 50%, resp., in HVs.  Rapid and dose-dependent redns. in HCV-RNA were obsd. in GT1-infected subjects.  In non-cirrhotic, GT1-4-infected subjects receiving AL-335 800 mg QD, potent antiviral activity was obsd., regardless of genotype (mean max. redns. in HCV-RNA of 4.0-4.8 log10 IU/mL).  The same dose in GT1-infected cirrhotic subjects resulted in a 3.5 log10 IU/mL mean max. redn. in HCV-RNA.  Conclusions AL-335 was well tolerated when administered as single and multiple doses, with an acceptable pharmacokinetic profile.  The drug also demonstrated potent antiviral activity in HCV GT1-4-infected subjects, including GT1-infected subjects with cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyNd9ewfVm6rVg90H21EOLACvtfcHk0lgG7bxK3izJ4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFKgsr8%253D&md5=670b9fe950238a1d0d2da630c38a3768</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0204974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0204974%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DM.%26aulast%3DBerliba%26aufirst%3DE.%26aulast%3DTsertsvadze%26aufirst%3DT.%26aulast%3DStreinu-Cercel%26aufirst%3DA.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DAstruc%26aufirst%3DB.%26aulast%3DPatat%26aufirst%3DA.%26aulast%3DWestland%26aufirst%3DC.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DVuong%26aufirst%3DJ.%26aulast%3DKhorlin%26aufirst%3DN.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DFry%26aufirst%3DJ.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520AL-335%2520in%2520healthy%2520volunteers%2520and%2520hepatitis%2520C%2520virus-infected%2520subjects%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0204974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, J.</span></span> <span> </span><span class="NLM_article-title">Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">S82</span>, <span class="refDoi"> DOI: 10.1016/s0168-8278(17)30429-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2FS0168-8278%2817%2930429-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=S82&author=E.+Ganeauthor=M.+Stedmanauthor=D.+Apelianauthor=C.+Westlandauthor=J.+Vuongauthor=M.+Patelauthor=T.+Kakudaauthor=S.+Chandaauthor=L.+Blattauthor=L.+Beigelmanauthor=D.+Smithauthor=J.+Fry&title=Short+duration+treatment+with+AL-335+and+odalasvir%2C+with+or+without+simeprevir%2C+in+treatment+na%C3%AFve+patients+with+hepatitis+C+infection+with+or+without+cirrhosis&doi=10.1016%2Fs0168-8278%2817%2930429-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2817%2930429-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252817%252930429-4%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%26aulast%3DStedman%26aufirst%3DM.%26aulast%3DApelian%26aufirst%3DD.%26aulast%3DWestland%26aufirst%3DC.%26aulast%3DVuong%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DKakuda%26aufirst%3DT.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DFry%26aufirst%3DJ.%26atitle%3DShort%2520duration%2520treatment%2520with%2520AL-335%2520and%2520odalasvir%252C%2520with%2520or%2520without%2520simeprevir%252C%2520in%2520treatment%2520na%25C3%25AFve%2520patients%2520with%2520hepatitis%2520C%2520infection%2520with%2520or%2520without%2520cirrhosis%26jtitle%3DJ.%2520Hepatol.%26date%3D2017%26volume%3D66%26spage%3DS82%26doi%3D10.1016%2Fs0168-8278%2817%2930429-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pianko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Ari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laursen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstoft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernsler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutko, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.-Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plank, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, R.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1016/s2468-1253(17)30159-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fs2468-1253%2817%2930159-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=28802816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BC1cfntVCltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=805-813&author=E.+J.+Ganeauthor=S.+Piankoauthor=S.+K.+Robertsauthor=A.+J.+Thompsonauthor=S.+Zeuzemauthor=E.+Zuckermanauthor=Z.+Ben-Ariauthor=G.+R.+Fosterauthor=K.+Agarwalauthor=A.+L.+Laursenauthor=J.+Gerstoftauthor=W.+Gaoauthor=H.-C.+Huangauthor=B.+Fitzgeraldauthor=D.+Fernslerauthor=J.+J.+Liauthor=A.+Grandhiauthor=H.+Liuauthor=F.-H.+Suauthor=S.+Wanauthor=Z.+Zengauthor=H.-L.+Chenauthor=F.+J.+Dutkoauthor=B.-Y.+T.+Nguyenauthor=J.+Wahlauthor=M.+N.+Robertsonauthor=E.+Barrauthor=W.+W.+Yehauthor=R.+M.+Plankauthor=J.+R.+Buttertonauthor=R.+Esteban&title=Safety+and+efficacy+of+an+8-week+regimen+of+grazoprevir+plus+ruzasvir+plus+uprifosbuvir+compared+with+grazoprevir+plus+elbasvir+plus+uprifosbuvir+in+participants+without+cirrhosis+infected+with+hepatitis+C+virus+genotypes+1%2C+2%2C+or+3+%28C-CREST-1+and+C-CREST-2%2C+part+A%29%3A+two+randomised%2C+phase+2%2C+open-label+trials&doi=10.1016%2Fs2468-1253%2817%2930159-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials</span></div><div class="casAuthors">Gane Edward J; Pianko Stephen; Roberts Stuart K; Thompson Alexander J; Zeuzem Stefan; Zuckerman Eli; Ben-Ari Ziv; Foster Graham R; Agarwal Kosh; Laursen Alex L; Gerstoft Jan; Gao Wei; Huang Hsueh-Cheng; Fitzgerald Brian; Fernsler Doreen; Li Jerry J; Grandhi Anjana; Liu Hong; Su Feng-Hsiu; Wan Shuyan; Zeng Zhen; Chen Huei-Ling; Dutko Frank J; Nguyen Bach-Yen T; Wahl Janice; Robertson Michael N; Barr Eliav; Yeh Wendy W; Plank Rebeca M; Butterton Joan R; Esteban Rafael</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">805-813</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed.  The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these combination regimens in individuals infected with genotypes 1, 2, or 3.  METHODS:  Part A of these phase 2, randomised, multicentre, open-label, clinical trials enrolled participants from 11 countries, aged 18 years or older, chronically infected with HCV genotypes 1, 2, or 3, with HCV RNA of at least 10 000 IU/mL, without evidence of cirrhosis, who had not received previous treatment for HCV infection.  Within each HCV genotype, participants were randomly assigned (1:1:1:1) with a block size of 4, to open-label treatment to one of four treatment groups: grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (300 mg/day); grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (450 mg/day); grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (300 mg/day); or grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (450 mg/day), according to a computer-generated allocation schedule.  Randomisation was centrally implemented using an interactive voice response system and integrated web response system.  The primary endpoint was the proportion of participants achieving sustained virological response at 12 weeks (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the end of all study therapy) in the per-protocol analysis set, which included all participants who were randomised and received at least one dose of study drug.  The trials are registered with ClinicalTrials.gov, numbers NCT02332707 and NCT02332720.  FINDINGS:  241 participants were randomised between Feb 18, 2015, and March 16, 2015. 240 participants completed 8 weeks of treatment and reached follow-up 12 weeks after the end of treatment.  Of the four regimens, grazoprevir plus ruzasvir plus uprifosbuvir 450 mg had the most consistently high SVR12 (>90%) for participants infected with genotype 1 (21 [91%] of 23), genotype 2 (15 [94%] of 16), and genotype 3 (20 [91%] of 22).  In particular, among those with genotype 2 infection, the grazoprevir plus ruzasvir plus uprifosbuvir 450 mg regimen had a higher SVR12 (15 [94%] of 16) than the grazoprevir plus ruzasvir plus uprifosbuvir 300 mg regimen (ten [71%] of 14), grazoprevir plus elbasvir plus uprifosbuvir 300 mg regimen (11 [69%] of 16), or grazoprevir plus elbasvir plus uprifosbuvir 450 mg regimen (nine [60%] of 15).  Overall, the most common adverse events were headache (55 [23%] of 240), fatigue (47 [20%] of 240), and nausea (32 [13%] of 240).  Two (<1%) of 240 participants had serious adverse events (pharyngeal abscess and keratitis), which were not considered drug related by the respective investigators.  INTERPRETATION:  These results support further evaluation of the three-drug direct-acting antiviral agent regimen of grazoprevir 100 mg plus ruzasvir 60 mg plus uprifosbuvir 450 mg among a more diverse HCV-infected population, including those with compensated cirrhosis, previous treatment with an interferon-containing regimen, and HCV-HIV co-infection.  FUNDING:  Merck & Co, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwDc6dMJIt6RBrI9DTGjC0fW6udTcc2ebgGXInEBiRe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfntVCltg%253D%253D&md5=e6db5c94fdb651b61ecb5f2e555c9dd5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fs2468-1253%2817%2930159-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs2468-1253%252817%252930159-0%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DZuckerman%26aufirst%3DE.%26aulast%3DBen-Ari%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DLaursen%26aufirst%3DA.%2BL.%26aulast%3DGerstoft%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DFitzgerald%26aufirst%3DB.%26aulast%3DFernsler%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DGrandhi%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DF.-H.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.-L.%26aulast%3DDutko%26aufirst%3DF.%2BJ.%26aulast%3DNguyen%26aufirst%3DB.-Y.%2BT.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26aulast%3DBarr%26aufirst%3DE.%26aulast%3DYeh%26aufirst%3DW.%2BW.%26aulast%3DPlank%26aufirst%3DR.%2BM.%26aulast%3DButterton%26aufirst%3DJ.%2BR.%26aulast%3DEsteban%26aufirst%3DR.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520an%25208-week%2520regimen%2520of%2520grazoprevir%2520plus%2520ruzasvir%2520plus%2520uprifosbuvir%2520compared%2520with%2520grazoprevir%2520plus%2520elbasvir%2520plus%2520uprifosbuvir%2520in%2520participants%2520without%2520cirrhosis%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotypes%25201%252C%25202%252C%2520or%25203%2520%2528C-CREST-1%2520and%2520C-CREST-2%252C%2520part%2520A%2529%253A%2520two%2520randomised%252C%2520phase%25202%252C%2520open-label%2520trials%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D2%26spage%3D805%26epage%3D813%26doi%3D10.1016%2Fs2468-1253%2817%2930159-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leisvuori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lönnberg, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 3’,5’-cyclic phosphate and thiophosphate esters of 2’-C-methyl ribonucleosides</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1512</span>– <span class="NLM_lpage">1520</span>, <span class="refDoi"> DOI: 10.1002/hlca.201200099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1002%2Fhlca.201200099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGhtrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2012&pages=1512-1520&author=A.+Leisvuoriauthor=Z.+Ahmedauthor=M.+Oraauthor=L.+Beigelmanauthor=L.+Blattauthor=H.+L%C3%B6nnberg&title=Synthesis+of+3%E2%80%99%2C5%E2%80%99-cyclic+phosphate+and+thiophosphate+esters+of+2%E2%80%99-C-methyl+ribonucleosides&doi=10.1002%2Fhlca.201200099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 3',5'-Cyclic Phosphate and Thiophosphate Esters of 2'-C-Methyl Ribonucleosides</span></div><div class="casAuthors">Leisvuori, Anna; Ahmed, Zafar; Ora, Mikko; Beigelman, Leonid; Blatt, Lawrence; Loennberg, Harri</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1512-1520</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta</span>)
        </div><div class="casAbstract">2'-C-Methylnucleosides are known to exhibit antiviral activity against Hepatitis C virus.  Since the inhibitory activity depends on their intracellular conversion to 5'-triphosphates, dosing as appropriately protected 5'-phosphates or 5'-phosphorothioates appears attractive.  For this purpose, four potential prodrugs of 2'-C-methylguanosine, i.e., 3',5'-cyclic phosphorothioate of 2'-C-methylguanosine I and 2'-C,O6-dimethylguanosine resp., the S-[(pivaloyloxy)methyl] ester of 2'-C,O6-dimethylguanosine 3',5'-cyclic phosphorothioate and the O-Me ester of 2'-C,O6-dimethylguanosine 3',5'-cyclic phosphate resp., have been prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNgtFTyoHvUrVg90H21EOLACvtfcHk0ljr3FMuHqbZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGhtrvM&md5=07896f17fd724c34be943518191aca31</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fhlca.201200099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.201200099%26sid%3Dliteratum%253Aachs%26aulast%3DLeisvuori%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DZ.%26aulast%3DOra%26aufirst%3DM.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DL%25C3%25B6nnberg%26aufirst%3DH.%26atitle%3DSynthesis%2520of%25203%25E2%2580%2599%252C5%25E2%2580%2599-cyclic%2520phosphate%2520and%2520thiophosphate%2520esters%2520of%25202%25E2%2580%2599-C-methyl%2520ribonucleosides%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2012%26volume%3D95%26spage%3D1512%26epage%3D1520%26doi%3D10.1002%2Fhlca.201200099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Beigelman, L.</span>; <span class="NLM_string-name">Dyatkina, N.</span>; <span class="NLM_string-name">Symons, J. A.</span>; <span class="NLM_string-name">Smith, D. B.</span></span> <span> </span><span class="NLM_article-title">Substituted Nucleosides, Nucleotides and Analogs Thereof</span>. U.S. Patent <span class="NLM_patent">20,150,366,887 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+M.+Blatt&author=L.+Beigelman&author=N.+Dyatkina&author=J.+A.+Symons&author=D.+B.+Smith&title=Substituted+Nucleosides%2C+Nucleotides+and+Analogs+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DSubstituted%2520Nucleosides%252C%2520Nucleotides%2520and%2520Analogs%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, C.</span>; <span class="NLM_string-name">Wucherpfennig, K.</span>; <span class="NLM_string-name">Pyrdol, J.</span>; <span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Methods for treating cancer with anti bip or anti mica antibodies</span>. <span class="NLM_patent">WO 2015179627 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+Harvey&author=K.+Wucherpfennig&author=J.+Pyrdol&author=G.+Dranoff&title=Methods+for+treating+cancer+with+anti+bip+or+anti+mica+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DC.%26atitle%3DMethods%2520for%2520treating%2520cancer%2520with%2520anti%2520bip%2520or%2520anti%2520mica%2520antibodies%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Surleraux, D.</span>; <span class="NLM_string-name">Gosselin, G.</span></span> <span> </span><span class="NLM_article-title">Compounds and Pharmaceutical Compositions for Treatment of Viral Infections</span>. <span class="NLM_patent">TW I515000 B</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Surleraux&author=G.+Gosselin&title=Compounds+and+Pharmaceutical+Compositions+for+Treatment+of+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSurleraux%26aufirst%3DD.%26atitle%3DCompounds%2520and%2520Pharmaceutical%2520Compositions%2520for%2520Treatment%2520of%2520Viral%2520Infections%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owen, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyden, J. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffatt, J. G.</span></span> <span> </span><span class="NLM_article-title">4’-Substituted nucleosides. 3. Synthesis of some 4’-fluorouridine derivatives</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3010</span>– <span class="NLM_lpage">3017</span>, <span class="refDoi"> DOI: 10.1021/jo00880a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00880a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADyaE28XltVyqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1976&pages=3010-3017&author=G.+R.+Owenauthor=J.+P.+H.+Verheydenauthor=J.+G.+Moffatt&title=4%E2%80%99-Substituted+nucleosides.+3.+Synthesis+of+some+4%E2%80%99-fluorouridine+derivatives&doi=10.1021%2Fjo00880a018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">4'-Substituted nucleosides.  3.  Synthesis of some 4'-fluorouridine derivatives</span></div><div class="casAuthors">Owen, Geoffrey R.; Verheyden, Julien P. H.; Moffatt, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3010-17</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The reaction of 1-(5-deoxy-2,3-O-isopropylidene-β-D-erythro-pent-4-enofuranosyl)uracil with IF in CH2Cl2 leads to the stereospecific formation of 5'-deoxy-4'-fluoro-5'-iodo-2',3'-O-isopropylideneuridine which can be converted into the 5'-azido deriv. (I) by vigorous treatment with LiN3 in DMF.  Treatment of I with nitrosyl tetrafluoroborate gave 2,5'-anhydro-4'-fluoro-2',3'-O-isopropylideneuridine which can be hydrolyzed to 4'-fluoro-2',3'-O-isopropylideneuridine (II).  The latter compd. was converted into 4'-fluoro-5'-O-sulfamoyluridine, the uracil analog. of nucleocidin, by treatment with sulfamoyl chloride followed by mild acidic hydrolysis.  4'-Fluorouridine 5'-phosphate was prepd. via conversion of II to its bis(2,2,2-trichloroethyl)phosphate ester followed by deblocking.  The unusual stabilities of 4'-fluorouridine derivs. are discussed.  In addn., treatment of 2',3'-methoxymethylene- and 2',3'-methoxyethylideneuridine derivs. with nitrosyl tetrafluoroborate gave 2,2'-anhydro-1-β-D-arabinofuranosyluracils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwRHEkJ1WrxrVg90H21EOLACvtfcHk0lg1_sBECHjCZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltVyqs7c%253D&md5=047a45d0822a2efd40ef282597a45140</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo00880a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00880a018%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DG.%2BR.%26aulast%3DVerheyden%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DMoffatt%26aufirst%3DJ.%2BG.%26atitle%3D4%25E2%2580%2599-Substituted%2520nucleosides.%25203.%2520Synthesis%2520of%2520some%25204%25E2%2580%2599-fluorouridine%2520derivatives%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1976%26volume%3D41%26spage%3D3010%26epage%3D3017%26doi%3D10.1021%2Fjo00880a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajwanshi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinkade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-nucleosides as favipiravir (T-705) analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4611</span>– <span class="NLM_lpage">4624</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslWhsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4611-4624&author=G.+Wangauthor=J.+Wanauthor=Y.+Huauthor=X.+Wuauthor=M.+Prhavcauthor=N.+Dyatkinaauthor=V.+K.+Rajwanshiauthor=D.+B.+Smithauthor=A.+Jekleauthor=A.+Kinkadeauthor=J.+A.+Symonsauthor=Z.+Jinauthor=J.+Devalauthor=Q.+Zhangauthor=Y.+Tamauthor=S.+Chandaauthor=L.+Blattauthor=L.+Beigelman&title=Synthesis+and+anti-influenza+activity+of+pyridine%2C+pyridazine%2C+and+pyrimidine+C-nucleosides+as+favipiravir+%28T-705%29+analogues&doi=10.1021%2Facs.jmedchem.5b01933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues</span></div><div class="casAuthors">Wang, Guangyi; Wan, Jinqiao; Hu, Yujian; Wu, Xiangyang; Prhavc, Marija; Dyatkina, Natalia; Rajwanshi, Vivek K.; Smith, David B.; Jekle, Andreas; Kinkade, April; Symons, Julian A.; Jin, Zhinan; Deval, Jerome; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita; Blatt, Lawrence; Beigelman, Leonid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4611-4624</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Influenza viruses are responsible for seasonal epidemics and occasional pandemics which cause significant morbidity and mortality.  Despite available vaccines, only partial protection is achieved.  Currently, there are two classes of widely approved anti-influenza drugs: M2 ion channel blockers and neuraminidase inhibitors.  However, the worldwide spread of drug-resistant influenza strains poses an urgent need for novel antiviral drugs, particularly with a different mechanism of action.  Favipiravir (T-705), a broad-spectrum antiviral agent, has shown potent anti-influenza activity in cell-based assays, and its riboside I triphosphate inhibited influenza polymerase.  In one of our approaches to treat influenza infection, we designed, prepd., and tested a series of C-nucleoside analogs, which have an analogy to I and were expected to act by a similar antiviral mechanism as favipiravir.  Compd. II of this report exhibited potent inhibition of influenza virus replication in MDCK cells, and its triphosphate was a substrate of and demonstrated inhibitory activity against influenza A polymerase.  Metabolites of II are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRioGBuwYw4bVg90H21EOLACvtfcHk0ljCzKcki4bhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslWhsrs%253D&md5=971a0286f4635e72134d99f9f86320da</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01933%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DRajwanshi%26aufirst%3DV.%2BK.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DJekle%26aufirst%3DA.%26aulast%3DKinkade%26aufirst%3DA.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520anti-influenza%2520activity%2520of%2520pyridine%252C%2520pyridazine%252C%2520and%2520pyrimidine%2520C-nucleosides%2520as%2520favipiravir%2520%2528T-705%2529%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4611%26epage%3D4624%26doi%3D10.1021%2Facs.jmedchem.5b01933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoycheva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jekle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-HCV activities of 4’-fluoro-2’-substituted uridine triphosphates and nucleotide prodrugs: discovery of 4’-fluoro-2’- C-methyluridine 5’-phosphoramidate prodrug (AL-335) for the treatment of hepatitis C infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4555</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVenu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4555-4570&author=G.+Wangauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=C.+Williamsauthor=V.+Serebryanyauthor=Y.+Huauthor=Y.+Huangauthor=J.+Wanauthor=X.+Wuauthor=J.+Devalauthor=A.+Fungauthor=Z.+Jinauthor=H.+Tanauthor=K.+Shawauthor=H.+Kangauthor=Q.+Zhangauthor=Y.+Tamauthor=A.+Stoychevaauthor=A.+Jekleauthor=D.+B.+Smithauthor=L.+Beigelman&title=Synthesis+and+anti-HCV+activities+of+4%E2%80%99-fluoro-2%E2%80%99-substituted+uridine+triphosphates+and+nucleotide+prodrugs%3A+discovery+of+4%E2%80%99-fluoro-2%E2%80%99-+C-methyluridine+5%E2%80%99-phosphoramidate+prodrug+%28AL-335%29+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Facs.jmedchem.9b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'-C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Wang, Guangyi; Dyatkina, Natalia; Prhavc, Marija; Williams, Caroline; Serebryany, Vladimir; Hu, Yujian; Huang, Yongfei; Wan, Jinqiao; Wu, Xiangyang; Deval, Jerome; Fung, Amy; Jin, Zhinan; Tan, Hua; Shaw, Kenneth; Kang, Hyunsoon; Zhang, Qingling; Tam, Yuen; Stoycheva, Antitsa; Jekle, Andreas; Smith, David B.; Beigelman, Leonid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4555-4570</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C is a major liver disease caused by hepatitis C virus.  Current std. of care for HCV using direct-acting antiviral agents in combination can achieve cure rates above 95%.  However, the long term use of these drugs may lead to viral resistance and a higher rate of adverse effects.  Toward this goal, we made a significant effort in search of safe and effective nucleoside HCV inhibitors.  In this article, we report synthesis and biol. evaluation of a series of 4'-fluoro-2'-C-substituted uridines, e.g. I.  Triphosphates of the uridine analogs exhibited potent inhibition of HCV NS5B polymerase with IC50 values as low as 27 nM.  In an HCV sub-genomic replicon assay, the phosphoramidate prodrugs of these uridine analogs demonstrated very potent activity with EC50 values as low as 20 nM.  A lead compd. (Sp)-I demonstrated high levels of the NTP in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose.  Compd. (Sp)-I (AL-335) was selected for clin. development where it showed promising results in Phase 1 and II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCi7dY7StL_rVg90H21EOLACvtfcHk0ljCzKcki4bhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVenu7g%253D&md5=e20e066b0ac49975f6ad82c5ff9c82b3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00143%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DStoycheva%26aufirst%3DA.%26aulast%3DJekle%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520anti-HCV%2520activities%2520of%25204%25E2%2580%2599-fluoro-2%25E2%2580%2599-substituted%2520uridine%2520triphosphates%2520and%2520nucleotide%2520prodrugs%253A%2520discovery%2520of%25204%25E2%2580%2599-fluoro-2%25E2%2580%2599-%2520C-methyluridine%25205%25E2%2580%2599-phosphoramidate%2520prodrug%2520%2528AL-335%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4555%26epage%3D4570%26doi%3D10.1021%2Facs.jmedchem.9b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailopulo, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poopeiko, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prikota, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivets, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvasyuk, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiviral and cytostatic properties of 3’-deoxy-3’-fluoro- and 2’-azido-3’-fluoro-2’,3’-dideoxy-D-ribofuranosides of natural heterocyclic bases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2195</span>– <span class="NLM_lpage">2202</span>, <span class="refDoi"> DOI: 10.1021/jm00111a040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00111a040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADyaK3MXksFSitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=2195-2202&author=I.+A.+Mikhailopuloauthor=N.+E.+Poopeikoauthor=T.+I.+Prikotaauthor=G.+G.+Sivetsauthor=E.+I.+Kvasyukauthor=J.+Balzariniauthor=E.+De+Clercq&title=Synthesis+and+antiviral+and+cytostatic+properties+of+3%E2%80%99-deoxy-3%E2%80%99-fluoro-+and+2%E2%80%99-azido-3%E2%80%99-fluoro-2%E2%80%99%2C3%E2%80%99-dideoxy-D-ribofuranosides+of+natural+heterocyclic+bases&doi=10.1021%2Fjm00111a040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases</span></div><div class="casAuthors">Mikhailopulo, I. A.; Poopeiko, N. E.; Prikota, T. I.; Sivets, G. G.; Kvasyuk, E. I.; Balzarini, J.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2195-202</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 3'-deoxy-3'-fluoro- and 2'-azido-2',3'-dideoxy-3'-fluoro-D-ribofuranosides of natural heterocyclic bases were synthesized with the use of universal carbohydrate precursors, viz., 1-O-acetyl-2,5-di-O-benzoyl-3-deoxy-3-fluoro-D-ribofuranose and Me 2-azido-5-O-benzoyl-2,3-dideoxy-3-fluoro-β-D-ribofuranoside, resp.  The cytostatic and antiviral activities of the compds. were evaluated against a variety of tumor cell lines and DNA/RNA viruses, resp.  As the most active compd., from both a cytostatic and antiviral activity viewpoint, emerged 3'-deoxy-3'-fluoroadenosine (I).  It inhibited the proliferation of some tumor cell lines (i.e. murine leukemia L1210 and human T-lymphocyte MT-4) at a concn. of 0.2-2 μg/mL, and proved inhibitory to the replication of pos.-stranded RNA viruses (i.e. polio, Coxsackie, Sindbis, Semliki forest), double-stranded RNA viruses (i.e. reo), and some DNA viruses (i.e. vaccinia) at a concn. of 1-4 μg/mL, which is well below the cytotoxicity threshold (40 μg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Utul8wVwtbVg90H21EOLACvtfcHk0ljCzKcki4bhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksFSitbg%253D&md5=55360c8e7cfa3f5f23a44f45af7c6e2f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00111a040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00111a040%26sid%3Dliteratum%253Aachs%26aulast%3DMikhailopulo%26aufirst%3DI.%2BA.%26aulast%3DPoopeiko%26aufirst%3DN.%2BE.%26aulast%3DPrikota%26aufirst%3DT.%2BI.%26aulast%3DSivets%26aufirst%3DG.%2BG.%26aulast%3DKvasyuk%26aufirst%3DE.%2BI.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSynthesis%2520and%2520antiviral%2520and%2520cytostatic%2520properties%2520of%25203%25E2%2580%2599-deoxy-3%25E2%2580%2599-fluoro-%2520and%25202%25E2%2580%2599-azido-3%25E2%2580%2599-fluoro-2%25E2%2580%2599%252C3%25E2%2580%2599-dideoxy-D-ribofuranosides%2520of%2520natural%2520heterocyclic%2520bases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D2195%26epage%3D2202%26doi%3D10.1021%2Fjm00111a040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic hydrochlorination of unactivated olefins with para-toluenesulfonyl chloride</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5758</span>– <span class="NLM_lpage">5760</span>, <span class="refDoi"> DOI: 10.1002/anie.200801760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1002%2Fanie.200801760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=18576460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsFKrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5758-5760&author=B.+Gasparauthor=E.+M.+Carreira&title=Catalytic+hydrochlorination+of+unactivated+olefins+with+para-toluenesulfonyl+chloride&doi=10.1002%2Fanie.200801760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic hydrochlorination of unactivated olefins with para-toluenesulfonyl chloride</span></div><div class="casAuthors">Gaspar, Boris; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">5758-5760</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The hydrochlorination of unactivated alkenes with p-toluenesulfonyl chloride is catalyzed by simple cobalt complexes of ligands I and II and proceeds under very mild conditions.  The ready availability of all components and the ease of execution render the method very convenient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJdFgqDojFSLVg90H21EOLACvtfcHk0liuEc3uUNjqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsFKrsr4%253D&md5=320a6e19ca59471cca3ff3c7af8ad443</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.200801760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200801760%26sid%3Dliteratum%253Aachs%26aulast%3DGaspar%26aufirst%3DB.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DCatalytic%2520hydrochlorination%2520of%2520unactivated%2520olefins%2520with%2520para-toluenesulfonyl%2520chloride%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D5758%26epage%3D5760%26doi%3D10.1002%2Fanie.200801760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Hydrazines and azides via the metal-matalyzed hydrohydrazination and hydroazidation of olefins</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">11693</span>– <span class="NLM_lpage">11712</span>, <span class="refDoi"> DOI: 10.1021/ja062355+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja062355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVKhsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=11693-11712&author=J.+Waserauthor=B.+Gasparauthor=H.+Nambuauthor=E.+M.+Carreira&title=Hydrazines+and+azides+via+the+metal-matalyzed+hydrohydrazination+and+hydroazidation+of+olefins&doi=10.1021%2Fja062355%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrazines and Azides via the Metal-Catalyzed Hydrohydrazination and Hydroazidation of Olefins</span></div><div class="casAuthors">Waser, Jerome; Gaspar, Boris; Nambu, Hisanori; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">11693-11712</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery, study, and implementation of the Co- and Mn-catalyzed hydrohydrazination and hydroazidation reactions of olefins are reported.  These reactions are equiv. to direct hydroaminations of C-C double bonds with protected hydrazines or hydrazoic acid but are based on a different concept in which the H and the N atoms come from two different reagents, a silane and an oxidizing nitrogen source (azodicarboxylate or sulfonyl azide).  The hydrohydrazination reaction using di-tert-Bu azodicarboxylate is characterized by its ease of use, large functional group tolerance, and broad scope, including mono-, di-, tri-, and tetrasubstituted olefins.  Key to the development of the hydroazidation reaction was the use of sulfonyl azides as nitrogen sources and the activating effect of tert-Bu hydroperoxide.  The reaction was found to be efficient for the functionalization of mono-, di-, and trisubstituted olefins, and only a few functional groups are not tolerated.  The alkyl azides obtained are versatile intermediates and can be transformed to the free amines or triazoles without isolation of the azides.  Preliminary mechanistic investigations suggest a rate-limiting hydrocobaltation of the alkene, followed by an amination reaction.  Radical intermediates cannot be ruled out and may be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOxkf-FFSDurVg90H21EOLACvtfcHk0liuEc3uUNjqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVKhsbc%253D&md5=18f4f26d8922ea3f64ddbdf113f6db09</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fja062355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja062355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWaser%26aufirst%3DJ.%26aulast%3DGaspar%26aufirst%3DB.%26aulast%3DNambu%26aufirst%3DH.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DHydrazines%2520and%2520azides%2520via%2520the%2520metal-matalyzed%2520hydrohydrazination%2520and%2520hydroazidation%2520of%2520olefins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D11693%26epage%3D11712%26doi%3D10.1021%2Fja062355%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosserman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getty, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassini, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2283</span>– <span class="NLM_lpage">2295</span>, <span class="refDoi"> DOI: 10.1021/jm030424e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030424e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVygtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2283-2295&author=A.+B.+Eldrupauthor=C.+R.+Allersonauthor=C.+F.+Bennettauthor=S.+Beraauthor=B.+Bhatauthor=N.+Bhatauthor=M.+R.+Bossermanauthor=J.+Brooksauthor=C.+Burleinauthor=S.+S.+Carrollauthor=P.+D.+Cookauthor=K.+L.+Gettyauthor=M.+MacCossauthor=D.+R.+McMastersauthor=D.+B.+Olsenauthor=T.+P.+Prakashauthor=M.+Prhavcauthor=Q.+Songauthor=J.+E.+Tomassiniauthor=J.+Xia&title=Structure-activity+relationship+of+purine+ribonucleosides+for+inhibition+of+hepatitis+C+virus+RNA-dependent+RNA+polymerase&doi=10.1021%2Fjm030424e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase</span></div><div class="casAuthors">Eldrup, Anne B.; Allerson, Charles R.; Bennett, C. Frank; Bera, Sanjib; Bhat, Balkrishen; Bhat, Neelima; Bosserman, Michele R.; Brooks, Jennifer; Burlein, Christine; Carroll, Steven S.; Cook, P. Dan; Getty, Krista L.; MacCoss, Malcolm; McMasters, Daniel R.; Olsen, David B.; Prakash, Thazha P.; Prhavc, Marija; Song, Quanlai; Tomassini, Joanne E.; Xia, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2283-2295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a continued effort to identify inhibitors of hepatitis C viral (HCV) replication, we report here the synthesis and evaluation of a series of nucleoside analogs and their corresponding triphosphates.  Nucleosides were evaluated for their ability to inhibit HCV RNA replication in a cell-based, subgenomic replicon system, while nucleoside triphosphates were evaluated for their ability to inhibit in vitro RNA synthesis mediated by the HCV RNA-dependent RNA polymerase, NS5B.  2'-C-Methyladenosine and 2'-C-methylguanosine were identified as potent inhibitors of HCV RNA replication, and the corresponding triphosphates were found to be potent inhibitors of HCV NS5B-mediated RNA synthesis.  The data generated in the cell-based assay demonstrated a fairly stringent structure-activity relationship around the active nucleosides.  Increase in steric bulk beyond Me on C2, change in the stereo- or regiochem. of the Me substituent, or change of identity of the heterobase beyond that of the endogenous adenine or guanine was found to lead to loss of inhibitory activity.  The results highlight the importance of the ribo configuration 2'- and 3'-hydroxy pharmacophores for inhibition of HCV RNA replication in the cell-based assay and demonstrate that inclusion of the 2'-C-methylribonucleoside pharmacophore leads to increased resistance to adenosine deaminase and purine nucleoside phosphorylase mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN5TEtkVswmbVg90H21EOLACvtfcHk0lh7N-RNU61guA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVygtrg%253D&md5=a932a7398e472269f75c7ab029e8630f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm030424e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030424e%26sid%3Dliteratum%253Aachs%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26aulast%3DAllerson%26aufirst%3DC.%2BR.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DBera%26aufirst%3DS.%26aulast%3DBhat%26aufirst%3DB.%26aulast%3DBhat%26aufirst%3DN.%26aulast%3DBosserman%26aufirst%3DM.%2BR.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DCook%26aufirst%3DP.%2BD.%26aulast%3DGetty%26aufirst%3DK.%2BL.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DMcMasters%26aufirst%3DD.%2BR.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DTomassini%26aufirst%3DJ.%2BE.%26aulast%3DXia%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%2520of%2520purine%2520ribonucleosides%2520for%2520inhibition%2520of%2520hepatitis%2520C%2520virus%2520RNA-dependent%2520RNA%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2283%26epage%3D2295%26doi%3D10.1021%2Fjm030424e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Painter, G. R.</span>; <span class="NLM_string-name">Bluemling, G. R.</span></span> <span> </span><span class="NLM_article-title">Nucleotides and Nucleosides Therapeutic Composition and Uses Related Thereto</span>. <span class="NLM_patent">WO 2014124430 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+C.+Liotta&author=G.+R.+Painter&author=G.+R.+Bluemling&title=Nucleotides+and+Nucleosides+Therapeutic+Composition+and+Uses+Related+Thereto"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26atitle%3DNucleotides%2520and%2520Nucleosides%2520Therapeutic%2520Composition%2520and%2520Uses%2520Related%2520Thereto%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Öberg, B.</span></span> <span> </span><span class="NLM_article-title">Rational design of polymerase inhibitors as antiviral drugs</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2006.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1016%2Fj.antiviral.2006.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=16820225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BD28vptlyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=90-95&author=B.+%C3%96berg&title=Rational+design+of+polymerase+inhibitors+as+antiviral+drugs&doi=10.1016%2Fj.antiviral.2006.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of polymerase inhibitors as antiviral drugs</span></div><div class="casAuthors">Oberg Bo</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">90-5</span>
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    </div><div class="casAbstract">Almost all viruses have polymerases which are suitable targets for antiviral drugs.  The development of selective polymerase inhibitors started with screening of compounds in virus-infected cell cultures and the mechanism of action was investigated once an inhibitor had been found.  Especially nucleoside analogs were screened as their triphosphates were potential substrates for polymerases.  However, the stepwise phosphorylation by cellular, and sometimes viral, kinases to the active triphosphate prevented a truly rational design of polymerase inhibitors.  Nucleotide analogs offers a type of compounds which could be designed in a more rational way than nucleoside analogs since the first, most selective, phosphorylation step is eliminated in the path to the active inhibitor.  The development of pyrophosphate analogs made rational design possible since these compounds act directly on the viral enzyme, but the room for structural variation was limited.  The non-nucleoside HIV reverse transcriptase inhibitors are direct inhibitors and can thus be designed in a truly rational way by use of structure information on the enzyme-inhibitor complex by use of X-ray and NMR.  This rational design of allosteric inhibitors is also being used in the development of inhibitors to other viral polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUCeYK-aH6vudfST00W0BcfW6udTcc2ebU78Sncylcjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vptlyisg%253D%253D&md5=b02d814cb215117f07e86ea4b727cb18</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2006.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2006.05.012%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596berg%26aufirst%3DB.%26atitle%3DRational%2520design%2520of%2520polymerase%2520inhibitors%2520as%2520antiviral%2520drugs%26jtitle%3DAntiviral%2520Res.%26date%3D2006%26volume%3D71%26spage%3D90%26epage%3D95%26doi%3D10.1016%2Fj.antiviral.2006.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N6- or O6-substituted purine or 2-aminopurine nucleoside monophosphates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5902</span>– <span class="NLM_lpage">5914</span>, <span class="refDoi"> DOI: 10.1021/jm200650j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200650j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlSmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5902-5914&author=E.+Murakamiauthor=H.+Baoauthor=R.+T.+Mosleyauthor=J.+Duauthor=M.+J.+Sofiaauthor=P.+A.+Furman&title=Adenosine+deaminase-like+protein+1+%28ADAL1%29%3A+characterization+and+substrate+specificity+in+the+hydrolysis+of+N6-+or+O6-substituted+purine+or+2-aminopurine+nucleoside+monophosphates&doi=10.1021%2Fjm200650j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Deaminase-like Protein 1 (ADAL1): Characterization and Substrate Specificity in the Hydrolysis of N6- or O6-Substituted Purine or 2-Aminopurine Nucleoside Monophosphates</span></div><div class="casAuthors">Murakami, Eisuke; Bao, Haiying; Mosley, Ralph T.; Du, Jinfa; Sofia, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5902-5914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human N6-methyl-AMP/dAMP aminohydrolase has been shown to be involved in metab. of pharmacol. important N6-substituted purine nucleosides and 5'-monophosphate prodrugs thereof.  This enzyme was cloned and expressed in E. coli, and mass spectroscopic anal. followed by amino acid sequence analyses indicated that the protein was adenosine deaminase-like protein isoform 1 (ADAL1).  An extensive structure-activity relationship study showed that ADAL1 was able to catalyze removal of different alkyl groups not only from N6-substituted purine or 2-aminopurine nucleoside monophosphates but also from O6-substituted compds.  The ADAL1 activity was susceptible to modifications in the phosphate moiety but not to changes in the sugar moiety.  Overall, our data indicated that ADAL1 specifically acts at the 6-position of purine and 2-aminopurine nucleoside monophosphates.  Our results may help designing of new therapeutic nucleoside/nucleotide prodrugs with desired metabolic profiles.  Furthermore, amino acid sequence anal. in conjunction with crystallog. data and metal anal. suggested that ADAL1 contains a catalytic zinc ion.  Finally, a potential physiol. role of ADAL1 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCnGE5y2oXY7Vg90H21EOLACvtfcHk0liLDzSXPnAwGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlSmtbo%253D&md5=669d646f91563308262b0c010df3a0c6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm200650j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200650j%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DAdenosine%2520deaminase-like%2520protein%25201%2520%2528ADAL1%2529%253A%2520characterization%2520and%2520substrate%2520specificity%2520in%2520the%2520hydrolysis%2520of%2520N6-%2520or%2520O6-substituted%2520purine%2520or%25202-aminopurine%2520nucleoside%2520monophosphates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5902%26epage%3D5914%26doi%3D10.1021%2Fjm200650j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madela, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljarah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrica, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleiman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorovits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obikhod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernachio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamurty, C. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battina, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8632</span>– <span class="NLM_lpage">8645</span>, <span class="refDoi"> DOI: 10.1021/jm2011673</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2011673" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FmtlWjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8632-8645&author=C.+McGuiganauthor=K.+Madelaauthor=M.+Aljarahauthor=C.+Bourdinauthor=M.+Arricaauthor=E.+Barrettauthor=S.+Jonesauthor=A.+Kolykhalovauthor=B.+Bleimanauthor=K.+D.+Bryantauthor=B.+Gangulyauthor=E.+Gorovitsauthor=G.+Hensonauthor=D.+Hunleyauthor=J.+Hutchinsauthor=J.+Muhammadauthor=A.+Obikhodauthor=J.+Pattiauthor=C.+R.+Waltersauthor=J.+Wangauthor=J.+Vernachioauthor=C.+V.+S.+Ramamurtyauthor=S.+K.+Battinaauthor=S.+Chamberlain&title=Phosphorodiamidates+as+a+promising+new+phosphate+prodrug+motif+for+antiviral+drug+discovery%3A+application+to+anti-HCV+agents&doi=10.1021%2Fjm2011673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents</span></div><div class="casAuthors">McGuigan Christopher; Madela Karolina; Aljarah Mohamed; Bourdin Claire; Arrica Maria; Barrett Emma; Jones Sarah; Kolykhalov Alexander; Bleiman Blair; Bryant K Dawn; Ganguly Babita; Gorovits Elena; Henson Geoffrey; Hunley Damound; Hutchins Jeff; Muhammad Jerry; Obikhod Aleksandr; Patti Joseph; Walters C Robin; Wang Jin; Vernachio John; Ramamurty Changalvala V S; Battina Srinivas K; Chamberlain Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8632-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We herein report phosphorodiamidates as a significant new phosphate prodrug motif.  Sixty-seven phosphorodiamidates are reported of two 6-O-alkyl 2'-C-methyl guanosines, with significant variation in the diamidate structure.  Both symmetrical and asymmetric phosphorodiamidates are reported, derived from various esterified amino acids, both d and l, and also from various simple amines.  All of the compounds were evaluated versus hepatitis C virus in replicon assay, and nanomolar activity levels were observed.  Many compounds were noncytotoxic at 100 μM, leading to high antiviral selectivities.  The agents are stable in acidic, neutral, and moderately basic media and in selected biological media but show efficient processing by carboxypeptidases and efficiently yield the free nucleoside monophosphate in cells.  On the basis of in vitro data, eight leads were selected for additional in vivo evaluation, with the intent of selecting one candidate for progression toward clinical studies.  This phosphorodiamidate prodrug method may have broad application outside of HCV and antivirals as it offers many of the advantages of phosphoramidate ProTides but without the chirality issues present in most cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ8wY11iyNsRLDWw4HIq2sfW6udTcc2ebjH9x14pyp8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FmtlWjsQ%253D%253D&md5=5b7d43c2582a96a963e3927988054df7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm2011673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2011673%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMadela%26aufirst%3DK.%26aulast%3DAljarah%26aufirst%3DM.%26aulast%3DBourdin%26aufirst%3DC.%26aulast%3DArrica%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DKolykhalov%26aufirst%3DA.%26aulast%3DBleiman%26aufirst%3DB.%26aulast%3DBryant%26aufirst%3DK.%2BD.%26aulast%3DGanguly%26aufirst%3DB.%26aulast%3DGorovits%26aufirst%3DE.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DHunley%26aufirst%3DD.%26aulast%3DHutchins%26aufirst%3DJ.%26aulast%3DMuhammad%26aufirst%3DJ.%26aulast%3DObikhod%26aufirst%3DA.%26aulast%3DPatti%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DC.%2BR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DVernachio%26aufirst%3DJ.%26aulast%3DRamamurty%26aufirst%3DC.%2BV.%2BS.%26aulast%3DBattina%26aufirst%3DS.%2BK.%26aulast%3DChamberlain%26aufirst%3DS.%26atitle%3DPhosphorodiamidates%2520as%2520a%2520promising%2520new%2520phosphate%2520prodrug%2520motif%2520for%2520antiviral%2520drug%2520discovery%253A%2520application%2520to%2520anti-HCV%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8632%26epage%3D8645%26doi%3D10.1021%2Fjm2011673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapati Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of diastereomerically pure nucleotide phosphoramidates</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">8311</span>– <span class="NLM_lpage">8319</span>, <span class="refDoi"> DOI: 10.1021/jo201492m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo201492m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=8311-8319&author=B.+S.+Rossauthor=P.+Ganapati+Reddyauthor=H.-R.+Zhangauthor=S.+Rachakondaauthor=M.+J.+Sofia&title=Synthesis+of+diastereomerically+pure+nucleotide+phosphoramidates&doi=10.1021%2Fjo201492m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diastereomerically Pure Nucleotide Phosphoramidates</span></div><div class="casAuthors">Ross, Bruce S.; Ganapati Reddy, P.; Zhang, Hai-Ren; Rachakonda, Suguna; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8311-8319</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prodrugs of therapeutic nucleoside monophosphates masked as phosphoramidate derivs. have become an increasingly important class of antiviral drugs in pharmaceutical research for delivering nucleotides in vitro and in vivo.  Conventionally, phosphoramidate derivs. are prepd. as a mixt. of two diastereomers.  We report a class of stable phosphoramidate reagents contg. an amino acid ester and two phenolic groups, one unsubstituted and the other with electron-withdrawing substituents.  The reagents can be isolated as single diastereomers and reacted with the 5'-hydroxyl group of nucleosides through selective nucleophilic displacement of the substituted phenol to prep. single diastereomer phosphoramidate products.  This method has been used to prep. the HCV clin. candidate PSI-7977 I in high yield and high diastereomeric purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgDGdlH3gLa7Vg90H21EOLACvtfcHk0ljBQQDNdwgoEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F&md5=747a893daa7d9c4784cc29619d05ab81</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo201492m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo201492m%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DGanapati%2BReddy%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520of%2520diastereomerically%2520pure%2520nucleotide%2520phosphoramidates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D8311%26epage%3D8319%26doi%3D10.1021%2Fjo201492m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoycheva, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2’-fluoro-4’-chloromethyl-cytidine triphosphate</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e1004995</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1004995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1371%2Fjournal.ppat.1004995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=26098424" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&author=J.+Devalauthor=J.+Hongauthor=G.+Wangauthor=J.+Taylorauthor=L.+K.+Smithauthor=A.+Fungauthor=S.+K.+Stevensauthor=H.+Liuauthor=Z.+Jinauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=A.+D.+Stoychevaauthor=V.+Serebryanyauthor=J.+Liuauthor=D.+B.+Smithauthor=Y.+Tamauthor=Q.+Zhangauthor=M.+L.+Mooreauthor=R.+Fearnsauthor=S.+M.+Chandaauthor=L.+M.+Blattauthor=J.+A.+Symonsauthor=L.+Beigelman&title=Molecular+basis+for+the+selective+inhibition+of+respiratory+syncytial+virus+RNA+polymerase+by+2%E2%80%99-fluoro-4%E2%80%99-chloromethyl-cytidine+triphosphate&doi=10.1371%2Fjournal.ppat.1004995"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004995%26sid%3Dliteratum%253Aachs%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DL.%2BK.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DStoycheva%26aufirst%3DA.%2BD.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMoore%26aufirst%3DM.%2BL.%26aulast%3DFearns%26aufirst%3DR.%26aulast%3DChanda%26aufirst%3DS.%2BM.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DMolecular%2520basis%2520for%2520the%2520selective%2520inhibition%2520of%2520respiratory%2520syncytial%2520virus%2520RNA%2520polymerase%2520by%25202%25E2%2580%2599-fluoro-4%25E2%2580%2599-chloromethyl-cytidine%2520triphosphate%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26doi%3D10.1371%2Fjournal.ppat.1004995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span> <span> </span><span class="NLM_article-title">Addressing the selectivity and toxicity of antiviral nucleosides</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2040206618758524</span>, <span class="refDoi"> DOI: 10.1177/2040206618758524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1177%2F2040206618758524" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2040206618758524&author=J.+Y.+Feng&title=Addressing+the+selectivity+and+toxicity+of+antiviral+nucleosides&doi=10.1177%2F2040206618758524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1177%2F2040206618758524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040206618758524%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26atitle%3DAddressing%2520the%2520selectivity%2520and%2520toxicity%2520of%2520antiviral%2520nucleosides%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2018%26volume%3D26%26spage%3D2040206618758524%26doi%3D10.1177%2F2040206618758524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadyar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakowicz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span> <span> </span><span class="NLM_article-title">Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1128/aac.01922-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1128%2FAAC.01922-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=26596942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFKit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=806-817&author=J.+Y.+Fengauthor=Y.+Xuauthor=O.+Barauskasauthor=J.+K.+Perryauthor=S.+Ahmadyarauthor=G.+Stepanauthor=H.+Yuauthor=D.+Babusisauthor=Y.+Parkauthor=K.+McCutcheonauthor=M.+Perronauthor=B.+E.+Schultzauthor=R.+Sakowiczauthor=A.+S.+Ray&title=Role+of+mitochondrial+RNA+polymerase+in+the+toxicity+of+nucleotide+inhibitors+of+hepatitis+C+virus&doi=10.1128%2Faac.01922-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus</span></div><div class="casAuthors">Feng, Joy Y.; Xu, Yili; Barauskas, Ona; Perry, Jason K.; Ahmadyar, Shekeba; Stepan, George; Yu, Helen; Babusis, Darius; Park, Yeojin; McCutcheon, Krista; Perron, Michel; Schultz, Brian E.; Sakowicz, Roman; Ray, Adrian S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">806-817</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Toxicity has emerged during the clin. development of many but not all nucleotide inhibitors (NI) of hepatitis C virus (HCV).  To better understand the mechanism for adverse events, clin. relevant HCV NI were characterized in biochem. and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration.  NI that were incorporated by the mitochondrial RNA polymerase (PolRMT) inhibited mitochondrial protein synthesis and showed a corresponding decrease in mitochondrial oxygen consumption in cells.  The nucleoside released by the prodrug balapiravir (R1626), 4'-azido cytidine, was a highly selective inhibitor of mitochondrial RNA transcription.  The nucleotide prodrug of 2'-C-Me guanosine, BMS-986094, showed a primary effect on mitochondrial function at submicromolar concns., followed by general cytotoxicity.  In contrast, NI contg. multiple ribose modifications, including the active forms of mericitabine and sofosbuvir, were poor substrates for PolRMT and did not show mitochondrial toxicity in cells.  In general, these studies identified the prostate cell line PC-3 as more than an order of magnitude more sensitive to mitochondrial toxicity than the commonly used HepG2 cells.  In conclusion, analogous to the role of mitochondrial DNA polymerase gamma in toxicity caused by some 2'-deoxynucleotide analogs, there is an assocn. between HCV NI that interact with PolRMT and the observation of adverse events.  More broadly applied, the sensitive methods for detecting mitochondrial toxicity described here may help in the identification of mitochondrial toxicity prior to clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJLNn7rQbeOrVg90H21EOLACvtfcHk0ljElffC4v3m4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFKit70%253D&md5=7cc35537b70729a9de882d2ac4b18a98</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FAAC.01922-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01922-15%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DAhmadyar%26aufirst%3DS.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DMcCutcheon%26aufirst%3DK.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSakowicz%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DA.%2BS.%26atitle%3DRole%2520of%2520mitochondrial%2520RNA%2520polymerase%2520in%2520the%2520toxicity%2520of%2520nucleotide%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D806%26epage%3D817%26doi%3D10.1128%2Faac.01922-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1862</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1021/jm5017279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5017279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1862-1878&author=G.+Wangauthor=J.+Devalauthor=J.+Hongauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=J.+Taylorauthor=A.+Fungauthor=Z.+Jinauthor=S.+K.+Stevensauthor=V.+Serebryanyauthor=J.+Liuauthor=Q.+Zhangauthor=Y.+Tamauthor=S.+M.+Chandaauthor=D.+B.+Smithauthor=J.+A.+Symonsauthor=L.+M.+Blattauthor=L.+Beigelman&title=Discovery+of+4%E2%80%B2-chloromethyl-2%E2%80%B2-deoxy-3%E2%80%B2%2C5%E2%80%B2-di-O-isobutyryl-2%E2%80%B2-fluorocytidine+%28ALS-8176%29%2C+a+first-in-class+RSV+polymerase+inhibitor+for+treatment+of+human+respiratory+syncytial+virus+infection&doi=10.1021%2Fjm5017279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection</span></div><div class="casAuthors">Wang, Guangyi; Deval, Jerome; Hong, Jin; Dyatkina, Natalia; Prhavc, Marija; Taylor, Joshua; Fung, Amy; Jin, Zhinan; Stevens, Sarah K.; Serebryany, Vladimir; Liu, Jyanwei; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita M.; Smith, David B.; Symons, Julian A.; Blatt, Lawrence M.; Beigelman, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1862-1878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading pathogen of childhood and is assocd. with significant morbidity and mortality.  To date, ribavirin is the only approved small mol. drug, which has limited use.  The only other RSV drug is palivizumab, a monoclonal antibody, which is used for RSV prophylaxis.  Clearly, there is an urgent need for small mol. RSV drugs.  This article reports the design, synthesis, anti-RSV activity, metab., and pharmacokinetics of a series of 4'-substituted cytidine nucleosides.  Among tested compds. 4'-chloromethyl-2'-deoxy-2'-fluorocytidine I exhibited the most promising activity in the RSV replicon assay with an EC50 of 0.15 μM.  The 5'-triphosphate of I (I-TP)inhibited RSV polymerase with an IC50 of 0.02 μM without appreciable inhibition of human DNA and RNA polymerases at 100 μM.  ALS-8176 II, the 3',5'-di-O-isobutyryl prodrug of I, demonstrated good oral bioavailability and a high level of I-TP in vivo.  Compd. II is a first-in-class nucleoside RSV polymerase inhibitor that demonstrated excellent anti-RSV efficacy and safety in a phase 2 clin. RSV challenge study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaKHh4AhV9drVg90H21EOLACvtfcHk0ljElffC4v3m4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D&md5=da9e883eb67f20ca259dec06a6a05367</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm5017279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5017279%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DChanda%26aufirst%3DS.%2BM.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204%25E2%2580%25B2-chloromethyl-2%25E2%2580%25B2-deoxy-3%25E2%2580%25B2%252C5%25E2%2580%25B2-di-O-isobutyryl-2%25E2%2580%25B2-fluorocytidine%2520%2528ALS-8176%2529%252C%2520a%2520first-in-class%2520RSV%2520polymerase%2520inhibitor%2520for%2520treatment%2520of%2520human%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1862%26epage%3D1878%26doi%3D10.1021%2Fjm5017279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Körner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herian, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theilmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenschlager, R.</span></span> <span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1126/science.285.5424.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line&doi=10.1126%2Fscience.285.5424.110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0liwMgypbpAm9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113%26doi%3D10.1126%2Fscience.285.5424.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span>; <span class="NLM_string-name">Vernachio, J.</span>; <span class="NLM_string-name">Battina, S.</span>; <span class="NLM_string-name">Ramamurty, C. V.</span>; <span class="NLM_string-name">Srinivas Rao, C.</span>; <span class="NLM_string-name">McGuigan, C.</span>; <span class="NLM_string-name">Brancale, A.</span></span> <span> </span><span class="NLM_article-title">Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment of Viral Infections</span>. U.S. Patent <span class="NLM_patent">20,140,286,903 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Chamberlain&author=J.+Vernachio&author=S.+Battina&author=C.+V.+Ramamurty&author=C.+Srinivas+Rao&author=C.+McGuigan&author=A.+Brancale&title=Substituted+Purine+Nucleosides%2C+Phosphoramidate+and+Phosphordiamidate+Derivatives+for+Treatment+of+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%26atitle%3DSubstituted%2520Purine%2520Nucleosides%252C%2520Phosphoramidate%2520and%2520Phosphordiamidate%2520Derivatives%2520for%2520Treatment%2520of%2520Viral%2520Infections%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7202</span>– <span class="NLM_lpage">7218</span>, <span class="refDoi"> DOI: 10.1021/jm100863x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-2%E2%80%B2-deoxy-2%E2%80%B2-%CE%B1-fluoro-2%E2%80%B2-%CE%B2-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus&doi=10.1021%2Fjm100863x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0liwMgypbpAm9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-2%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-%25CE%25B1-fluoro-2%25E2%2580%25B2-%25CE%25B2-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218%26doi%3D10.1021%2Fjm100863x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S.</span>; <span class="NLM_string-name">Hutchins, J.</span>; <span class="NLM_string-name">Medela, K.</span>; <span class="NLM_string-name">McGuigan, C.</span>; <span class="NLM_string-name">Vernachio, J.</span>; <span class="NLM_string-name">Aljarah, M.</span>; <span class="NLM_string-name">Gilles, A.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidate Derivatives of Guanosine Nucleoside Compounds for Treatment of Viral Infections</span>. <span class="NLM_patent">WO 2010081082 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Chamberlain&author=J.+Hutchins&author=K.+Medela&author=C.+McGuigan&author=J.+Vernachio&author=M.+Aljarah&author=A.+Gilles&title=Phosphoramidate+Derivatives+of+Guanosine+Nucleoside+Compounds+for+Treatment+of+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%26atitle%3DPhosphoramidate%2520Derivatives%2520of%2520Guanosine%2520Nucleoside%2520Compounds%2520for%2520Treatment%2520of%2520Viral%2520Infections%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span> <span> </span><span class="NLM_article-title">Efficiency of incorporation and chain termination determines the inhibition potency of 2’-modified nucleotide analogs against hepatitis C virus polymerase</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3636</span>– <span class="NLM_lpage">3645</span>, <span class="refDoi"> DOI: 10.1128/aac.02666-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1128%2FAAC.02666-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=24733478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3636-3645&author=A.+Fungauthor=Z.+Jinauthor=N.+Dyatkinaauthor=G.+Wangauthor=L.+Beigelmanauthor=J.+Deval&title=Efficiency+of+incorporation+and+chain+termination+determines+the+inhibition+potency+of+2%E2%80%99-modified+nucleotide+analogs+against+hepatitis+C+virus+polymerase&doi=10.1128%2Faac.02666-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase</span></div><div class="casAuthors">Fung, Amy; Jin, Zhinan; Dyatkina, Natalia; Wang, Guangyi; Beigelman, Leo; Deval, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3636-3645, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ribonucleotide analog inhibitors of the RNA-dependent RNA polymerase of hepatitis C virus (HCV) represent one of the most exciting recent developments in HCV antiviral therapy.  Although it is well established that these mols. cause chain termination by competing at the triphosphate level with natural nucleotides for incorporation into elongating RNA, strategies to rationally optimize antiviral potency based on enzyme kinetics remain elusive.  In this study, we used the isolated HCV polymerase elongation complex to det. the pre-steady-state kinetics of incorporation of 2'F-2'C-Me-UTP, the active metabolite of the anti-HCV drug sofosbuvir. 2'F-2'C-Me-UTP was efficiently incorporated by HCV polymerase with apparent Kd (equil. const.) and kpol (rate of nucleotide incorporation at satg. nucleotide concn.) values of 113 ± 28 μM and 0.67 ± 0.05 s-1, resp., giving an overall substrate efficiency (kpol/Kd) of 0.0059 ± 0.0015 μM-1 s-1.  We also measured the substrate efficiency of other UTP analogs and found that substitutions at the 2' position on the ribose can greatly affect their level of incorporation, with a rank order of OH > F > NH2 > F-C-Me > C-Me > N3 > ara.  However, the efficiency of chain termination following the incorporation of UMP analogs followed a different order, with only 2'F-2'C-Me-, 2'C-Me-, and 2'ara-UTP causing complete and immediate chain termination.  The chain termination profile of the 2'-modified nucleotides explains the apparent lack of correlation obsd. across all mols. between substrate efficiency at the single-nucleotide level and their overall inhibition potency.  To our knowledge, these results provide the first attempt to use pre-steady-state kinetics to uncover the mechanism of action of 2'-modified NTP analogs against HCV polymerase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUNCxRgeI-hrVg90H21EOLACvtfcHk0ljzyHsVibNr1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7zL&md5=6eda107d20100519f19d4399d1550cac</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1128%2FAAC.02666-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02666-14%26sid%3Dliteratum%253Aachs%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DDeval%26aufirst%3DJ.%26atitle%3DEfficiency%2520of%2520incorporation%2520and%2520chain%2520termination%2520determines%2520the%2520inhibition%2520potency%2520of%25202%25E2%2580%2599-modified%2520nucleotide%2520analogs%2520against%2520hepatitis%2520C%2520virus%2520polymerase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3636%26epage%3D3645%26doi%3D10.1128%2Faac.02666-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolomanov, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gildea, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puschmann, H.</span></span> <span> </span><span class="NLM_article-title">OLEX2: a complete structure solution, refinement and analysis program</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1107/s0021889808042726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1107%2FS0021889808042726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=339-341&author=O.+V.+Dolomanovauthor=L.+J.+Bourhisauthor=R.+J.+Gildeaauthor=J.+A.+K.+Howardauthor=H.+Puschmann&title=OLEX2%3A+a+complete+structure+solution%2C+refinement+and+analysis+program&doi=10.1107%2Fs0021889808042726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">OLEX2: a complete structure solution, refinement and analysis program</span></div><div class="casAuthors">Dolomanov, Oleg V.; Bourhis, Luc J.; Gildea, Richard J.; Howard, Judith A. K.; Puschmann, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-341</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">New software, OLEX2, was developed for the detn., visualization and anal. of mol. crystal structures.  The software has a portable mouse-driven workflow-oriented and fully comprehensive graphical user interface for structure soln., refinement and report generation, as well as novel tools for structure anal.  OLEX2 seamlessly links all aspects of the structure soln., refinement and publication process and presents them in a single workflow-driven package, with the ultimate goal of producing an application which will be useful to both chemists and crystallographers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIYSUbyzIgxbVg90H21EOLACvtfcHk0ljzyHsVibNr1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSnsbg%253D&md5=7a2f9697b13b8e76de0e7dc5074ab229</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0021889808042726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889808042726%26sid%3Dliteratum%253Aachs%26aulast%3DDolomanov%26aufirst%3DO.%2BV.%26aulast%3DBourhis%26aufirst%3DL.%2BJ.%26aulast%3DGildea%26aufirst%3DR.%2BJ.%26aulast%3DHoward%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DPuschmann%26aufirst%3DH.%26atitle%3DOLEX2%253A%2520a%2520complete%2520structure%2520solution%252C%2520refinement%2520and%2520analysis%2520program%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2009%26volume%3D42%26spage%3D339%26epage%3D341%26doi%3D10.1107%2Fs0021889808042726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure refinement with SHELXL</span>. <i>Acta Crystallogr., Sect. C: Struct. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1107/s2053229614024218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1107%2FS2053229614024218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=25643710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=3-8&author=G.+M.+Sheldrick&title=Crystal+structure+refinement+with+SHELXL&doi=10.1107%2Fs2053229614024218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure refinement with SHELXL</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section C: Structural Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">ACSCGG</span>;
        ISSN:<span class="NLM_cas:issn">2053-2296</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The improvements in the crystal structure refinement program SHELXL have been closely coupled with the development and increasing importance of the CIF (Crystallog. Information Framework) format for validating and archiving crystal structures.  An important simplification is that now only one file in CIF format (for convenience, referred to simply as 'a CIF') contg. embedded reflection data and SHELXL instructions is needed for a complete structure archive; the program SHREDCIF can be used to ext. the and files required for further refinement with SHELXL.  Recent developments in SHELXL facilitate refinement against neutron diffraction data, the treatment of H atoms, the detn. of abs. structure, the input of partial structure factors and the refinement of twinned and disordered structures.  SHELXL is available free to academics for the Windows, Linux and Mac OS X operating systems, and is particularly suitable for multiple-core processors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk1_pNHwXR7Vg90H21EOLACvtfcHk0ljzyHsVibNr1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D&md5=4a860804b50fc183e8a701098b98ef59</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS2053229614024218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053229614024218%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DCrystal%2520structure%2520refinement%2520with%2520SHELXL%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520C%253A%2520Struct.%2520Chem.%26date%3D2015%26volume%3D71%26spage%3D3%26epage%3D8%26doi%3D10.1107%2Fs2053229614024218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">A short history ofSHELX</span>. <i>Acta Crystallogr., Sect. A: Found. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/s0108767307043930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=10.1107%2FS0108767307043930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=18156677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=112-122&author=G.+M.+Sheldrick&title=A+short+history+ofSHELX&doi=10.1107%2Fs0108767307043930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of SHELX</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section A: Foundations of Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACACEQ</span>;
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An account is given of the development of the SHELX system of computer programs from SHELX-76 to the present day.  In addn. to identifying useful innovations that have come into general use through their implementation in SHELX, a crit. anal. is presented of the less-successful features, missed opportunities and desirable improvements for future releases of the software.  An attempt is made to understand how a program originally designed for photog. intensity data, punched cards and computers over 10000 times slower than an av. modern personal computer has managed to survive for so long.  SHELXL is the most widely used program for small-mol. refinement and SHELXS and SHELXD are often employed for structure soln. despite the availability of objectively superior programs.  SHELXL also finds a niche for the refinement of macromols. against high-resoln. or twinned data; SHELXPRO acts as an interface for macromol. applications.  SHELXC, SHELXD and SHELXE are proving useful for the exptl. phasing of macromols., esp. because they are fast and robust and so are often employed in pipelines for high-throughput phasing.  This paper could serve as a general literature citation when one or more of the open-source SHELX programs (and the Bruker AXS version SHELXTL) are employed in the course of a crystal-structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLPYyJyJ2RbVg90H21EOLACvtfcHk0ljzyHsVibNr1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO&md5=8f91f10be4a9df74b2a9dad522c71e6e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0108767307043930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767307043930%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DA%2520short%2520history%2520ofSHELX%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D112%26epage%3D122%26doi%3D10.1107%2Fs0108767307043930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span> <i>COSMO-V1.61 Software
for the CCD Detector Systems for Determining
Data Collection Parameters</i>; <span class="NLM_publisher-name">Bruker Analytical
X-ray Systems</span>: <span class="NLM_publisher-loc">Madison, WI</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+COSMO-V1.61+Software%0Afor+the+CCD+Detector+Systems+for+Determining%0AData+Collection+Parameters%3B+Bruker+Analytical%0AX-ray+Systems%3A+Madison%2C+WI%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DCOSMO-V1.61%2520Software%250Afor%2520the%2520CCD%2520Detector%2520Systems%2520for%2520Determining%250AData%2520Collection%2520Parameters%26pub%3DBruker%2520Analytical%250AX-ray%2520Systems%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span> <i>SAINT-8.34A-2013
Software for the Integration of CCD Detector
System</i>; <span class="NLM_publisher-name">Bruker Analytical X-ray Systems</span>: <span class="NLM_publisher-loc">Madison, WI</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+SAINT-8.34A-2013%0ASoftware+for+the+Integration+of+CCD+Detector%0ASystem%3B+Bruker+Analytical+X-ray+Systems%3A+Madison%2C+WI%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSAINT-8.34A-2013%250ASoftware%2520for%2520the%2520Integration%2520of%2520CCD%2520Detector%250ASystem%26pub%3DBruker%2520Analytical%2520X-ray%2520Systems%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i71"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00935">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11754"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00935?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00935</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00935/suppl_file/jm0c00935_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00935/suppl_file/jm0c00935_si_001.csv">jm0c00935_si_001.csv (3.56 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00935&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00935%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00935" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992aaebb7c2388","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
